WO2003082272A1 - Substituted benzazoles and use thereof as raf kinase inhibitors - Google Patents

Substituted benzazoles and use thereof as raf kinase inhibitors Download PDF

Info

Publication number
WO2003082272A1
WO2003082272A1 PCT/US2003/010117 US0310117W WO03082272A1 WO 2003082272 A1 WO2003082272 A1 WO 2003082272A1 US 0310117 W US0310117 W US 0310117W WO 03082272 A1 WO03082272 A1 WO 03082272A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
methyl
substituted
amino
hydrogen
Prior art date
Application number
PCT/US2003/010117
Other languages
French (fr)
Inventor
Paul A. Renhowe
Savithri Ramurthy
Payman Amiri
Barry Haskell Levine
Daniel J. Poon
Sharadha Subramanian
Leonard Sung
Wendy Fantl
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ535985A priority Critical patent/NZ535985A/en
Priority to SI200331745T priority patent/SI1499311T1/en
Application filed by Chiron Corporation filed Critical Chiron Corporation
Priority to APAP/P/2004/003161A priority patent/AP1913A/en
Priority to KR1020047015523A priority patent/KR101071123B1/en
Priority to EP03745683A priority patent/EP1499311B1/en
Priority to BR0308854-5A priority patent/BR0308854A/en
Priority to IL16430203A priority patent/IL164302A0/en
Priority to EA200401284A priority patent/EA007987B1/en
Priority to DE60329910T priority patent/DE60329910D1/en
Priority to DK03745683.7T priority patent/DK1499311T3/en
Priority to CA2480638A priority patent/CA2480638C/en
Priority to AU2003226211A priority patent/AU2003226211B2/en
Priority to MXPA04009541A priority patent/MXPA04009541A/en
Priority to AT03745683T priority patent/ATE447404T1/en
Priority to JP2003579810A priority patent/JP4628678B2/en
Publication of WO2003082272A1 publication Critical patent/WO2003082272A1/en
Priority to IL164302A priority patent/IL164302A/en
Priority to NO20044617A priority patent/NO330563B1/en
Priority to HK05101491.7A priority patent/HK1067945A1/en
Priority to HK05110735.4A priority patent/HK1078779A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Definitions

  • the present invention relates to new substituted benz-azole-like compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cancer.
  • Raf serine/threonine kinases are essential components of the Ras/Mitogen-
  • Raf genes code for highly conserved serine-threonine-specific protein kinases which are known to bind to the ras oncogene. They are part of a signal transduction pathway believed to consist of receptor tyrosme kinases, p21 ras, Raf protein kinases, Mekl (ERK activator or MAPKK) kinases and ERK (MAPK) kinases, which ultimately phosphorylate transcription factors.
  • MAPK Activated Protein Kinase
  • Raf kinases are activated by Ras and phosphorylate and activate two isoforms of Mitogen-Activated Protein Kinase Kinase (called Mekl and Mek2), that are dual specificity threonine/tyrosine kinases. Both Mek isoforms activate Mitogen Activated Kinases 1 and 2 (MAPK, also called Extracellular Ligand Regulated Kinase 1 and 2 or Erkl and Erk2).
  • MEPK Mitogen Activated Kinases 1 and 2
  • the MAPKs phosphorylate many substrates including transcription factors and in so doing set up their transcriptional program.
  • Raf kinase participation in the Ras/MAPK pathway influences and regulates many cellular functions such as proliferation, differentiation, survival, oncogenic transformation and apoptosis.
  • Raf-1 phosphorylates and activates Mekl, resulting in the propagation of the signal to downstream effectors, such as MAPK (mitogen-activated protein kinase) (Crews et al. (1993) Cell 74:215).
  • MAPK mitogen-activated protein kinase
  • the Raf serine/threonine kinases are considered to be the primary Ras effectors involved in the proliferation of animal cells (Avruch et al. (1994) Ti-ends Biochem. Sci. 19:279).
  • Raf kinase has three distinct isoforms, Raf-1 (c-Raf), A-Raf, and B-Raf, distinguished by their ability to interact with Ras, to activate MAPK kinase pathway, tissue distribution and sub-cellular localization (Marias et. Al., Biochem. J. 351: 289-305, 2000; Weber et. al., Oncogene 19:169-176, 2000; Pritchard et. al., Mol. Cell. Biol. 15:6430-6442, 1995).
  • Raf kinases are activated by Ras and phosphorylate and activate two isoforms of Mitogen-Activated Protein Kinase Kinase (called Mekl and Mek2) that are dual specificity threonine/tyrosine kinases. Both Mek isoforms activate Mitogen Activated Kinases 1 and 2 (MAPK, also called Extracellular Ligand Regulated Kinase 1 and 2 or Erkl and Erk2).
  • MEPK Mitogen Activated Kinases 1 and 2
  • the MAPKs phosphorylate many substrates including cytosolic proteins and ETS family of transcription factors.
  • Raf kinase participation in the Ras/MAPK pathway influences and regulates many cellular functions such as proliferation, differentiation, survival, cell cycle progression and apoptosis.
  • Inhibitors of Raf/MEK/ERK pathway at the level of Raf kinases can potentially be effective as therapeutic agents against tumors with over-expressed or mutated receptor tyrosine kinases, activated intracellular tyrosine kinases, tumors with aberrantly expressed Grb2 (an adapter protein that allows stimulation of Ras by the Sos exchange factor) as well as tumors harboring activating mutations of Raf itself.
  • Grb2 an adapter protein that allows stimulation of Ras by the Sos exchange factor
  • Raf kinase inhibitors have been described as exhibiting efficacy in inhibiting tumor cell proliferation in vitro and/or in vivo assays (see, e.g., U.S. Pat. Nos. 6,391,636, 6,358,932, 6,037,136, 5,717,100, 6,458,813, 6,204,467, and 6,268,391).
  • Other patents and patent applications suggest the use of Raf kinase inhibitors for treating leukemia (see, e.g., U.S. Patent Nos. 6,268,391, and 6,204,467, and published U.S. Patent Application Nos.
  • a ] ⁇ is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroaryUieteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;
  • A2 is substituted or unsubstituted heteroaryl
  • Rl is O or H, and R 2 is NR 5 R ⁇ or hydroxyl; or Rj is taken together with R 2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
  • R3 is hydrogen, halogen, loweralkyl, or loweralkoxy
  • R4 is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl
  • R5 and R 6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and the pharmaceutically acceptable salts, esters and prodrugs thereof.
  • new substituted benz-azole compounds are provided of the formula (II):
  • X l5 Ar l 5 Ar 2 , R l5 R 2 and R3 are as defined above; and the pharmaceutically acceptable salts, esters, tautomers and. rodrugs thereof.
  • new substituted benz-azole compounds are provided of the formula (IV):
  • X j , Ar 1; Ri , R and R 3 are as defined above; and the pharmaceutically acceptable salts, esters, tautomers and prodrugs thereof.
  • the present invention provides methods for treating Raf related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III), (IV) or (V) effective to reduce or prevent tumor growth in the subject.
  • the present invention provides methods for treating Raf related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III), (IV) or (V) effective to reduce or prevent tumor growth in the subject in combination with at least one additional agent for the treatment of cancer.
  • the present invention provides therapeutic compositions comprising at least one compound of formula (I), (II), (III), (IV) or (V) in combination with one or more additional agents for the, treatment of cancer, as are commonly employed in cancer therapy.
  • the compounds of the invention are useful in the treatment of cancers, including carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon), myeloid disorders (e.g., myeloid leukemia) and adenomas (e.g., villous colon adenoma).
  • the invention further provides compositions, methods of use, and methods of manufacture as described in the detailed description of the invention.
  • new substituted benz-azole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof are provided of the formula (I):
  • a j is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;
  • a 2 is substituted or unsubstituted heteroaryl;
  • Rl is O or H, and R 2 is NR 5 R6 or hydroxyl; or Ri is taken together with R 2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
  • R3 is hydrogen, halogen, loweralkyl, or loweralkoxy
  • R4 is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl
  • R5 and R6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl
  • R5 and R ⁇ are taken together to form substituted or unsubstituted heterocyclo or heteroaryl
  • the pharmaceutically acceptable salts, esters and prodrugs thereof are taken together to form substituted or unsubstituted heterocyclo or heteroaryl
  • new substituted benz-azole compounds are provided of the formula (II):
  • the present invention provides methods of treating human or animal subjects suffering from a Raf related disorder, such as cancer.
  • a Raf related disorder such as cancer.
  • the present invention provides methods of treating a human or animal subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a compound of formula I, II, III, IV or V above, either alone or in combination with other anticancer agents.
  • the present invention provides methods for treating Raf related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III), (IV) or (V) effective to reduce or prevent tumor growth in the subject.
  • the present invention provides methods for treating Raf related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III), (IV) or (V) effective to reduce or prevent tumor growth in the subject in combination with at least one additional agent for the treatment of cancer.
  • a compound of formula (I), (II), (III), (IV) or (V) effective to reduce or prevent tumor growth in the subject in combination with at least one additional agent for the treatment of cancer.
  • the present invention contemplates, but is not limited to, administration of numerous anticancer agents such as: agents that induce apoptosis; polynucleotides (e.g., ribozymes); polypeptides (e.g., enzymes); drugs; biological mimetics; alkaloids; alkylating agents; antitumor antibiotics; antimetabolites; hormones; platinum compounds; monoclonal antibodies conjugated with anticancer drugs, toxins, and/or radionuclides; biological response modifiers (e.g. interferons [e.g. IF ⁇ -a, etc.] and interleukins [e.g.
  • IL-2 IL-2, etc.], etc.
  • adoptive immunotherapy agents hematopoietic growth factors; agents that induce tumor cell differentiation (e.g. all-trans-retinoic acid, etc.); gene therapy reagents; antisense therapy reagents and nucleotides; tumor vaccines; inhibitors of angiogenesis, and the like.
  • chemotherapeutic compounds and anticancer therapies suitable for coadministration with the disclosed compounds of formula (I), (II), (III), (IV) or (V) are known to those skilled in the art.
  • anticancer agents to be used in combination with compounds of the present invention comprise agents that induce or stimulate apoptosis.
  • Agents that induce apoptosis include, but are not limited to, radiation (e.g., W); kinase inhibitors (e.g., Epidermal Growth Factor Receptor [EGFR] kinase inhibitor, Vascular Growth Factor Receptor [VGFR] kinase inhibitor, Fibroblast Growth Factor Receptor [FGFR] kinase inhibitor, Platelet-derived Growth Factor Receptor [PGFR] I kinase inhibitor, and Bcr-Abl kinase inhibitors such as STI-571, Gleevec, and Glivec]); antisense molecules; antibodies [e.g., Herceptin and Rituxan]; anti-estrogens [e.g., raloxifene and tamoxifen]; anti-androgens [e.g., flutamide, bicalu
  • the present invention provides pharmaceutical compositions comprising at least one compound of formula I, II, III, TV or V together with a pharmaceutically acceptable carrier suitable for administration to a human or animal subject, either alone or together with other anticancer agents.
  • the present invention provides methods of manufacture of compounds of formula I, II, III, IV or V as described herein.
  • the present invention provides compounds which are inhibitors of the enzyme raf kinase. Since the enzyme is a downstream effector of p21 ras , the instant inhibitors are useful in pharmaceutical compositions for human or veterinary use where inhibition of the raf kinase pathway is indicated, e.g., in the treatment of tumors and/or cancerous cell growth mediated by raf kinase.
  • the compounds are useful in the treatment of human or animal, e.g., murine cancer, since the progression of these cancers is dependent upon the ras protein signal transduction cascade and therefore is susceptible to treatment by interruption of the cascade by inhibiting raf kinase activity.
  • the compounds of the invention are useful in treating solid cancers, such as, for example, carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon, myeloid disorders (e.g., myeloid leukemia) or adenomas (e.g., villous colon adenoma).
  • solid cancers such as, for example, carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon, myeloid disorders (e.g., myeloid leukemia) or adenomas (e.g., villous colon adenoma).
  • Raf inhibitor is used herein to refer to a compound that exhibits an IC 50 with respect to Raf Kinase activity of no more than about 100 ⁇ M and more typically not more than about 50 ⁇ M, as measured in the RafTMek Filtration Assay described generally hereinbelow.
  • Preferred isoforms of Raf Kinase in which the compounds of the present invention will be shown to inhibit include A-Raf, B-Raf, and C-Raf (Raf-1).
  • IC 50 is that concentration of inhibitor which reduces the activity of an enzyme (e.g., Raf kinase) to half-maximal level. Representative compounds of the present invention have been discovered to exhibit inhibitory activity against Raf.
  • Compounds of the present invention preferably exhibit an IC 50 with respect to Raf of no more than about 10 ⁇ M, more preferably, no more than about 5 ⁇ M, even more preferably not more than about 1 ⁇ M, and most preferably, not more than about 200 nM, as measured in the Raf kinase assays described herein.
  • benz-azoles includes benzimidazoles, benzothiazoles and benzoxazoles.
  • alkyl refers to alkyl groups that do not contain heteroatoms.
  • the phrase includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like.
  • the phrase also includes branched chain isomers of straight chain alkyl groups, including but not limited to, the following which are provided by way of example: -CH(CH ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -CH(CH 2 CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 2 CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , -CH 2 CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH(CH 2 CH 3 ) 2 , -CH 2 C(CH 3 ) 3 , -CH 2 C(CH 2 CH 3 ) 3 , -CH(CH 3 )CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH 2 CH(CH 3 ) 2 , -CH 2 CH 2 CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH 2 CH(CH 3 ) 2 , -CH 2 CH(CH 3 )(CH 2 CH
  • alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl and such rings substituted with straight and branched chain alkyl groups as defined above.
  • alkyl groups includes primary alkyl groups, secondary alkyl groups, and tertiary alkyl groups.
  • Preferred alkyl groups include straight and branched chain alkyl groups and cyclic alkyl groups having 1 to 12 carbon atoms.
  • loweralkyl includes both substituted or unsubstituted straight or branched chain alkyl groups having from 1 to 6 carbon atoms.
  • Representative loweralkyl groups include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, trifluoromethyl, pentafluoroethyl and the like.
  • Loweralkyl groups may be substituted, such as with halo, hydroxy, amino, nitro and/or cyano groups, and the like.
  • halo-substituted and hydroxy-substiruted loweralkyl include chloromethyl, trichloromethyl, chloroethyl, hydroxyethyl, and the like.
  • Other suitable substituted loweralkyl moieties include, for example, aralkyl, aminoalkyl, aminoaralkyl, carbonylaminoalkyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, aralkylcarbonyl- aminoalkyl, aminoalkoxyalkyl and arylaminoalkyl.
  • Loweralkoxy refers to RO- wherein R is loweralkyl.
  • Representative examples of loweralkoxy groups include methoxy, ethoxy, t-butoxy, trifluoromethoxy and the like.
  • halogen refers to chloro, bromo, fluoro and iodo groups.
  • Haloalkyl refers to an alkyl radical substituted with one or more halogen atoms.
  • haloloweralkyl refers to a loweralkyl radical substituted with one or more halogen atoms.
  • haloalkoxy refers to an alkoxy radical substituted with one or more halogen atoms.
  • haloloweralkoxy refers to a loweralkoxy radical substituted with one or more halogen atoms.
  • Amino refers herein to the group -NH 2 .
  • alkylamino refers herein to the group -NRR' where R and R' are each independently selected from hydrogen or a lower alkyl.
  • arylamino refers herein to the group -NRR' where R is aryl and
  • R' is hydrogen, a lower alkyl, or an aryl.
  • aralkylamino refers herein to the group -NRR' where R is a lower aralkyl and R' is hydrogen, a loweralkyl, an aryl, or a loweraralkyl.
  • alkoxyalkyl refers to the group -aUq-O-au where aU is alkyl or alkenyl, and alk 2 is alkyl or alkenyl.
  • loweralkoxyalkyl refers to an alkoxyalkyl where alki is loweralkyl or loweralkenyl, and alk 2 is loweralkyl or loweralkenyl.
  • aryloxyalkyl refers to the group -alkyl-O-aryl.
  • aralkoxy alkyl refers to the group -alkylenyl-O-aralkyl, where aralkyl is a loweraralkyl.
  • alkoxyalkylamino refers herein to the group -NR-(alkoxyalkyl), where R is typically hydrogen, loweraralkyl, or loweralkyl.
  • aminoloweralkoxy alkyl refers herein to an aminoalkoxyalkyl in which the alkoxyalkyl is a loweralkoxyalkyl.
  • aminocarbonyl refers herein to the group -C(O)-NH 2 .
  • Substituted aminocarbonyl refers herein to the group -C(O)-NRR' where R is loweralkyl and R' is hydrogen or a loweralkyl.
  • arylaminocarbonyl refers herein to the group -C(O)-NRR' where R is an aryl and R' is hydrogen, loweralkyl or aryl.
  • aralkylaminocarbonyl refers herein to the group -C(O)-NRR' where R is loweraralkyl and R' is hydrogen, loweralkyl, aryl, or loweraralkyl.
  • aminosulfonyl refers herein to the group -S(O) 2 -NH 2 .
  • Substituted aminosulfonyl refers herein to the group -S(O) 2 -NRR' where R is loweralkyl and R' is hydrogen or a loweralkyl.
  • aralkylaminosulfonlyaryl refers herein to the group -aryl-S(O) 2 -NH-aralkyl, where the aralkyl is loweraralkyl.
  • Carbonyl refers to the divalent group -C(O)-.
  • Carbonyloxy refers generally to the group -C(O)-O. Such groups include esters, -C(O)-O-R, where R is loweralkyl, cycloalkyl, aryl, or loweraralkyl.
  • carbonyloxycycloalkyl refers generally herein to both an “carbonyloxycarbocycloalkyl” and an “carbonyloxyheterocycloalkyl", i.e., where R is a carbocycloalkyl or heterocycloalkyl, respectively.
  • arylcarbonyloxy refers herein to the group - C(O)-O-aryl, where aryl is a mono- or polycyclic, carbocycloaryl or heterocycloaryl.
  • aralkylcarbonyloxy refers herein to the group -C(O)-O-aralkyl, where the aralkyl is loweraralkyl.
  • alkylsulfonyl refers herein to the group -SO 2 -.
  • Alkylsulfonyl refers to a substituted sulfonyl of the structure -SO 2 R- in which R is alkyl.
  • Alkylsulfonyl groups employed in compounds of the present invention are typically loweralkylsulfonyl groups having from 1 to 6 carbon atoms in its backbone structure.
  • alkylsulfonyl groups employed in compounds of the present invention include, for example, methylsulfonyl (i.e., where R is methyl), ethylsulfonyl (i.e., where R is ethyl), propylsulfonyl (i.e., where R is propyl), and the like.
  • arylsulfonyl refers, herein to the group -SO 2 -aryl.
  • aralkylsulfonyl refers. herein to the group -SO 2 -aralkyl, in which the aralkyl is loweraralkyl.
  • sulfonamido refers herein to -SO 2 NH 2 .
  • carbonylamino refers to the divalent group -NH-C(O)- in which the hydrogen atom of the amide nitrogen of the carbonylamino group can be replaced a loweralkyl, aryl, or loweraralkyl group.
  • groups include moieties such as carbamate esters (-NH-C(O)-O-R) and amides -NH-C(O)-O-R, where R is a straight or branched chain loweralkyl, cycloalkyl, or aryl or loweraralkyl.
  • loweralkylcarbonylamino refers to alkylcarbonylamino where R is a loweralkyl having from 1 to about 6 carbon atoms in its backbone structure.
  • arylcarbonylamino refers to group -NH-C(O)-R where R is an aryl.
  • aralkylcarbonylamino refers to carbonylamino where R is a lower aralkyl.
  • aminocarbonyl refers to the divalent group -C(O)-NH- in which the hydrogen atom of the amide nitrogen of the carbonylamino group can be replaced a loweralkyl, aryl, or loweraralkyl group, as described above.
  • the hydrogen atoms at any of the nitrogens can be replaced with a suitable substituent, such as loweralkyl, aryl, or loweraralkyl.
  • a suitable substituent such as loweralkyl, aryl, or loweraralkyl.
  • Cycloalkyl refers to a mono- or polycyclic, heterocyclic or carbocyclic alkyl substituent. Typical cycloalkyl substituents have from 3 to 8 backbone (i.e., ring) atoms in which each backbone atom is either carbon or a heteroatom.
  • the term "heterocycloalkyl” refers herein to cycloalkyl substituents that have from 1 to 5, and more typically from 1 to 4 heteroatoms in the ring structure. Suitable heteroatoms employed in compounds of the present invention are nitrogen, oxygen, and sulfur. Representative heterocycloalkyl moieties include, for example, morpholino, piperazinyl, piperadinyl and the like.
  • Carbocycloalkyl groups are cycloalkyl groups in which all ring atoms are carbon.
  • polycyclic refers herein to fused and non-fused alkyl cyclic structures.
  • substituted heterocycle or “heterocyclic group” or heterocycle as used herein refers to any 3- or 4-membered ring containing a heteroatom selected from nitrogen, oxygen, and sulfur or a 5- or 6-membered ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, or sulfur; wherein the 5-membered ring has 0-2 double bonds and the 6-membered ring has 0-3 double bonds; wherein the nitrogen and sulfur atom maybe optionally oxidized; wherein the nitrogen and sulfur heteroatoms maybe optionally quarternized; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another 5- or 6-membered heterocyclic ring independently defined above.
  • heterocycle thus includes rings in which nitrogen is the heteroatom as well as partially and fully-saturated rings.
  • Preferred heterocycles include, for example: diazapinyl, pyrryl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazoyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, pyrazinyl, piperazinyl, N-methyl piperazinyl, azetidinyl, N-methylazetidinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quin
  • heterocyclic groups may be attached at various positions as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein.
  • heterocyclics include, for example, imidazolyl, pyridyl, piperazinyl, azetidinyl, thiazolyl, furanyl, triazolyl benzimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, indolyl, naphthpyridinyl, indazolyl, and quinolizinyl.
  • Aryl refers to optionally substituted monocyclic and polycyclic aromatic groups having from 3 to 14 backbone carbon or hetero atoms, and includes both carbocyclic aryl groups and heterocyclic aryl groups.
  • Carbocyclic aryl groups are aryl groups in which all ring atoms in the aromatic ring are carbon.
  • heteroaryl refers herein to aryl groups having from 1 to 4 heteroatoms as ring atoms in an aromatic ring with the remainder of the ring atoms being carbon atoms.
  • polycyclic aryl refers herein to fused and norf-fused cyclic structures in which at least one cyclic structure is aromatic, such as, for example, benzodioxozolo (which has a heterocyclic structure fused to a phenyl group, i.e.,
  • aryl moieties employed as substituents in compounds of the present invention include phenyl, pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyrazinyl, triazolyl, thiophenyl, furanyl, quinolinyl, purinyl, naphthyl, benzothiazolyl, benzopyridyl, and benzimidazolyl, and the like.
  • aralkyl refers to an alkyl group substituted with an aryl group. Typically, aralkyl groups employed in compounds of the present invention have from 1 to 6 carbon atoms incorporated within the alkyl portion of the aralkyl group. Suitable aralkyl groups employed in compounds of the present invention include, for example, benzyl, picolyl, and the like.
  • heteroaryl groups include, for example, those shown below. These heteroaryl groups can be further substituted and may be attached at various positions as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein.
  • heteroaryl's include, for example, imidazolyl, pyridyl, piperazinyl, azetidinyl, thiazolyl, triazolyl benzimidazolyl, benzothiazolyl, and benzoxazolyl.
  • the term "biaryl” refers to a group or substituent to which two aryl groups, which are not condensed to each other, are bound.
  • Exemplary biaryl compounds include, for example, phenylbenzene, diphenyldiazene, 4-methylthio-l-phenylbenzene, phenoxybenzene, (2-phenylethynyl)benzene, diphenyl ketone, .
  • Preferred optionally substituted biaryl groups include: 2-(phenylamino)-N-[4-(2-phenylethynyl)- phenyl]acetamide, 1 ,4-diphenylbenzene, N-[4-(2-phenylethynyl)phenyl]-2-[benzyl- amino]acetamide, 2-amino-N-[4-(2-phenylethynyl)phenyl]propanamide, 2-amino-N-[4- (2- ⁇ henylethynyl)phenyl]acetamide, 2-(cyclopropylamino)-N-[4-(2-phenylethynyl)- phenyl]acetamide, 2-(ethylamino)-N-[4-(2-phenylethynyl)- phenyl]acetamide, 2-(ethylamino)-N-[4-(2-phenylethynyl)- phen
  • [4-(2-phenylethynyl)phenyl]acetamide 4-phenyl-l-phenoxybenzene, N-(2-aminoethyl)- [4-(2-phenylethynyl)phenyl] carboxamide, 2- ⁇ [(4-fluorophenyl)methyl] amino ⁇ -N- [4-(2- phenylethynyl)phenyl]acetamide, 2- ⁇ [(4-methylphenyl)methyl]amino ⁇ -N-[4-(2-phenyl- ethynyl)phenyl]acetamide, 4-phenyl-l-(trifluoromethyl)benzene, l-butyl-4-phenyl- benzene, 2-(cyclohexylamino)-N-[4-(2-phenylethynyl)phenyl]acetamide, 2-(ethylmethyl- amino)-N-[4-(2-phenylethy
  • heteroarylaryl refers to a biaryl group where one of the aryl groups is a heteroaryl group.
  • exemplary heteroarylaryl groups include, for example, 2-phenylpyridine, phenylpyrrole, 3-(2-phenylethynyl)pyridine, phenylpyrazole, 5-(2-phenylethynyl)-l,3-dihydropyrimidine-2,4-dione, 4-phenyl-l,2,3-thiadiazole, 2-(2- phenylethynyl)pyrazine, 2-phenylthiophene, phenylimidazole, 3-(2-piperazinylphenyl)- furan, 3-(2,4-dichlorophenyl)-4-methylpyrrole, and the like.
  • Preferred optionally substituted heteroarylaryl groups include: 5-(2-phenylethynyl)pyrimidine-2-ylamine, l-methoxy-4-(2-thienyl)benzene, l-methoxy-3-(2-thienyl)benzene, 5-methyl-2-phenyl- pyridine, 5-methyl-3-phenylisoxazole, 2-[3-(1rifluoromethyl)phenyl] ⁇ uran, 3-fluoro-5- (2-furyl)-2-methoxy- 1 -prop-2-enylbenzene, (hydroxyimino)(5-phenyl(2-thienyl))- methane, 5-[(4-methylpiperazinyl)methyl]-2-phenylthiophene, 2-(4-ethylphenyl)thio- phene, 4-methylthio-l-(2-thienyl)benzene, 2-(3-nitrophenyl)thiophene, (tert-but
  • heteroarylheteroaryl refers to a biaryl group where both of the aryl groups is a heteroaryl group.
  • heteroarylheteroaryl groups include, for example, 3-pyridylimidazole, 2-imidazolylpyrazine, and the like.
  • Preferred optionally substituted heteroarylheteroaryl groups include: 2-(4-piperazinyl-3-pyridyl)furan, diethyl-
  • Optionally substituted or “substituted” refers to the replacement of hydrogen with a monovalent or divalent radical. Suitable substitution groups include, for example, hydroxyl, nitro, amino, imino, cyano, halo, thio, sulfonyl, thioamido, amidino, imidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfonamido, carboxyl, formyl, loweralkyl, haloloweralkyl, loweralkyamino, haloloweralkylamino, loweralkoxy, haloloweralkoxy, loweralkoxyalkyl, alkylcarbonyl, aminocarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, alkylthio, aminoalkyl, cyanoalkyl, aryl
  • substitution group can itself be substituted.
  • the group substituted onto the substitution group can be carboxyl, halo; nitro, amino, cyano, hydroxyl, loweralkyl, loweralkoxy, aminocarbonyl, -SR, thioamido, -SO 3 H, -SO 2 R or cycloalkyl, where R is typically hydrogen, hydroxyl or loweralkyl.
  • substituted substituent when the substituted substituent includes a straight chain group, the substitution can occur, either within the chain (e.g., 2-hydroxypropyl, 2-aminobutyl, and the like) or at the chain terminus (e.g., 2-hydroxyethyl, 3-cyanopropyl, and the like).
  • Substituted substitutents can be straight chain, branched or cyclic arrangements of covalently bonded carbon or heteroatoms.
  • carboxy-protecting group refers to a carbonyl group which has been esterified with one of the commonly used carboxylic acid protecting ester groups employed to block or protect the carboxylic acid function while reactions involving other functional sites of the compound are carried out.
  • a carboxy protecting group can be attached to a solid support whereby the compound remains connected to the solid support as the carboxylate until cleaved by hydrolytic methods to release the corresponding free acid.
  • Representative carboxy-protecting groups include, for example, loweralkyl esters, secondary amides and the like.
  • pharmaceutically acceptable salts refers to the nontoxic acid or alkaline earth metal salts of the compounds of Formula I.
  • salts can be prepared in situ during the final isolation and purification of the compounds of Formula I, or by separately reacting the base or acid functions with a suitable organic or inorganic acid or base, respectively.
  • Representative salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-napth- alenesulfonate, o
  • the basic nitrogen-containing groups can be quaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
  • loweralkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides
  • dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates
  • long chain halides such
  • acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulfuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, methanesulfonic acid, succinic acid and citric acid.
  • Basic addition salts can be prepared in situ during the final isolation and purification of the compox ⁇ nds of formula (I), or separately by reacting carboxylic acid moieties with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia, or an organic primary, secondary or tertiary amine.
  • Pharmaceutically acceptable salts include, but are not limited to, cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, aluminum salts and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
  • Other representative organic amines useful for the formation of base addition salts include diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.
  • ester refers to esters, which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
  • Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
  • esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
  • prodrugs refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
  • cancer refers to cancer diseases that can be beneficially treated by the inhibition of Raf kinase, including, for example, solid cancers, such as carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon), myeloid disorders (e.g., myeloid leukemia) and adenomas (e.g., villous colon adenoma).
  • solid cancers such as carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon), myeloid disorders (e.g., myeloid leukemia) and adenomas (e.g., villous colon adenoma).
  • Ari may be, for example, phenyl which may be substituted by one or more substitutents selected from the group consisting of hydroxyl, nitro, cyano, halo, and substituted or unsubstituted amino, imino, thio, sulfonyl, thioamido, amidino, imidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfonamido, carboxyl, formyl, loweralkyl, haloloweralkyl, loweralkyamino, haloloweralkylamino, loweralkoxy, haloloweralkoxy, loweralkoxyalkyl, alkylcarbonyl, aminocarbonyl, loweralkylaminocarbonyl, heterocycloalkylloweralkylaminocarbonyl, carboxylloweralkylaminocarbonyl,
  • Ar 2 may be, for example, pyridyl, which may be substituted by one or more substitutents selected from the group consisting of hydroxyl, nitro, cyano, halo, and substituted or unsubstituted amino, imino, thio, sulfonyl, thioamido, amidino, imidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfonamido, carboxyl, formyl, loweralkyl, .
  • substitutents selected from the group consisting of hydroxyl, nitro, cyano, halo, and substituted or unsubstituted amino, imino, thio, sulfonyl, thioamido, amidino, imidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfona
  • haloloweralkyl loweralkyamino, haloloweralkylamino, loweralkoxy, haloloweralkoxy, loweralkoxyalkyl, alkylcarbonyl, aminocarbonyl, loweralkylaminocarbonyl, heterocycloalkylloweralkylaminocarbonyl, carboxylloweralkylaminocarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, alkylthio, aminoalkyl, cyanoalkyl, aryl and the like.
  • the compounds of the invention include, for example, 4-[(2- ⁇ [4-chloro-3-(trifluoromethyl)phenyl]amino ⁇ -lH-benz- imidazol-6-yl)oxy]-N-methylpyridine-2-carboxamide, 4-( ⁇ 2-[(3-chlorophenyl)amino]- lH-benzimidazol-6-yl ⁇ oxy)-N-methylpyridine-2-carboxamide, 4-( ⁇ 2-[(4-bromophenyl)- amino]-lH-benzimidazol-6-yl ⁇ oxy)-N-methylpyridine-2-carboxamide, 4-( ⁇ 2-[(3-chloro- 4-fluorophenyl)amino]-lH-benzimidazol-6-yl ⁇ oxy)-N-methylpyridine-2-carboxamide, N-methyl-4- ⁇ [2-(phenylamino)-lH-benzimidazol-6-yl]oxy ⁇ pyridine
  • the present invention relates to the processes for preparing the compounds of Formulas I, II, III, IV and V and to the synthetic intermediates useful in such processes.
  • the compounds of the invention comprise asymmetrically substituted carbon atoms.
  • Such asymmetrically substituted carbon atoms can result in the compounds of the invention comprising mixtures of stereoisomers at a particular asymmetrically substituted carbon atom or a single stereoisomer.
  • racemic mixtures, mixtures of diastereomers, as well as single diastereomers of the compounds of the invention are included in the present invention.
  • S and R configuration, as used herein, are as defined by the IUPAC 1974 RECOMMENDATIONS FOR SECTION E, FUNDAMENTAL STEREOCHEMISTRY, Pure Appl. Chem. 45:13-30 (1976).
  • the terms ⁇ and ⁇ are employed for ring positions of cyclic compounds.
  • the ⁇ -side of the reference plane is that side on which the preferred substituent lies at the lower numbered position. Those substituents lying on the opposite side of the reference plane are assigned ⁇ descriptor. It should be noted that this usage differs from that for cyclic stereoparents, in which " ⁇ ” means “below the plane” and denotes absolute configuration.
  • ⁇ and ⁇ configuration are as defined by the CHEMICAL ABSTRACTS INDEX GUIDE-APPENDIX IV (1987) paragraph 203.
  • the present invention also relates to the processes for preparing the compounds of the invention and to the synthetic intermediates useful in such processes, as described in detail below. Synthetic Methods
  • Compounds of the invention containing a benzimidazole core may be prepared using a number of methods familiar to one of skill in the art.
  • suitably functionalized diamines may be coupled with various thioisocyanates to form the intermediate thioureas.
  • Cyclization to form the benzimidazole moiety may be effected under known conditions such as with treatment carbodiimides or alkyl halides as in the following schemes.
  • diamines may be reacted sequentially with carbonyl diimidazole and phosphoryl chloride followed by coupling with the appropriate amine.
  • Compounds containing a benzothiazole core may also be prepared according to known methods.
  • An ortho-halothioisocyanate may be reacted with an amine to form a thiourea. Reduction with NaH then allows formation of the thiazole ring.
  • Benzothiazoles may generally be substituted in accordance with the present invention, such as through the following synthetic pathway:
  • Benzoxzoles may generally be synthesized through the following pathway:
  • the compounds of the invention are useful in vitro or in vivo in inhibiting the growth of cancer cells.
  • the compounds may be used alone or in compositions together with a pharmaceutically acceptable carrier or excipient.
  • suitable pharmaceutically acceptable carriers or excipients include, for example, processing agents and drug delivery modifiers and enhancers, such as, for example, calcium phosphate, magnesium stearate, -talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, hydroxypropyl- ⁇ -cyclodextrin, polyvinyl- pyrrolidinone, low melting waxes, ion exchange resins, and the like, as well as combinations of any two or more thereof.
  • Other suitable pharmaceutically acceptable excipients are described in "Remington's Pharmaceutical Sciences," Mack Pub. Co., New Jersey (1991), incorporated herein by reference.
  • Effective amounts of the compounds of the invention generally include any amount sufficient to detectably inhibit Raf activity by any of the assays described herein, by other Raf kinase activity assays known to those having ordinary skill in the art or by detecting an inhibition or alleviation of symptoms of cancer.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. The therapeutically effective amount for a given situation can be readily determined by routine experimentation and is within the skill and judgment of the ordinary clinician.
  • a therapeutically effective dose will generally be a total daily dose administered to a host in single or divided doses may be in amounts, for example, of from 0.001 to 1000 mg/kg body weight daily and more preferred from 1.0 to 30 mg/kg body weight daily. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.
  • the compounds of the present invention may be administered orally, parenterally, sublingually, by aerosolization or inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or ionophoresis devices.
  • parenteral includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
  • mjectable preparations for example, sterile mjectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile mjectable preparation may also be a sterile mjectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-propanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols, which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
  • a suitable nonirritating excipient such as cocoa butter and polyethylene glycols, which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
  • Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
  • the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweetening, flavoring, and perfuming agents.
  • the compounds of the present invention can also be administered in the form of liposomes.
  • liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium.
  • any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used.
  • the present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like.
  • the preferred lipids are the phospholipids and phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.W., p. 33 et seq. (1976).
  • the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more other agents used in the treatment of cancer.
  • agents useful in combination with the compounds of the invention for the treatment of cancer include, for example, irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib (Gleevec), anthracyclines, rituximab, trastuzumab, as well as other cancer chemotherapeutic agents.
  • the compounds of the invention and the other anticancer agents can be administered at the recommended maximum clinical dosage or at lower doses. Dosage levels of the active compounds in the compositions of the invention may be varied so as to obtain a desired therapeutic response depending on the route of administration, severity of the disease and the response of the patient.
  • the combination can be administered as separate compositions or as a single dosage form containing both agents.
  • the therapeutic agents can be formulated as separate compositions, which are given at the same time or different times, or the therapeutic agents, can be given as a single composition.
  • Antiestrogens such as tamoxifen, inhibit breast cancer growth through induction of cell cycle arrest, that requires the action of the cell cycle inhibitor p27Kip.
  • tamoxifen activation of the Ras-Raf-MAP Kinase pathway alters the phosphorylation status of p27Kip such that its inhibitory activity in arresting the cell cycle is attenuated, thereby contributing to antiestrogen resistance (Donovan et al, J. Biol. Chem. 275:40888, 2001).
  • As reported by Donovan et al. inhibition of MAPK signaling through treatment with MEK inhibitor changed the phosphorylation status of p27 in hormone refactory breast cancer cell lines and in so doing restored hormone sensitivity.
  • the compounds of formulas (I), (II), (III), (IN) and (V) may be used in the treatment of hormone dependent cancers, such as breast and prostate cancers, to reverse hormone resistance commonly seen in these cancers with conventional anticancer agents.
  • chromosomal translocation is responsible for the constitutively activated BCR-AB1 tyrosine kinase.
  • CML chronic myelogenous leukemia
  • the afflicted patients are responsive to Geevec, a small molecule tyrosine kinase inhibitor, as a result of inhibition of Abl kinase activity.
  • Geevec a small molecule tyrosine kinase inhibitor
  • many patients with advanced stage disease respond to Gleevec initially, but then relapse later due to resistance-conferring mutations in the Abl kinase domain.
  • BCR-Avl employs the Raf kinase pathway to elicit its effects.
  • the compounds of formulas (I), (II), (III), (IV) and (V) are used in combination with at least one additional agent, such as Gleevec, in the treatment of hematological cancers, such as chronic myelogenous leukemia (CML), to reverse or prevent resistance to the at least one additional agent.
  • additional agent such as Gleevec
  • CML chronic myelogenous leukemia
  • Examples 2-108 The compounds shown in the following Table 1 (Examples 2-108) were prepared from following the procedure described for Example 1.
  • Step 2 Synthesis of 4-( ⁇ 2-[(4-bromophenyl)amino]-l-methyl-lH-benzimidazol- 5-yl ⁇ oxy)-N-methylpyridine-2-carboxamide: A solution of the diamine 4- ⁇ [3-amino-4-(methylamino)phenyl]oxy ⁇ -N- methylpyridine-2-carboxamide (leq) in methanol was treated with 4-bromophenyl- isothiocyanate (leq) and stirred at 60°C-65°C for 2 hours. The reaction mixture was cooled down to room temperature and methyl iodide (leq) was added and stirred overnight at 60°C.
  • the resulting reaction mixture was cooled with an ice bath, and stirred vigorously for 1.5 h at rt. 3 ' 5 ' 6
  • the reaction was then poured over ice water and the resulting phases were partitioned and separated.
  • the aqueous phase was extracted with CH 2 C1 2 (3 X 100 mL) and the combined organic layers were washed with brine (2 X 100 mL), dried (MgSO 4 ), and concentrated.
  • Examples 121-384 The compounds shown in the following Table 3 (Examples 121-384) were prepared from following the procedure described for Example 120a.
  • Step 8 Synthesis of 4- ⁇ 2-[(4-bromophenyl)amino]-l-methylbenzimidazol-5-yl- oxy ⁇ pyridine-2-carboxylic acid
  • Potassium carbonate (9.00g) was dried in vacuo with heating, cooled to RT under nitrogen. 4-amino-3-ntrophenol (3.355 g), 4-chioro-2-cyanopyridine (3.00 g) and DMSAO (30 mL, anhydrous) were added. The system was stirred under nitrogen as it was heated to 103°C, and held at this temperature 1 hr. The reaction was then cooled to RT, poured onto ice/H 2 O (500 mL) the precipitate was collected, washed (H 2 O), dissolved (EtOAc), dried (Na 2 SO 4 ), filtered and stripped to a solid.
  • Step 1 Synthesis of 2-amino-4-methoxyphenol
  • MS: MH+ 140.
  • Step 2 Synthesis of 5-methoxybenzoxazole-2-thiol
  • 2-amino-4-methoxyphenol(leq) and O-ethylxanthic acid, potassium salt (l.leq) in pyridine was refluxed for two hours.
  • the resultant mixture was poured in to ice/water containing hydrochloric acid to yield a 5-methoxybenzoxazole-2- thiol as a tan solid.
  • MS: MH+ 182
  • Step 3 Synthesis of 2-chloro-5-methoxybenzoxazole
  • the mixture containing 5-methoxybenzoxazole-2-thiol was heated in thionyl chloride with a drop of DMF.
  • the resultant mixture was concentrated and partitioned between ethyl acetate and water.
  • the organic layer was washed with brine and dried and concentrated. Purification on a silica gel column gave 2-chloro-5-methoxybenzoxazole ' as a white solid.
  • MS: MH+ 184.
  • Step 1 Synthesis of 4- ⁇ 2-[(4-bromo-3-methylphenyl)amino]-l-methyl- benzimidazol-5-yloxy)pyridine-2-carboxylic acid
  • 4-bromo-3-methylbenzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS.
  • iodomethane (leq) and heated to 60°C for 2 h.
  • Step 1 Synthesis of 4- ⁇ l-methyl-2-[(4-methylphenyl)amino]benzimidazol-5- yloxy)pyridine-2-carboxylic acid
  • 4-methylbenzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS.
  • iodomethane (leq) and heated to 60°C for 2 h.
  • Example 627 Step 1. Synthesis of [4-(2- ⁇ [4-(chloromethyl)phenyl] carbonylamino)- 1- methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-methylcarboxamide A solution of sodium thiocyanate (leq) in acetone was added slowly in to a solution of 4-(chloromethyl)benzoylchloride (leq) in acetone at 0°C. The mixture was then filtered in to a solution of ⁇ 4-[3-amino-4-(methylamino)phenoxy](2-pyridyl) ⁇ -N- methylcarboxamide (leq) in acetone.
  • N-acylthiourea was followed by LC/MS.
  • the mixture was concentrated and taken in tetrahydrofuran and to it was added l-ethyl-(3-dimethylaminopropyl)carbodimidehydrochloride (2eq) and stirred at ambient temperature for 16 h.
  • the mixture was concentrated and partitioned between ethyl acetate and water.
  • the organic layer was then dried and concentrated to yield [4-(2- ⁇ [4- (chloromethyl)phenyl]carbonylamino)-l-methylbenzimidazol-5-yloxy)(2-pyridyl)]-N- methylcarboxamide.
  • MS: MH + 449. , Step 2.
  • Example 628 Step 1. Synthesis of N-methyl[4-(l -methyl-2- ⁇ 2- ⁇ 4-[(4-methylpiperazinyl)- methylphenyl ⁇ -benzimidazol-5-yloxy)(2-pyridyl)] carboxamide
  • ⁇ 4-[3-amino-4-(methylamino)phenoxy](2-pyridyl) ⁇ -N- methylcarboxamide (leq) in tetrhydrofuran was added 4-(chloromethyl)benzoylchloride (leq) and triethylamine (2eq). N-acylation is completed in 0.5 h.
  • the reaction mixture was concentrated and partitioned between ethyl acetate and water.
  • Step 3 Synthesis of 4-(4-(3-pyridyl)pyrimidin-2-yloxy)benzene-l,2-diamine
  • the mixture containing 2-nitro-4-(4-(3- ⁇ yridyl)pyrimidin-2-yloxy)phenylamine in methanol with catalytic amount of 10% Pd/C was hydrogenated until disappearance of yellow color to yield 4-(4-(3-pyridyl)pyrimidin-2-yloxy)benzene-l,2-diamine.
  • MS: MH + 279.
  • Step 3 Synthesis of ⁇ 4-[(4-methylpiperazinyl)methyl]phenyl ⁇ -N-[5-(4-(3- pyridyl)pyrimidin-2-yloxy)benzimidazol-2-yl]carboxamide.
  • a solution of sodium thiocyanate (leq) in acetone was added slowly in to a solution of 4-(chloromethyl)benzoylchloride (leq) in acetone at 0°C. The mixture was then filtered in to a solution of 4-(4-(3-pyridyl)pyrimidin-2-yloxy)benzene-l,2-diamine (leq) in acetone.
  • N-acylthiourea was followed by LC/MS.
  • the mixture was concentrated and taken in tetrahydrofuran and to it was added l-ethyl-(3- dimethylaminopropyl)carbodimidehydrochloride (2eq) and stirred at ambient temperature for 16 h.
  • the mixture was concentrated and partitioned between ethyl acetate and water.
  • the organic layer was then dried and concentrated to yield [4-(chloromethyl)phenyl]-N- [5-(4-(3-pyridyl)pyrimidin-2-yloxy)benzimidazol-2-yl]carboxamide.
  • Step 3 Synthesis of 4-[(4-ethylpiperazinyl)methyl]benzeneisothiocyanate
  • sodium bicarbonate (2eq) and thiophosgene (2eq) The mixture was brought to ambient temperature and concentrated and partitioned between ethyl acetate and water. The organic layer was dried with sodium bicarbonate and sodium sulfate and concentrated to yield 4-[(4-ethylpiperazinyl)methyl]benzeneisotl ⁇ iocyanate.
  • MS: MH 261.
  • Step 2 Synthesis of ⁇ 4-[4-amino-3-(methylamino)phenoxy](2-pyridyl) ⁇ -N- methylcarboxamide
  • the mixture containing 5-fluro-2-nitrophenylamine (leq), Potassium bis(trimethylsilyl)amide (2eq) was stirred in dimethylformamide for 2 hours at room temperature.
  • To this mixture was added (3-hydroxyphenyl)-N-methylcarboxamide (leq) and Potassium carbonate (1.2eq) and stirred at 90°C for 16 h.
  • the reaction mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was separated and washed with brine, dried, filtered and concentrated in vacuum to give brown solid.
  • Step 1 Synthesis of ((5-aminobenzimidazol-2-yl)(4-bromophenylamine)
  • a solution of the 4-nitrobenzene-l,2-diamine in methanol was treated with 4- bromo phenyl isothiocyanate (leq) and stirred at 60°C for 2 hours.
  • the reaction mixture was cooled down to room temperature and iodomethane (leq) was added and stirred overnight at 60°C.
  • the reaction was concentrated and purified on silica gel to yield (4- bromophenyl)(5-nitrobenzimidazol-2-yl)amine.
  • the product was taken in methanol and hydrogenated with catalytic amount of 10%Pd/C to give ((5-aminobenzimidazol-2-yl)(4- bromophenylamine).
  • MS: MH + 302.
  • Step 2 Synthesis of N-methyl[4-(l-methyl-2- ⁇ [4-(2-morpholin-4-ylethyl)phenyl]- amino-benzimidazol-5-oxy)(2-pyridyl)] carboxamide CHIR- 164277
  • 4-( ⁇ 1 -methyl-5-[2-(N-methylcarbamoyl)(4-pyridyloxy))]benzimidazol-2-yl ⁇ - amino)benzoic acid (leq) in tetrahydrofuran was added morpholine (2eq) and N,N- diisopropylethylamine(4eq) and HBTU(2eq) and stir at ambient temperature for 16 h.
  • Example 700 Step 1 Synthesis of 4- ⁇ 2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-l- methylbenzimidazol-5-yloxy)pyridine-2-carboxylic acid
  • Example 703 Synthesis of ⁇ 4-[2-methoxy-4-(methylamino)-5-nitrophenoxy](2-pyridyl) ⁇ -N- methylcarboxamide
  • Step 2 Synthesis of methyl(6-nitro(2 h-benzo[3,4-d]l,3-dioxalan-5-yl)amine
  • methyl amine in ether and ethanol 1.5:1
  • 5,6- dinitro-2 h-benzol[d]l,3-dioxalane was added to a stirred solution of methyl amine in ether and ethanol (1.5:1)
  • the solvent was evaporated under vacuum and the solid was washed with water and dried to give methyl(6-nitro(2 h-benzo[3.4-d]l,3-dioxaln-5-yl))amine.
  • Step 4 Synthesis of ⁇ 4-[2-methoxy-4-(methylamino)-5-nitrophenoxy](2- pyridyl) ⁇ -N-methylcarboxamide
  • potassium-t-butoxide 1.2eq
  • Step 5 Synthesis of ⁇ 4-[3-amino-6-methoxy-4-(methylamino)phenoxy](2- pyridyl) ⁇ -N-methylcarboxamide
  • methanol was hydrogenated with 10%Pd/C.
  • the catalyst was filtered off and the solvent was concentrated to yield ⁇ 4-[3-amino-6-methoxy-4- (methylamino)phenoxy] (2-pyridyl) ⁇ -N-methylcarboxamide.
  • Step 6 Synthesis of methyl5-[3-amino-4-(methylamino)phenoxy]pyridine-3- carboxylate
  • the mixture containing methyl4-[4-(amethylamino)-3-nitrophenoxy]pyridine-3- carboxylate was hydrogenated with 10%Pd/C to yield methyl5-[3-amino-4- (methylamino)phenoxy]pyridine-3 -carboxylate.
  • MS: MH+ 273.
  • Step 7 Synthesis of methyl5- ⁇ 2-[(4-bromophenyl)amino]-l-methylbenzimidazol- 5-yloxy ⁇ pyridine-3 -carboxylate
  • methanol 8 ml
  • 4-bromophenylisothiocyanate leq
  • the reaction mixture was cooled down to room temperature and methyl iodide (leq) was added and stirred overnight at 60°C.
  • Step 8 Synthesis of (5- ⁇ 2-[(4-bromophenyl)amino]-l-methylbenzimidazol-5- yloxy)-(3-pyridyl))-N-methylcarboxamide
  • methyl5- ⁇ 2-[(4-bromophenyl)amino]-l-methylbenzimidaz ⁇ l-5- yloxy ⁇ pyridine-3-carboxylate was stirred at ambient temperature for 16 h.
  • Step 3 Synthesis of 2-(Dimethylamino)-5-isothiocynanate pyridine: 2-(Dimethylamino)-5-aminopyridine (1.0 eq) was taken up in acetone and cooled to 0C. Thiophosgene (1.6 eq) was added dropwise and the reaction was stirred for 30 minutes at 0C before the excess thiophosgene and acetone were removed by evaporation under reduced pressure.
  • reaction flask was flame dried and cooled under nitrogen.
  • a solution of 8 (l.Oeq) in THF was added to the reaction flask followed by triisopropyl borate (1.2eq).
  • the reaction solution was placed in a dry ice/acetone bath to stir at approximately -72°C.
  • N-butyl lithium (1.5eq, 2.5M solution in hexane) was added drop wise over 40 minutes.
  • the reaction solution was stirred for another 30 minutes in the dry ice/acetone bath.
  • the reaction solution was then transferred to a saturated NaCl/dry ice bath to stir at approx. -25°C and stirred for 20 minutes before 2N HCI (2.0eq) was added.
  • the reaction solution was then removed from the bath to stir and warm to RT.
  • Step 1 4-[2-(3-Isopropyl-phenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]- pyridine-2-carboxylic acid (2-phenylmethanesulfonylamino-ethyl)-amide
  • Example 804-812 were prepared from following the procedure described for Example 803.
  • Step 1 4- ⁇ 2-(3-(l-Benzyl-lH- [1,2,3] triazol-4-yl)-phenyl amino] -1 -methyl- 1H- benzoimidazol-5-yloxy ⁇ -pyridine-2-carboxylic acid methyl amide
  • benzyl azide (leq) in t-butanol (0.1M) was added sodium ascorbate (0.05eq), and copper (II) sulfate pentahydrate (O.Oleq).
  • the resulting mixture was allowed to stir for 1 hour at room temperature. The mixture was then diluted with water and the solid collect via suction filtration.
  • Step 4 Synthesis of 4-[2-(2,3-Dihydro-lH-indol-6-ylamino)-l-methyl-lH- benzoimidazol-5-yloxy]-pyridine-2-carboxylic acid methylamide.
  • Step 1 Synthesis of 4- ⁇ 1 -Methyl-2- [l-(4-morpholin-4-yl-butylryl)-2,3-dihydro- lH-indol-6-ylamino]-lH-benzoimidazol-5-yloxy ⁇ -pyridine-2-carboxylic acid methylamide To .
  • Example 816-819 were prepared from following the procedure described for Example 815.
  • Step 4 4-[l-Methyl-2-(3-trifluoromethylsulfanyl-phenylamino)-lH- benzoimidazol-5-yloxy]-pyridine-2-carboxylic acid (2-hydroxy-ethyl)-amide:
  • Step 1 Synthesis of 4-[2-(4-Fluoro-phenylamino)-l-methyl-lH-benzoimidazol-5- yloxy]- ⁇ yridine-2-carboxylic acid tert-butyl ester: A round bottom flask was charged with 4-fluorophenylisothiocyanate (leq), 4-(3- Amino-4-methylamino-phenoxy)-pyridine-2-carboxylic acid tert-butyl ester (leq), and MeOH. The reaction was maintained stirring at room temperature overnight. Ferric chloride, (1.5eq) was added and the resulting mixture was stirred overnight. The reaction was partitioned with EtOAc and water, and filtered through Celite.
  • Step 2 Synthesis of 4-[2-(4-Fluoro-phenylamino)-l-methyl-lH-benzoimidazol-5- yloxy]-pyridine-2-carboxylic acid: A stirring solution of 4-[2-(4-Fluoro-phenylamino)-l-methyl-lH-benzoimidazol-
  • a 250 mL reaction tube was charged with benzyl alcohol 1 (1.0 g, 3.6 mmol), MnO 2 (4.7 g, 54 mmol) and EtOAc (20 mL). The reaction tube was sealed was heated to 120 °C with stirring for 2 h. The reaction was allowed to cool to rt, then filtered through Celite and washed successively with EtOAc, MeOH, and EtOH.
  • a reaction tube was charged with suspension of 1 (330 mg, 1.15 mmol) and Lindlar catalyst (245 mg, 10 mol %) in methanol (5 mL), sealed, and placed on a Parr shaker. The reaction was pressurized with H 2 (60 psi) and maintained for 1 h. The reaction was filtered through Celite and the remaining solids were washed with MeOH. The combined organics were concentrated to give 2 as a brown semi-solid which was taken on without further purification.
  • Example 991 Synthesis of Benzyl Alcohol Series: ⁇ 4- [2-(4-Chloro-phenylamino)- 1 - methyl- 1 H-benzoimidazol-5-yloxy] -pyridin-2-yl ⁇ -methanol Step 1. Synthesis of [4-(3-Amino-4-methylamino-phenoxy)-pyridin-2-yl]- methanol
  • Step 2 Synthesis of ⁇ 4-[2-(4-Chloro-phenylamino)- 1 -methyl- 1 H-benzoimidazol- 5-yloxy]-pyridin-2-yl ⁇ -methanol.
  • Example 999 4-[2-(4-Bromo-phenvlamino)-l-methvl-lH-benzoimidazol-5-vloxy1- pyridine-2-carboxylic acid phenylamide.
  • Procedure for Synthesis of Anilide Series (4-Br and 3-iPr west-ends) Synthesis of 4-[2-(4-Bromo-phenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]- pyridine-2-carboxylic acid phenylamide.
  • Example 1014 4- [ 1 -Methyl-2-(3 -phenoxy-phenylamino)- 1 H-benzoimidazol-5-yloxy]- pyridine-2-carboxylic acid methylamide Step 1. Synthesis of 3 -phenoxyphenylisothiocyanate
  • Example 1031 4-[l-Methyl-2-(4-methylbenzylamino)-lH-benzoimidazol-5-yloxy]-pyridine-2- carboxylic acid methylamide.
  • Example 1032 4-[2-(4-Bromophenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]-pyridine-2- carboxylic acid (3 -pyrrolidin- l-yl-propyl)-amide.
  • Step 2 (4-Bromophenyl)-[ 1 -methyl-5-(2-methylaminomethyl-pyridin-4-yloxy)- 1H benzoimidazol-2-yl]-amine.
  • Example 1053 [5-(2-Aminomethyl-pyridin-4-yloxy)- 1 -methyl- 1 H-benzoimidazol-2 ⁇ yl]-(4- bromophenyl)-amine.
  • Example 1054 ⁇ 4-[2-(4-Bromophenylamino)- 1 -methyl- 1 H-benzoimidazol-5-yloxy]-pyridin-2-yl- methyl]-carbamic acid methyl ester.
  • Example 1056 4-[2-(3 -Ethylphenylamino)- 1 -methyl- 1 H-benzoimidazol-5-yloxy]- pryidine-2-carboxylic acid [3-(2-oxo-pyrrolidin-y ⁇ )-propyl]-amide.
  • Acid chloride 1 (2.12 g, 10 mmol) was treated with N-methylmorpholine (4.5 mL, 41 mmol) and N-(3-aminopropyl)-pyrrolidinone 2 (1.6 mL, 11 mmol) in dry THF (40 mL). The reaction was maintained overnight and concentrated. The residue was
  • Step 2 4-(4-Methylamino-3-nitrophenoxy)-pyridine-2-carboxylic acid [3-(2-oxo- pyrrolidin-yl)-propyl]-amide
  • Amide 3 can be purified by flash chromatography (95:5 CH 2 Cl 2 -MeOH). It can also be further purified by recrystallization from MeCN.
  • Step 3 4-(3-Amino-4-methylamino-phenoxy)-pyridine-2-carboxlic acid [3-(2- oxo-pyrrolidin-yl)-propyl]-amide
  • Step 4 4-[2-(3-Ethylphenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]- pryidine-2-carboxylic acid [3-(2-oxo-pyrrolidin-yl)-propyl]-amide.
  • Step 2 4,4'-dimethylamino-3,3'-diamino diphenyl ether
  • Example 1100 bis-5- [2-(3 -Bromophenylamino)- 1 -methyl- 1 H-benzoimidazole] -ether.
  • Example 1113 4-[2-(3-Furan-3-yl-phenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]- pyrindine-2-carboxylic acid methyl amide.
  • Assay buffer 50 mM Tris, pH 7.5, 15 mM MgCl 2 , 0.1 mM EDTA, 1 mM DTT
  • Wash buffer 25 mM Hepes, pH 7.4, 50 mM sodium pyrophosphate, 500 mM NaCl
  • Raf and Mek were combined at 2X final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl 2 . 0.1 mM EDTA and 1 mM DTT) and dispensed 15 ⁇ l per well in polypropylene assay plates (Falcon U-bottom polypropylene 96 well assay plates #35-1190. Background levels are determined in wells containing Mek and DMSO without Raf.
  • the activity of various isoforms of Raf serine/threonine kinases can be measured by providing ATP, MEK substrate, and assaying the transfer of phosphate moiety to the
  • Recombinant isoforms of Raf were obtained by purification from sf9 insect cells infected with a human Raf recombinant baculovirus expression vector.
  • Recombinant kinase inactive MEK was expressed in E. coli and labeled with Biotin post purification.
  • test compounds were serially diluted in DMSO then mixed with Raf (0.50 nM) and kinase inactive biotin-MEK (50 nM) in reaction buffer plus ATP (1 uM). Reactions were subsequently incubated for 2 hours at room temperature and stopped by the addition of 0.5 M EDTA.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

New substituted benz-azole compounds of formula (I), compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

Description

SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS
FIELD OF THE INVENTION The present invention relates to new substituted benz-azole-like compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cancer.
BACKGROUND OF THE INVENTION The Raf serine/threonine kinases are essential components of the Ras/Mitogen-
Activated Protein Kinase (MAPK) signaling module that controls a complex transcriptional program in response to external cellular stimuli. Raf genes code for highly conserved serine-threonine-specific protein kinases which are known to bind to the ras oncogene. They are part of a signal transduction pathway believed to consist of receptor tyrosme kinases, p21 ras, Raf protein kinases, Mekl (ERK activator or MAPKK) kinases and ERK (MAPK) kinases, which ultimately phosphorylate transcription factors. In this pathway Raf kinases are activated by Ras and phosphorylate and activate two isoforms of Mitogen-Activated Protein Kinase Kinase (called Mekl and Mek2), that are dual specificity threonine/tyrosine kinases. Both Mek isoforms activate Mitogen Activated Kinases 1 and 2 (MAPK, also called Extracellular Ligand Regulated Kinase 1 and 2 or Erkl and Erk2). The MAPKs phosphorylate many substrates including transcription factors and in so doing set up their transcriptional program. Raf kinase participation in the Ras/MAPK pathway influences and regulates many cellular functions such as proliferation, differentiation, survival, oncogenic transformation and apoptosis. Both the essential role and the position of Raf in many signaling pathways have been demonstrated from studies using deregulated and dominant inhibitory Raf mutants in mammalian cells as well as from studies employing biochemical and genetic techniques model organisms. In many cases, the activation of Raf by receptors that stimulate cellular tyrosine phosphorylation is dependent on the activity of Ras, indicating that Ras functions upstream of Raf. Upon activation, Raf-1 then phosphorylates and activates Mekl, resulting in the propagation of the signal to downstream effectors, such as MAPK (mitogen-activated protein kinase) (Crews et al. (1993) Cell 74:215). The Raf serine/threonine kinases are considered to be the primary Ras effectors involved in the proliferation of animal cells (Avruch et al. (1994) Ti-ends Biochem. Sci. 19:279).
Raf kinase has three distinct isoforms, Raf-1 (c-Raf), A-Raf, and B-Raf, distinguished by their ability to interact with Ras, to activate MAPK kinase pathway, tissue distribution and sub-cellular localization (Marias et. Al., Biochem. J. 351: 289-305, 2000; Weber et. al., Oncogene 19:169-176, 2000; Pritchard et. al., Mol. Cell. Biol. 15:6430-6442, 1995). Raf kinases are activated by Ras and phosphorylate and activate two isoforms of Mitogen-Activated Protein Kinase Kinase (called Mekl and Mek2) that are dual specificity threonine/tyrosine kinases. Both Mek isoforms activate Mitogen Activated Kinases 1 and 2 (MAPK, also called Extracellular Ligand Regulated Kinase 1 and 2 or Erkl and Erk2). The MAPKs phosphorylate many substrates including cytosolic proteins and ETS family of transcription factors. Raf kinase participation in the Ras/MAPK pathway influences and regulates many cellular functions such as proliferation, differentiation, survival, cell cycle progression and apoptosis. Activating mutation of one of the Ras genes can be seen in -20% of all tumors and the Raf/MEK/ERK pathway is activated in -30% of all tumors (Bos et. al., Cancer Res. 49:4682-4689, 1989) (Hoshino et. al., Oncogene 18:813-822, 1999). Recent studies have shown that B-Raf mutation in the skin nevi is a critical step in the initiation of melanocytic neoplasia (Pollock et. al, Nature Genetics 25: 1-2, 2002). Furthermore, most recent studies have emerged that activating mutation in the kinase domain of B-Raf occurs in -66% of melanomas, 12% of colon carcinoma and 14% of liver cancer (Davies et. al., Nature 417:949-954, 2002) (Yuen et. al, Cancer Research 62:6451-6455, 2002) (Brose et. al., Cancer Research 62:6997-7000, 2002).
Inhibitors of Raf/MEK/ERK pathway at the level of Raf kinases can potentially be effective as therapeutic agents against tumors with over-expressed or mutated receptor tyrosine kinases, activated intracellular tyrosine kinases, tumors with aberrantly expressed Grb2 (an adapter protein that allows stimulation of Ras by the Sos exchange factor) as well as tumors harboring activating mutations of Raf itself. In the early clinical trails inhibitor of Raf-1 kinase that also inhibit B-Raf have shown promise as therapeutic agents in cancer therapy (Crump, Current Pharmaceutical Design 8: 2243-2248, 2002; Sebastien et. al., Current Pharmaceutical Design 8: 2249-2253, 2002).
Disruption of Raf expression in cell lines through the application of RNA antisense technology has been shown to suppress both Ras and Raf-mediated tumorigenicity (Kolch et al., Nature 349:416-428, 1991; Monia et al., Nature Medicine 2(6):668-675, 1996).
Several Raf kinase inhibitors have been described as exhibiting efficacy in inhibiting tumor cell proliferation in vitro and/or in vivo assays (see, e.g., U.S. Pat. Nos. 6,391,636, 6,358,932, 6,037,136, 5,717,100, 6,458,813, 6,204,467, and 6,268,391). Other patents and patent applications suggest the use of Raf kinase inhibitors for treating leukemia (see, e.g., U.S. Patent Nos. 6,268,391, and 6,204,467, and published U.S. Patent Application Nos. 20020137774; 20020082192; 20010016194; and 20010006975), or for treating breast cancer (see, e.g., U.S. Patent Nos. 6,358,932, 5,717,100, 6,458,813, 6,268,391, and 6,204,467, and published U.S. Patent Application No. 20010014679).
SUMMARY OF THE INVENTION New substituted benz-azole compounds and pharmaceutically acceptable salts thereof or esters having a solubility enhancing moieties or prodrugs thereof are provided of the formula (I):
Figure imgf000004_0001
wherem, Xi and X2 are independently selected from =N-, -NR4-, -O- or -S-, provided that if Xi is -NR4-, -O- or -S-, then X2 is =N-, or if X2 is -NRr, -O- or -S-, then X2 is =N-, and both X\ and X2 are not =N-; Y is O or S;
A]^ is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroaryUieteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;
A2 is substituted or unsubstituted heteroaryl;
Rl is O or H, and R2 is NR5 Rβ or hydroxyl; or Rj is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl;
R5 and R6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and the pharmaceutically acceptable salts, esters and prodrugs thereof.
In other embodiments, new substituted benz-azole compounds are provided of the formula (II):
Figure imgf000005_0001
wherein and Y, Arj, Ar2, Ri, R2, R3 and R4 are as defined above; and the pharmaceutically acceptable salts, esters, and prodrugs thereof. In other embodiments, new substituted benz-azole compounds are provided of the formula (III):
Figure imgf000005_0002
wherein Xl5 Arl 5 Ar2, Rl5 R2 and R3 are as defined above; and the pharmaceutically acceptable salts, esters, tautomers and. rodrugs thereof. In other embodiments, new substituted benz-azole compounds are provided of the formula (IV):
Figure imgf000006_0001
wherein Xj , Y, Ar^, Ri , R2 and R3 are as defined above; and the pharmaceutically acceptable salts, esters, tautomers and prodrugs thereof. In yet other embodiments, new substituted benz-azole compounds are provided of the formula (N):
Figure imgf000006_0002
wherein Xj, Ar1; Ri , R and R3 are as defined above; and the pharmaceutically acceptable salts, esters, tautomers and prodrugs thereof.
In other aspects, the present invention provides methods for treating Raf related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III), (IV) or (V) effective to reduce or prevent tumor growth in the subject. In yet other aspects, the present invention provides methods for treating Raf related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III), (IV) or (V) effective to reduce or prevent tumor growth in the subject in combination with at least one additional agent for the treatment of cancer. In yet other aspects, the present invention provides therapeutic compositions comprising at least one compound of formula (I), (II), (III), (IV) or (V) in combination with one or more additional agents for the, treatment of cancer, as are commonly employed in cancer therapy. The compounds of the invention are useful in the treatment of cancers, including carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon), myeloid disorders (e.g., myeloid leukemia) and adenomas (e.g., villous colon adenoma).
The invention further provides compositions, methods of use, and methods of manufacture as described in the detailed description of the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
In accordance with one aspect of the present invention, new substituted benz-azole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof are provided of the formula (I):
Figure imgf000007_0001
wherein, Xj and X2 are independently selected from =N-, -NR4-, -O- or -S-, provided that if Xι is -NR4-, -O- or -S-, then X2 is =N-, or if X2 is -NR4-, -O- or -S-, then X2 is =N-, and both Xi and X2 are not =N-;Y is O or S; Y is O or S;
Aj is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl; A2 is substituted or unsubstituted heteroaryl;
Rl is O or H, and R2 is NR5 R6 or hydroxyl; or Ri is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy; R4 is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl; R5 and R6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and Rβ are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and the pharmaceutically acceptable salts, esters and prodrugs thereof.
In other embodiments, new substituted benz-azole compounds are provided of the formula (II):
wherein and Y, Ari, Ar2, Rj, R , R3 and R4 are as defined above; and the pharmaceutically acceptable salts, esters, and prodrugs thereof. In other embodiments, new substituted benz-azole compounds are provided of the formula (III):
Figure imgf000008_0002
wherein Xl5 Arj, Ar , Ri, R2 and R3 are as defined above; and the pharmaceutically acceptable salts, esters, tautomers and prodrugs thereof. In other embodiments, new substituted benz-azole compounds are provided of the formula (IN):
Figure imgf000008_0003
wherein Xl5 Y, Ar1} R R2 and R3 are as defined above; and the pharmaceutically acceptable salts, esters, tautomers and prodrugs thereof. In yet other embodiments, new substituted benz-azole compounds are provided of the formula (N):
Figure imgf000009_0001
wherein Xι, Aτι, Rj, R2 and R3 are as defined above; and the pharmaceutically acceptable salts, esters, tautomers and prodrugs thereof.
In another aspect, the present invention provides methods of treating human or animal subjects suffering from a Raf related disorder, such as cancer. Thus, the present invention provides methods of treating a human or animal subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a compound of formula I, II, III, IV or V above, either alone or in combination with other anticancer agents.
In other aspects, the present invention provides methods for treating Raf related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III), (IV) or (V) effective to reduce or prevent tumor growth in the subject.
In yet other aspects, the present invention provides methods for treating Raf related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III), (IV) or (V) effective to reduce or prevent tumor growth in the subject in combination with at least one additional agent for the treatment of cancer. A number of suitable anticancer agents to be used as combination therapeutics are contemplated for use in the methods of the present invention. Indeed, the present invention contemplates, but is not limited to, administration of numerous anticancer agents such as: agents that induce apoptosis; polynucleotides (e.g., ribozymes); polypeptides (e.g., enzymes); drugs; biological mimetics; alkaloids; alkylating agents; antitumor antibiotics; antimetabolites; hormones; platinum compounds; monoclonal antibodies conjugated with anticancer drugs, toxins, and/or radionuclides; biological response modifiers (e.g. interferons [e.g. IFΝ-a, etc.] and interleukins [e.g. IL-2, etc.], etc.); adoptive immunotherapy agents; hematopoietic growth factors; agents that induce tumor cell differentiation (e.g. all-trans-retinoic acid, etc.); gene therapy reagents; antisense therapy reagents and nucleotides; tumor vaccines; inhibitors of angiogenesis, and the like. Numerous other examples of chemotherapeutic compounds and anticancer therapies suitable for coadministration with the disclosed compounds of formula (I), (II), (III), (IV) or (V) are known to those skilled in the art.
In preferred embodiments, anticancer agents to be used in combination with compounds of the present invention comprise agents that induce or stimulate apoptosis. Agents that induce apoptosis include, but are not limited to, radiation (e.g., W); kinase inhibitors (e.g., Epidermal Growth Factor Receptor [EGFR] kinase inhibitor, Vascular Growth Factor Receptor [VGFR] kinase inhibitor, Fibroblast Growth Factor Receptor [FGFR] kinase inhibitor, Platelet-derived Growth Factor Receptor [PGFR] I kinase inhibitor, and Bcr-Abl kinase inhibitors such as STI-571, Gleevec, and Glivec]); antisense molecules; antibodies [e.g., Herceptin and Rituxan]; anti-estrogens [e.g., raloxifene and tamoxifen]; anti-androgens [e.g., flutamide, bicalutamide, finasteride, amino- glutethamide, ketoconazole, and corticosteroids]; cyclooxygenase 2 (COX-2) inhibitors [e.g., Celecoxib, meloxicam, NS-398, and non-steroidal antiinflammatory drugs (NSAIDs)]; and cancer chemotherapeutic drugs [e.g., irinotecan (Camptosar), CPT-11, fiudarabine (Fludara), dacarbazine (DTIC), dexamethasone, mitoxantrone, Mylotarg, VP- 16, cisplatinum, 5-FU, Doxrubicin, Taxotere or taxol]; cellular signaling molecules; ceramides and cytokines; and staurosprine, and the like.
In other aspects, the present invention provides pharmaceutical compositions comprising at least one compound of formula I, II, III, TV or V together with a pharmaceutically acceptable carrier suitable for administration to a human or animal subject, either alone or together with other anticancer agents.
In other aspects, the present invention provides methods of manufacture of compounds of formula I, II, III, IV or V as described herein.
In yet other aspects, the present invention provides compounds which are inhibitors of the enzyme raf kinase. Since the enzyme is a downstream effector of p21ras, the instant inhibitors are useful in pharmaceutical compositions for human or veterinary use where inhibition of the raf kinase pathway is indicated, e.g., in the treatment of tumors and/or cancerous cell growth mediated by raf kinase. In particular, the compounds are useful in the treatment of human or animal, e.g., murine cancer, since the progression of these cancers is dependent upon the ras protein signal transduction cascade and therefore is susceptible to treatment by interruption of the cascade by inhibiting raf kinase activity. Accordingly, the compounds of the invention are useful in treating solid cancers, such as, for example, carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon, myeloid disorders (e.g., myeloid leukemia) or adenomas (e.g., villous colon adenoma).
"Raf inhibitor" is used herein to refer to a compound that exhibits an IC50 with respect to Raf Kinase activity of no more than about 100 μM and more typically not more than about 50 μM, as measured in the RafTMek Filtration Assay described generally hereinbelow. Preferred isoforms of Raf Kinase in which the compounds of the present invention will be shown to inhibit, include A-Raf, B-Raf, and C-Raf (Raf-1). "IC50" is that concentration of inhibitor which reduces the activity of an enzyme (e.g., Raf kinase) to half-maximal level. Representative compounds of the present invention have been discovered to exhibit inhibitory activity against Raf. Compounds of the present invention preferably exhibit an IC50 with respect to Raf of no more than about 10 μM, more preferably, no more than about 5 μM, even more preferably not more than about 1 μM, and most preferably, not more than about 200 nM, as measured in the Raf kinase assays described herein.
As used herein, the term "benz-azoles" includes benzimidazoles, benzothiazoles and benzoxazoles.
The phrase "alkyl" refers to alkyl groups that do not contain heteroatoms. Thus the phrase includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like. The phrase also includes branched chain isomers of straight chain alkyl groups, including but not limited to, the following which are provided by way of example: -CH(CH )2, -CH(CH3)(CH2CH3), -CH(CH2CH3)2, -C(CH3)3, -C(CH2CH3)3, -CH2CH(CH3)2, -CH2CH(CH3)(CH2CH3), -CH2CH(CH2CH3)2, -CH2C(CH3)3, -CH2C(CH2CH3)3, -CH(CH3)CH(CH3)(CH2CH3), -CH2CH2CH(CH3)2, -CH2CH2CH(CH3)(CH2CH3), -CH2CH2CH(CH2CH3)2, -CH2CH2C(CH3)3, -CH2CH2C(CH2CH3)3, -CH(CH3)CH2. CH(GH3)2, -CH(CH3)CH(CH3)CH(CH3)2, -CH(CH2CH3)CH(CH3)CH(CH3)(CH2CH3), and others. The phrase also includes cyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl and such rings substituted with straight and branched chain alkyl groups as defined above. Thus the phrase alkyl groups includes primary alkyl groups, secondary alkyl groups, and tertiary alkyl groups.
Preferred alkyl groups include straight and branched chain alkyl groups and cyclic alkyl groups having 1 to 12 carbon atoms.
As used herein "loweralkyl" includes both substituted or unsubstituted straight or branched chain alkyl groups having from 1 to 6 carbon atoms. Representative loweralkyl groups include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, trifluoromethyl, pentafluoroethyl and the like. Loweralkyl groups may be substituted, such as with halo, hydroxy, amino, nitro and/or cyano groups, and the like.
Representative of halo-substituted and hydroxy-substiruted loweralkyl include chloromethyl, trichloromethyl, chloroethyl, hydroxyethyl, and the like. Other suitable substituted loweralkyl moieties include, for example, aralkyl, aminoalkyl, aminoaralkyl, carbonylaminoalkyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, aralkylcarbonyl- aminoalkyl, aminoalkoxyalkyl and arylaminoalkyl.
"Loweralkoxy" as used herein refers to RO- wherein R is loweralkyl. Representative examples of loweralkoxy groups include methoxy, ethoxy, t-butoxy, trifluoromethoxy and the like.
As used herein, the term "halogen" or "halo" refers to chloro, bromo, fluoro and iodo groups. "Haloalkyl" refers to an alkyl radical substituted with one or more halogen atoms. The term "haloloweralkyl" refers to a loweralkyl radical substituted with one or more halogen atoms. The term "haloalkoxy" refers to an alkoxy radical substituted with one or more halogen atoms. The term "haloloweralkoxy" refers to a loweralkoxy radical substituted with one or more halogen atoms.
"Amino" refers herein to the group -NH2. The term "alkylamino" refers herein to the group -NRR' where R and R' are each independently selected from hydrogen or a lower alkyl. The term "arylamino" refers herein to the group -NRR' where R is aryl and
R' is hydrogen, a lower alkyl, or an aryl. The term "aralkylamino" refers herein to the group -NRR' where R is a lower aralkyl and R' is hydrogen, a loweralkyl, an aryl, or a loweraralkyl.
The term "alkoxyalkyl" refers to the group -aUq-O-au where aU is alkyl or alkenyl, and alk2 is alkyl or alkenyl. The term "loweralkoxyalkyl" refers to an alkoxyalkyl where alki is loweralkyl or loweralkenyl, and alk2 is loweralkyl or loweralkenyl. The term "aryloxyalkyl" refers to the group -alkyl-O-aryl. The term
"aralkoxy alkyl" refers to the group -alkylenyl-O-aralkyl, where aralkyl is a loweraralkyl. The term "alkoxyalkylamino" refers herein to the group -NR-(alkoxyalkyl), where R is typically hydrogen, loweraralkyl, or loweralkyl. The term "aminoloweralkoxy alkyl" refers herein to an aminoalkoxyalkyl in which the alkoxyalkyl is a loweralkoxyalkyl. The term "aminocarbonyl" refers herein to the group -C(O)-NH2 . "Substituted aminocarbonyl" refers herein to the group -C(O)-NRR' where R is loweralkyl and R' is hydrogen or a loweralkyl. The term "arylaminocarbonyl" refers herein to the group -C(O)-NRR' where R is an aryl and R' is hydrogen, loweralkyl or aryl. "aralkylaminocarbonyl" refers herein to the group -C(O)-NRR' where R is loweraralkyl and R' is hydrogen, loweralkyl, aryl, or loweraralkyl.
"Aminosulfonyl" refers herein to the group -S(O)2-NH2. "Substituted aminosulfonyl" refers herein to the group -S(O)2-NRR' where R is loweralkyl and R' is hydrogen or a loweralkyl. The term "aralkylaminosulfonlyaryl" refers herein to the group -aryl-S(O)2-NH-aralkyl, where the aralkyl is loweraralkyl. "Carbonyl" refers to the divalent group -C(O)-.
"Carbonyloxy" refers generally to the group -C(O)-O. Such groups include esters, -C(O)-O-R, where R is loweralkyl, cycloalkyl, aryl, or loweraralkyl. The term "carbonyloxycycloalkyl" refers generally herein to both an "carbonyloxycarbocycloalkyl" and an "carbonyloxyheterocycloalkyl", i.e., where R is a carbocycloalkyl or heterocycloalkyl, respectively. The term "arylcarbonyloxy" refers herein to the group - C(O)-O-aryl, where aryl is a mono- or polycyclic, carbocycloaryl or heterocycloaryl. The term "aralkylcarbonyloxy" refers herein to the group -C(O)-O-aralkyl, where the aralkyl is loweraralkyl.
The term "sulfonyl" refers herein to the group -SO2-. "Alkylsulfonyl" refers to a substituted sulfonyl of the structure -SO2R- in which R is alkyl. Alkylsulfonyl groups employed in compounds of the present invention are typically loweralkylsulfonyl groups having from 1 to 6 carbon atoms in its backbone structure. Thus, typical alkylsulfonyl groups employed in compounds of the present invention include, for example, methylsulfonyl (i.e., where R is methyl), ethylsulfonyl (i.e., where R is ethyl), propylsulfonyl (i.e., where R is propyl), and the like. The term "arylsulfonyl" refers, herein to the group -SO2-aryl. The term "aralkylsulfonyl" refers. herein to the group -SO2-aralkyl, in which the aralkyl is loweraralkyl. The term "sulfonamido" refers herein to -SO2NH2. As used herein, the term "carbonylamino" refers to the divalent group -NH-C(O)- in which the hydrogen atom of the amide nitrogen of the carbonylamino group can be replaced a loweralkyl, aryl, or loweraralkyl group. Such groups include moieties such as carbamate esters (-NH-C(O)-O-R) and amides -NH-C(O)-O-R, where R is a straight or branched chain loweralkyl, cycloalkyl, or aryl or loweraralkyl. The term "loweralkylcarbonylamino" refers to alkylcarbonylamino where R is a loweralkyl having from 1 to about 6 carbon atoms in its backbone structure. The term "arylcarbonylamino" refers to group -NH-C(O)-R where R is an aryl. Similarly, the term "aralkylcarbonylamino " refers to carbonylamino where R is a lower aralkyl. As used herein, the term "aminocarbonyl" refers to the divalent group -C(O)-NH- in which the hydrogen atom of the amide nitrogen of the carbonylamino group can be replaced a loweralkyl, aryl, or loweraralkyl group, as described above.
As used herein, the term "guanidino" or "guanidyl" refers to moieties derived from guanidine, H2N-C(=NH)-NH2. Such moieties include those bonded at the nitrogen atom carrying the formal double bond (the "2"-position of the guanidine, e.g., diaminomethyleneamino, (H2N)2C=NH-) and those bonded at either of the nitrogen atoms carrying a formal single bond (the "1-" and/or "3 "-positions of the guandine, e.g., H2N-C(=NH)-NH-). The hydrogen atoms at any of the nitrogens can be replaced with a suitable substituent, such as loweralkyl, aryl, or loweraralkyl. As used herein, the term "amidino" refers to the moieties R-C(=N)-NR'- (the radical being at the "N1" nitrogen) and R(NR')C=N- (the radical being at the "N2" nitrogen), where R and R' can be hydrogen, loweralkyl, aryl, or loweraralkyl.
"Cycloalkyl" refers to a mono- or polycyclic, heterocyclic or carbocyclic alkyl substituent. Typical cycloalkyl substituents have from 3 to 8 backbone (i.e., ring) atoms in which each backbone atom is either carbon or a heteroatom. The term "heterocycloalkyl" refers herein to cycloalkyl substituents that have from 1 to 5, and more typically from 1 to 4 heteroatoms in the ring structure. Suitable heteroatoms employed in compounds of the present invention are nitrogen, oxygen, and sulfur. Representative heterocycloalkyl moieties include, for example, morpholino, piperazinyl, piperadinyl and the like. Carbocycloalkyl groups are cycloalkyl groups in which all ring atoms are carbon. When used in connection with cycloalkyl substituents, the term "polycyclic" refers herein to fused and non-fused alkyl cyclic structures. The term "substituted heterocycle" or "heterocyclic group" or heterocycle as used herein refers to any 3- or 4-membered ring containing a heteroatom selected from nitrogen, oxygen, and sulfur or a 5- or 6-membered ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, or sulfur; wherein the 5-membered ring has 0-2 double bonds and the 6-membered ring has 0-3 double bonds; wherein the nitrogen and sulfur atom maybe optionally oxidized; wherein the nitrogen and sulfur heteroatoms maybe optionally quarternized; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another 5- or 6-membered heterocyclic ring independently defined above. The term "heterocycle" thus includes rings in which nitrogen is the heteroatom as well as partially and fully-saturated rings. Preferred heterocycles include, for example: diazapinyl, pyrryl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazoyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, pyrazinyl, piperazinyl, N-methyl piperazinyl, azetidinyl, N-methylazetidinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, triazolyl and benzothienyl.
Heterocyclic moieties can be unsubstituted or monosubstituted or disubstituted with various substituents independently selected from hydroxy, halo, oxo (C=O), alkylimino (RN=, wherein R is a loweralkyl or loweralkoxy group), amino, alkylamino, dialkylamino, acylaminoalkyl, alkoxy, thioalkoxy, polyalkoxy, loweralkyl, cycloalkyl or haloalkyl.
The heterocyclic groups may be attached at various positions as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein.
Figure imgf000015_0001
Figure imgf000016_0001
, as described herein.
Representative heterocyclics include, for example, imidazolyl, pyridyl, piperazinyl, azetidinyl, thiazolyl, furanyl, triazolyl benzimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, indolyl, naphthpyridinyl, indazolyl, and quinolizinyl.
"Aryl" refers to optionally substituted monocyclic and polycyclic aromatic groups having from 3 to 14 backbone carbon or hetero atoms, and includes both carbocyclic aryl groups and heterocyclic aryl groups. Carbocyclic aryl groups are aryl groups in which all ring atoms in the aromatic ring are carbon. The term "heteroaryl" refers herein to aryl groups having from 1 to 4 heteroatoms as ring atoms in an aromatic ring with the remainder of the ring atoms being carbon atoms. When used in connection with aryl substituents, the term "polycyclic aryl" refers herein to fused and norf-fused cyclic structures in which at least one cyclic structure is aromatic, such as, for example, benzodioxozolo (which has a heterocyclic structure fused to a phenyl group, i.e.,
00- , naphthyl, and the like. Exemplary aryl moieties employed as substituents in compounds of the present invention include phenyl, pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyrazinyl, triazolyl, thiophenyl, furanyl, quinolinyl, purinyl, naphthyl, benzothiazolyl, benzopyridyl, and benzimidazolyl, and the like.
"Aralkyl" refers to an alkyl group substituted with an aryl group. Typically, aralkyl groups employed in compounds of the present invention have from 1 to 6 carbon atoms incorporated within the alkyl portion of the aralkyl group. Suitable aralkyl groups employed in compounds of the present invention include, for example, benzyl, picolyl, and the like.
Representative heteroaryl groups include, for example, those shown below. These heteroaryl groups can be further substituted and may be attached at various positions as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein.
Figure imgf000017_0001
Representative heteroaryl's include, for example, imidazolyl, pyridyl, piperazinyl, azetidinyl, thiazolyl, triazolyl benzimidazolyl, benzothiazolyl, and benzoxazolyl. The term "biaryl" refers to a group or substituent to which two aryl groups, which are not condensed to each other, are bound. Exemplary biaryl compounds include, for example, phenylbenzene, diphenyldiazene, 4-methylthio-l-phenylbenzene, phenoxybenzene, (2-phenylethynyl)benzene, diphenyl ketone, . (4-phenylbuta-l,3- diynyl)benzene, phenylbenzylamine, (phenylmethoxy)benzene, and the like. Preferred optionally substituted biaryl groups include: 2-(phenylamino)-N-[4-(2-phenylethynyl)- phenyl]acetamide, 1 ,4-diphenylbenzene, N-[4-(2-phenylethynyl)phenyl]-2-[benzyl- amino]acetamide, 2-amino-N-[4-(2-phenylethynyl)phenyl]propanamide, 2-amino-N-[4- (2-ρhenylethynyl)phenyl]acetamide, 2-(cyclopropylamino)-N-[4-(2-phenylethynyl)- phenyl]acetamide, 2-(ethylamino)-N-[4-(2-phenylethynyl)phenyl]acetamide, 2-[(2- me ylpropyl)amino]-N-[4-(2-phenylethynyl)phenyl]acetarnide, 5-phenyl-2H-benzo- [d]l,3-dioxolene, 2-chloro-l-methoxy-4-phenylbenzene, 2-[(imidazolylmethyl)amino]-N-
[4-(2-phenylethynyl)phenyl]acetamide, 4-phenyl-l-phenoxybenzene, N-(2-aminoethyl)- [4-(2-phenylethynyl)phenyl] carboxamide, 2- { [(4-fluorophenyl)methyl] amino } -N- [4-(2- phenylethynyl)phenyl]acetamide, 2-{[(4-methylphenyl)methyl]amino}-N-[4-(2-phenyl- ethynyl)phenyl]acetamide, 4-phenyl-l-(trifluoromethyl)benzene, l-butyl-4-phenyl- benzene, 2-(cyclohexylamino)-N-[4-(2-phenylethynyl)phenyl]acetamide, 2-(ethylmethyl- amino)-N-[4-(2-phenylethynyl)pheήyl]acetamide, 2-(butylamino)-N-[4-(2-phenyl- ethynyl)phenyl]acetamide, N-[4-(2-phenylethynyl)phenyl]-2-(4-pyridylamino)acetamide,
N-[4-(2-phenylethynyl)phenyl]-2-(quinuclidin-3-ylamino)acetamide, N-[4-(2-phenyl- ethynyl)phenyl]pyrrolidin-2-ylcarboxamide, 2-amino-3-methyl-N-[4-(2-phenylethynyl)- phenyl]butanamide, 4-(4-phenylbuta-l,3-diynyl)phenylamine, 2-(dimethylamino)-N-[4- (4-phenylbuta- 1 ,3 -diynyl)phenyl] acetamide, 2-(ethylamino)-N-[4-(4-phenylbuta- 1,3- diynyl)phenyl]acetamide, 4-ethyl-l-phenylbenzene, l-[4-(2-phenylethynyl)phenyl]ethan- 1 -one, N-( 1 -carbamoyl-2-hy droxypropyl) [4-(4-phenylbuta- 1 ,3 -diynyl)phenyl] carbox- amide, N-[4-(2-phenylethynyl)phenyl]propanamide, 4-methoxyphenyl phenyl ketone, phenyl-N-benzamide, (tert-butoxy)-N-[(4-phenylphenyl)methyl]carboxamide, 2-(3- phenylphenoxy)ethanehydroxamic acid, 3-phenylphenyl propanoate, l-(4-ethoxyphenyl)- 4-methoxybenzene, and [4-(2-phenylethynyl)phenyl]pyrrole.
The term "heteroarylaryl" refers to a biaryl group where one of the aryl groups is a heteroaryl group. Exemplary heteroarylaryl groups include, for example, 2-phenylpyridine, phenylpyrrole, 3-(2-phenylethynyl)pyridine, phenylpyrazole, 5-(2-phenylethynyl)-l,3-dihydropyrimidine-2,4-dione, 4-phenyl-l,2,3-thiadiazole, 2-(2- phenylethynyl)pyrazine, 2-phenylthiophene, phenylimidazole, 3-(2-piperazinylphenyl)- furan, 3-(2,4-dichlorophenyl)-4-methylpyrrole, and the like. Preferred optionally substituted heteroarylaryl groups include: 5-(2-phenylethynyl)pyrimidine-2-ylamine, l-methoxy-4-(2-thienyl)benzene, l-methoxy-3-(2-thienyl)benzene, 5-methyl-2-phenyl- pyridine, 5-methyl-3-phenylisoxazole, 2-[3-(1rifluoromethyl)phenyl]ιuran, 3-fluoro-5- (2-furyl)-2-methoxy- 1 -prop-2-enylbenzene, (hydroxyimino)(5-phenyl(2-thienyl))- methane, 5-[(4-methylpiperazinyl)methyl]-2-phenylthiophene, 2-(4-ethylphenyl)thio- phene, 4-methylthio-l-(2-thienyl)benzene, 2-(3-nitrophenyl)thiophene, (tert-butoxy)-N-
[(5-phenyl(3 -pyridyl))methyl] carboxamide, hydroxy-N-[(5 -phenyl(3 -pyridyl))methyl] - amide, 2-(phenylmethylthio)pyridine, and benzylimidazole. The term "heteroarylheteroaryl" refers to a biaryl group where both of the aryl groups is a heteroaryl group. Exemplary heteroarylheteroaryl groups include, for example, 3-pyridylimidazole, 2-imidazolylpyrazine, and the like.- Preferred optionally substituted heteroarylheteroaryl groups include: 2-(4-piperazinyl-3-pyridyl)furan, diethyl-
(3-pyrazin-2-yl(4-pyridyl))amine, and dimethyl {2-[2-(5-methylpyrazin-2-yl)ethynyl](4- pyridyl)} amine.
"Optionally substituted" or "substituted" refers to the replacement of hydrogen with a monovalent or divalent radical. Suitable substitution groups include, for example, hydroxyl, nitro, amino, imino, cyano, halo, thio, sulfonyl, thioamido, amidino, imidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfonamido, carboxyl, formyl, loweralkyl, haloloweralkyl, loweralkyamino, haloloweralkylamino, loweralkoxy, haloloweralkoxy, loweralkoxyalkyl, alkylcarbonyl, aminocarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, alkylthio, aminoalkyl, cyanoalkyl, aryl and the like.
The substitution group can itself be substituted. The group substituted onto the substitution group can be carboxyl, halo; nitro, amino, cyano, hydroxyl, loweralkyl, loweralkoxy, aminocarbonyl, -SR, thioamido, -SO3H, -SO2R or cycloalkyl, where R is typically hydrogen, hydroxyl or loweralkyl.
When the substituted substituent includes a straight chain group, the substitution can occur, either within the chain (e.g., 2-hydroxypropyl, 2-aminobutyl, and the like) or at the chain terminus (e.g., 2-hydroxyethyl, 3-cyanopropyl, and the like). Substituted substitutents can be straight chain, branched or cyclic arrangements of covalently bonded carbon or heteroatoms.
As used herein, the term "carboxy-protecting group" refers to a carbonyl group which has been esterified with one of the commonly used carboxylic acid protecting ester groups employed to block or protect the carboxylic acid function while reactions involving other functional sites of the compound are carried out. In addition, a carboxy protecting group can be attached to a solid support whereby the compound remains connected to the solid support as the carboxylate until cleaved by hydrolytic methods to release the corresponding free acid. Representative carboxy-protecting groups include, for example, loweralkyl esters, secondary amides and the like. As used herein, the term "pharmaceutically acceptable salts" refers to the nontoxic acid or alkaline earth metal salts of the compounds of Formula I. These salts can be prepared in situ during the final isolation and purification of the compounds of Formula I, or by separately reacting the base or acid functions with a suitable organic or inorganic acid or base, respectively. Representative salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-napth- alenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulfuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, methanesulfonic acid, succinic acid and citric acid. Basic addition salts can be prepared in situ during the final isolation and purification of the compoxαnds of formula (I), or separately by reacting carboxylic acid moieties with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia, or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, aluminum salts and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Other representative organic amines useful for the formation of base addition salts include diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. As used herein, the term "pharmaceutically acceptable ester" refers to esters, which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
The term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
The term "cancer" refers to cancer diseases that can be beneficially treated by the inhibition of Raf kinase, including, for example, solid cancers, such as carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon), myeloid disorders (e.g., myeloid leukemia) and adenomas (e.g., villous colon adenoma).
In illustrative embodiments of the invention, Ari may be, for example, phenyl which may be substituted by one or more substitutents selected from the group consisting of hydroxyl, nitro, cyano, halo, and substituted or unsubstituted amino, imino, thio, sulfonyl, thioamido, amidino, imidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfonamido, carboxyl, formyl, loweralkyl, haloloweralkyl, loweralkyamino, haloloweralkylamino, loweralkoxy, haloloweralkoxy, loweralkoxyalkyl, alkylcarbonyl, aminocarbonyl, loweralkylaminocarbonyl, heterocycloalkylloweralkylaminocarbonyl, carboxylloweralkylaminocarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, alkylthio, aminoalkyl, cyanoalkyl, aryl and the like. In other illustrative embodiments of the invention, Ar2 may be, for example, pyridyl, which may be substituted by one or more substitutents selected from the group consisting of hydroxyl, nitro, cyano, halo, and substituted or unsubstituted amino, imino, thio, sulfonyl, thioamido, amidino, imidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfonamido, carboxyl, formyl, loweralkyl, . haloloweralkyl, loweralkyamino, haloloweralkylamino, loweralkoxy, haloloweralkoxy, loweralkoxyalkyl, alkylcarbonyl, aminocarbonyl, loweralkylaminocarbonyl, heterocycloalkylloweralkylaminocarbonyl, carboxylloweralkylaminocarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, alkylthio, aminoalkyl, cyanoalkyl, aryl and the like.
In representative embodiments of the invention, the compounds of the invention include, for example, 4-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-lH-benz- imidazol-6-yl)oxy]-N-methylpyridine-2-carboxamide, 4-( {2-[(3-chlorophenyl)amino]- lH-benzimidazol-6-yl}oxy)-N-methylpyridine-2-carboxamide, 4-({2-[(4-bromophenyl)- amino]-lH-benzimidazol-6-yl}oxy)-N-methylpyridine-2-carboxamide, 4-({2-[(3-chloro- 4-fluorophenyl)amino]-lH-benzimidazol-6-yl}oxy)-N-methylpyridine-2-carboxamide, N-methyl-4-{[2-(phenylamino)-lH-benzimidazol-6-yl]oxy}pyridine-2-carboxamide, 4- [(2- { [4-bromo-2-(trifluoromethyl)phenyl] amino } - 1 H-benzimidazol-6-yl)oxy]-N- methylpyridine-2-carboxamide, N-methyl-4-({2-[(2-methylpropyl)amino]-lH-benz- imidazol-6-yl}oxy)pyridine-2-carboxamide, 4-[(2-{[4-(dimethylamino)naphthalen-l-yl]- amino } - 1 H-benzimidazol-6-yl)oxy]-N-methylpyridine-2-carboxamide, N-methyl-4-( {2- [(4-nitrophenyl)amino]- 1 H-benzimidazol-6-yl} oxy)pyridine-2-carboxamide, N-methyl-4- ( {2-[(phenylcarbonyl)amino]- 1 H-benzimidazol-6-yl} oxy)pyridine-2-carboxamide, N- memyl-4-({2-[(phenylmethyl)ammo]-lH-benzimidazol-6-yl}oxy)pyridine-2-carbox- amide, methyl 4-{[6-({2-[(methylamino)carbonyl]pyridin-4-yl}oxy)-lH-benzimidazol-2- yl]amino}benzoate, 4-({2-[(4-chlorophenyl)amino]-lH-benzimidazol-6-yl}oxy)-N- methylρyridine-2-carboxamide, 4- [(2- { [2-(ethyloxy)phenyl] amino } - 1 H-benzimidazol-6- yl)oxy]-N-methylpyridine-2-carboxamide, N-methyl-4-( {2-[(2-morpholin-4-ylethyl)- amino]-lH-benzimidazol-6-yl}oxy)pyridine-2-carboxamide, , 4-({2-[(4-iodophenyl)- amino]-lH-benzimidazol-6-yl}oxy)-N-methylpyridine-2-carboxamide, N-methyl-4-[(2- {[4-(1xifluoromethyl)phenyl]amino}-lH-benzimidazol-6-yl)oxy]pyridine-2 -carboxamide, 4-({2-[(furan-2-ylmethyl)amino]-lH-benzimidazol-6-yl}oxy)-N-methylpyridine-2- carboxamide, 4-({2-[(4-bromo-3-methylphenyl)amino]-lH-benzimidazol-6-yl}oxy)-N- methylpyridine-2-carboxamide, 4-({2-[(4-acetylphenyl)amino]-lH-benzimidazol-6-yl}- oxy)-N-methylpyridine-2-carboxamide, N-methyl-4-({2-[(2,4,6-trimethylphenyl)ammo]- 1 H-benzimidazol-6-yl } oxy)pyridine-2-carboxamide, 4- [(2- { [4-( 1 , 1 -dimethylethyl)- phenyl]amino}-lH-benzimidazol-6-yl)oxy]-N-methylpyridine-2-carboxamide, 4-({2-[(2- bromophenyl)amino]-lH-benzimidazol-6-yl}oxy)-N-methylpyridine-2-carboxamide, 4- ({2-[(3-bromophenyl)amino]-lH-benzimidazol-6-yl}oxy)-N-methylpyridine-2-carbox- amide, 4-( {2-[(2-chlorophenyl)amino]- 1 H-benzimidazol-6-yl} oxy)-N-methylpyridine-2- carboxamide, methyl 3-{[6-({2-[(methylamino)carbonyl]pyridin-4-yl}oxy)-lH- benzimidazol-2-yl] amino } thiophene-2-carboxylate, 4-( {2- [(4-bromophenyl)amino] - 1 H- benzimidazol-6-yl}oxy)-N-{(3R,5R)-5-[(methyloxy)methyl]pyrrolidin-3-yl}pyridine-2- carboxamide, 4-({2-[(4-bromophenyl)amino]-l-methyl-lH-benzimidazol-5-yl}oxy)-N- methylpyridine-2-carboxamide, 4- [(2- { [4-chloro-3 -(trifluoromethyl)phenyl] amino } - 1 - methyl-lH-benzimidazol-5-yl)oxy]-N-methylpyridine-2-carboxamide, N-methyl-4-[(l- memyl-2-{[4-(trifluoromethyl)phenyl]amino}-lH-benzimidazol-5-yl)oxy]pyridine-2- carboxamide, 4-({2-[(4-bromophenyl)amino]-l-methyl-lH-benzimidazol-5-yl}oxy)-N- ethylpyridine-2-carboxamide, 4-({2-[(4-bromophenyl)amino]-l-methyl-lH-benz- imidazol-5-yl}oxy)-N-(2-hydroxyethyl)pyridine-2-carboxamide, 4-({2-[(4-bromo- phenyl)amino]- 1 -methyl- 1 H-benzimidazol-5-yl} oxy)-N,N-dimethylpyridine-2-carbox- amide, 4-({2-[(4-bromophenyl)amino]-l-methyl-lH-benzimidazol-5-yl}oxy)-N-(2,2,2- trifluoroethyl)pyridine-2-carboxamide, N-(4-bromophenyl)- 1 -methyl-5- { [2-(pyrrolidin- 1 - ylcarbonyl)pyridin-4-yl] oxy } - 1 H-benzimidazol-2-amine, ethyl (3R)-3-(methyloxy)-4- [( {4-[(2- { [4-(trifluoromethyl)phenyl]amino } - 1 H-benzimidazol-5-yl)oxy]pyridin-2-yl} - carbonyl)amino]piperidine- 1 -carboxylate, 4-( {2-[(4-bromophenyl)amino]- 1 -methyl- 1 H- benzimidazol-5-yl}oxy)-N-[2-(dimemylaιnino)ethyl]pyridme-2-carboxamide, 4-({2-[(4- bromophenyl)amino]- 1 -methyl- 1 H-benzimidazol-5-yl} oxy)-N-(tetrahydrofuran-2-yl- methyl)pyridine-2-carboxamide, 4-({2-[(4-bromophenyl)amino]-l-methyl-lH-benz- imidazol-5-yl} oxy)-N-(2-morpholin-4-ylethyl)pyridine-2-carboxamide, 4-( {2-[(4-bromo- phenyl)amino]- 1 -methyl- 1 H-benzimidazol-5-yl} oxy)-N-(piρeridin-4-ylmethyl)pyridine- 2-carboxamide, 5-({2-[(3-aminopyrrolidin-l-yl)carbonyl]ρyridin-4-yl}oxy)-N-(4- bromophenyl)- 1 -methyl- 1 H-benzimidazol-2-amine, 4-( {2-[(4-bromophenyl)amino]- 1 - methyl- 1 H-benzimidazol-5-yl} oxy)-N-[ 1 -(diphenylmethyl)azetidin-3-yl]pyridine-2- carboxamide, 4-({2-[(4-bromophenyl)amino]-l-methyl-lH-benzimidazol-5-yl}oxy)-N- piperidin-3-ylpyridine-2-carboxamide, 4-({2-[(4-bromophenyl)amino]-l-methyl-lH- benzimidazol-5-yl}oxy)-N-(l,3-thiazol-2-yl)pyridine-2-carboxamide, and 4-({2-[(4- bromophenyl)amino]- 1 -methyl- 1 H-benzimidazol-5-yl} oxy)-N-[(l -ethylpyrrolidin-2-yl)- methyl]pyridine-2-carboxamide, (4- {2-[(4-bromophenyl)amino]benzothiazol-5-yloxy} (2- pyridyl))-N-methylcarboxamide, (4- {2-[(4-bromophenyl)amino]benzoxazol-5-yloxy } -(2- pyridyl))-N-methylcarboxamide, and other representative compounds set forth in the Examples.
In other aspects, the present invention relates to the processes for preparing the compounds of Formulas I, II, III, IV and V and to the synthetic intermediates useful in such processes.
The compounds of the invention comprise asymmetrically substituted carbon atoms. Such asymmetrically substituted carbon atoms can result in the compounds of the invention comprising mixtures of stereoisomers at a particular asymmetrically substituted carbon atom or a single stereoisomer. As a result, racemic mixtures, mixtures of diastereomers, as well as single diastereomers of the compounds of the invention are included in the present invention. The terms "S" and "R" configuration, as used herein, are as defined by the IUPAC 1974 RECOMMENDATIONS FOR SECTION E, FUNDAMENTAL STEREOCHEMISTRY, Pure Appl. Chem. 45:13-30 (1976). The terms α and β are employed for ring positions of cyclic compounds. The α-side of the reference plane is that side on which the preferred substituent lies at the lower numbered position. Those substituents lying on the opposite side of the reference plane are assigned β descriptor. It should be noted that this usage differs from that for cyclic stereoparents, in which "α" means "below the plane" and denotes absolute configuration. The terms α and β configuration, as used herein, are as defined by the CHEMICAL ABSTRACTS INDEX GUIDE-APPENDIX IV (1987) paragraph 203.
The present invention also relates to the processes for preparing the compounds of the invention and to the synthetic intermediates useful in such processes, as described in detail below. Synthetic Methods
Compounds of the invention containing a benzimidazole core may be prepared using a number of methods familiar to one of skill in the art. In one method, suitably functionalized diamines may be coupled with various thioisocyanates to form the intermediate thioureas. Cyclization to form the benzimidazole moiety may be effected under known conditions such as with treatment carbodiimides or alkyl halides as in the following schemes.
Figure imgf000025_0001
Figure imgf000025_0002
Scheme:
PdΛVHg
Figure imgf000026_0001
Figure imgf000026_0002
Alternatively the diamines may be reacted sequentially with carbonyl diimidazole and phosphoryl chloride followed by coupling with the appropriate amine.
ArNCS
Figure imgf000026_0003
Figure imgf000026_0005
Compounds containing the oxazole structure may similarly be prepared according to the methods above or according to other known general procedures. Haviv et al. (J. Med. Chem. 1988, 31:1719) describes a procedure for assembling oxazole cores wherein a hydroxy aniline is treated with ethyl potassium xanthate. The resulting sulfuryl benzoxazole may then be chlorinated and coupled with an amine.
Figure imgf000026_0006
Compounds containing a benzothiazole core may also be prepared according to known methods. An ortho-halothioisocyanate may be reacted with an amine to form a thiourea. Reduction with NaH then allows formation of the thiazole ring.
fTγNH2 ArNCS NaH
Figure imgf000027_0001
Figure imgf000027_0002
Benzothiazoles may generally be substituted in accordance with the present invention, such as through the following synthetic pathway:
Figure imgf000027_0003
Benzoxzoles may generally be synthesized through the following pathway:
Figure imgf000027_0004
The compounds of the invention are useful in vitro or in vivo in inhibiting the growth of cancer cells. The compounds may be used alone or in compositions together with a pharmaceutically acceptable carrier or excipient. Suitable pharmaceutically acceptable carriers or excipients include, for example, processing agents and drug delivery modifiers and enhancers, such as, for example, calcium phosphate, magnesium stearate, -talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, hydroxypropyl-β-cyclodextrin, polyvinyl- pyrrolidinone, low melting waxes, ion exchange resins, and the like, as well as combinations of any two or more thereof. Other suitable pharmaceutically acceptable excipients are described in "Remington's Pharmaceutical Sciences," Mack Pub. Co., New Jersey (1991), incorporated herein by reference.
Effective amounts of the compounds of the invention generally include any amount sufficient to detectably inhibit Raf activity by any of the assays described herein, by other Raf kinase activity assays known to those having ordinary skill in the art or by detecting an inhibition or alleviation of symptoms of cancer.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. The therapeutically effective amount for a given situation can be readily determined by routine experimentation and is within the skill and judgment of the ordinary clinician. For purposes of the present invention, a therapeutically effective dose will generally be a total daily dose administered to a host in single or divided doses may be in amounts, for example, of from 0.001 to 1000 mg/kg body weight daily and more preferred from 1.0 to 30 mg/kg body weight daily. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose. The compounds of the present invention may be administered orally, parenterally, sublingually, by aerosolization or inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or ionophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. mjectable preparations, for example, sterile mjectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile mjectable preparation may also be a sterile mjectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-propanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols, which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings. Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweetening, flavoring, and perfuming agents. The compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.W., p. 33 et seq. (1976).
While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more other agents used in the treatment of cancer. Representative agents useful in combination with the compounds of the invention for the treatment of cancer include, for example, irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib (Gleevec), anthracyclines, rituximab, trastuzumab, as well as other cancer chemotherapeutic agents. The above compounds to be employed in combination with the compounds of the invention will be used in therapeutic amounts as indicated in the Physicians' Desk Reference (PDR) 47th Edition (1993), which is incorporated herein by reference, or such therapeutically useful amounts as would be known to one of ordinary skill in the art.
The compounds of the invention and the other anticancer agents can be administered at the recommended maximum clinical dosage or at lower doses. Dosage levels of the active compounds in the compositions of the invention may be varied so as to obtain a desired therapeutic response depending on the route of administration, severity of the disease and the response of the patient. The combination can be administered as separate compositions or as a single dosage form containing both agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions, which are given at the same time or different times, or the therapeutic agents, can be given as a single composition.
Antiestrogens, such as tamoxifen, inhibit breast cancer growth through induction of cell cycle arrest, that requires the action of the cell cycle inhibitor p27Kip. Recently, it has been shown that activation of the Ras-Raf-MAP Kinase pathway alters the phosphorylation status of p27Kip such that its inhibitory activity in arresting the cell cycle is attenuated, thereby contributing to antiestrogen resistance (Donovan et al, J. Biol. Chem. 275:40888, 2001). As reported by Donovan et al., inhibition of MAPK signaling through treatment with MEK inhibitor changed the phosphorylation status of p27 in hormone refactory breast cancer cell lines and in so doing restored hormone sensitivity. Accordingly, in one aspect, the compounds of formulas (I), (II), (III), (IN) and (V) may be used in the treatment of hormone dependent cancers, such as breast and prostate cancers, to reverse hormone resistance commonly seen in these cancers with conventional anticancer agents.
In hematological cancers, such as chronic myelogenous leukemia (CML), chromosomal translocation is responsible for the constitutively activated BCR-AB1 tyrosine kinase. The afflicted patients are responsive to Geevec, a small molecule tyrosine kinase inhibitor, as a result of inhibition of Abl kinase activity. However, many patients with advanced stage disease respond to Gleevec initially, but then relapse later due to resistance-conferring mutations in the Abl kinase domain. In vitj-o studies have demonstrated that BCR-Avl employs the Raf kinase pathway to elicit its effects. In addition, inhibiting more than one kinase in the same pathway provides additional protection against resistance-conferring mutations. Accordingly, in another aspect of the invention, the compounds of formulas (I), (II), (III), (IV) and (V) are used in combination with at least one additional agent, such as Gleevec, in the treatment of hematological cancers, such as chronic myelogenous leukemia (CML), to reverse or prevent resistance to the at least one additional agent. The present invention will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.
Representative side chains for use in the compounds of the following examples may generally be prepared in accordance with the following procedures: Example 1
Synthesis of 4-[(2- { [4-chloro-3 -(trifluoromethyDphenyl] amino } - lH-benzimidazol-6-yDoxy1-Ν-methylpyridine-2-carboxamide The compound 4-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-lH-benz- imidazol-6-yl)oxy]-N-methylpyridine-2-carboxamide was synthesized as follows:
Figure imgf000032_0001
Step 1. Synthesis of 4-[(4-amino-3-nitrophenyl)oxy]-N-methylpyridine-2- carbbxamide:
A mixture containing 4-amino-3-nitrophenol (leq) and potassium bis(trimethylsilyl)amide (2eq) was stirred in dimethylformamide for 2 hours at room temperature. To this mixture was added (4-chloro(2-pyridyl))-N-methylcarboxamide (leq) and potassium carbonate (1.2eq) and stirred at 90°C for 3 days. The reaction mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was separated and washed with brine, dried, filtered, and concentrated in vacuum to give brown solid. Purification on silica gel (2% triethyl amine / 50% ethyl acetate in hexane) gave 4-[(4-amino-3-nitrophenyl)oxy]-N-methylpyridine-2-carbox- amide as an orange solid. The product gave satisfactory ΝMR. HPLC, 3.39 min; MS: MH+ = 289.
Step 2. Synthesis of 4-[(3,4-diaminophenyl)oxy]-Ν-methylpyridine-2- carboxamide:
The mixture containing [4-(3-amino-4-nitrophenoxy)(2-pyridyl)]-N- in methanol with catalytic amount of 10%Pd/C.was hydrogenated until disappearance of the yellow color to yield the product amine. HPLC, 2.5 mins; MS: MH+ = 259.
Step 3. Synthesis of 4-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-lLI- benzimidazol-6-yl)oxy]-N-methylpyridine-2-carboxamide:
The mixture containing 4-[(3,4-diaminophenyl)oxy]-N-methylpyridine-2- carboxamide (leq) and 4-chloro-3-(trifluoromethyl)benzeneisothiocyanate (leq) in tetrahydrofuran was stirred at room temperature for 16 hours to give the corresponding thiourea. To the resulting mixture was added l-ethyl-3-(3-dimethylamino- propyl)carbodiimide hydrochloride (2eq) and the mixture was stirred for another 10 hours. The mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was washed with brine and dried. Purification on HPLC gave 4-[(2- { [4-chloro-3 -(trifluoromethyl)phenyl] amino } - 1 H-benzimidazol-6-yl)oxy] -N-methyl- pyridine-2-carboxamide. MS: MH+ = 462
Examples 2-108 The compounds shown in the following Table 1 (Examples 2-108) were prepared from following the procedure described for Example 1.
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Example 109
Synthesis of (4- (2-[(4-bromophenvπamino1- benzothiazol-5-yloxyU2-pyridyl )-N-methylcarboxamide
Step 1. Synthesis of 2-bromo-5-methoxybenzothiazole
A solution of bromine (3.6eq) in chloroform (.75M) was added dropwise over a period of 1 hr to a stirred suspension of 5-methoxy-2-mercaptobenzothiazole (leq) in chloroform at 0°C. The mixture was stirred for 30 min before it was added slowly to water and stirred for further 20 min. The mixture was filtered to remove a cream solid. The organic phase was dried and evaporated to leave a brown solid. The brown solid was dissolved in ether and filtered. The residue was washed with ether and the filtrate and washings were combined and evaporated, chromatographed (4:1 hexanes and ethyl acetate) to give the title compound as a pale yellow solid. MS: MH = 244
Step 2. Synthesis of (4-bromophenyl)(5-methoxybenzothiazol-2-yl)amine
The mixture containing 2-brorno-5-methoxybenzthiazole (leq), 4-Bromoaniline
(2eq) and. disopropylethylamine was subjected to microwave in NMP at 220°C. The resultant mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was washed with brine and dried. Purification on silica gel gave the desired product. MS: MH+ = 335
Step 3. Synthesis of 2-[(4-bromophenyl)amino]benzothiazol-5-ol The mixture of (4-bromophenyl)(5-methoxybenzothiazol-2-yl)amine and hydro- bromic acid (48%) was subjected to the microwave at 150°C for 6 mins to yield the desired product. MS: MH+ = 321
Step 4. Synthesis of (4-{2-[(4-bromophenyl)amino]benzothiazol-5-yloxy}(2- pyridyl))-N-methylcarboxamide:
The mixture containing 2-[(4-bromophenyl)amino]benzothiazol-5-ol (leq), Potassiumbis(trimethylsilyl)amide (4eq), was stirred in dimethylformamide for 30 min at room temperature. To this mixture was added (4-chloro(2-pyridyl)-N-methyl- carboxamide (leq) and Potassium carbonate (1.2eq) and microwaved for 6 mins at. 150°C. The reaction mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was separated and washed with brine, dried, filtered and concentrated. Purification on Prep LC yielded the desired product. MS: MH+ = 455 Each of the Examples 110-119 shown in the following Table 2 were synthesized according to the procedure described in Example 109:
Figure imgf000046_0001
Example 120a
Synthesis of 4-( {2-[(4-bromophenyDamino]- 1 -methyl-
1 H-benzimidazol-5-y oxy -N-methylpyridine-2-carboxamide
The compound 4-({2-[(4-bromophenyl)amino]-l-methyl-lH-benzimidazol-5- yl}oxy)-N-methylpyridine-2-carboxamide was synthesized as follows:
Figure imgf000048_0001
Step 1. Synthesis of 4-{[3-amino-4-(methylamino)phenyl]oxy}-N-methyl- pyridine-2-carboxamide:
A solution of 4-[(4-amino-3-nitrophenyl)oxy]-Ν-methylpyridine-2-carboxamide (leq) in methylene chloride was treated with trifluoroacetic anhydride (leq) and stirred for 10 minutes at 0°C. The mixture was quenched with saturated NaHCO3 solution. The organic layer was separated and washed with water, brine, dried and evaporated.
MS: MH+=385.2.
To a solution of the trifluroacetamide (leq) in a mixture of toluene, acetonitrile and sodium hydroxide solution (50%) was added benzyltrimethylammonium- chloride (leq) and dimethyl sulfate (1.2eq). The biphasic mixture was stirred overnight at room temperature and evaporated. The mixture was taken up in ethyl acetate, washed with water, brine, dried and evaporated. The crude product was purified by column chromatography eluting with 1:1 hexanes and ethylacetate followed by 2% triethylamine in 1:1 hexanes and ethyl acetate followed by 2% triethylamine in 1:1 hexanes and ethyl acetate to afford N-methyl-4-{[4-(methylamino)-3-nitrophenyl]oxy}pyridine-2-carbox- amide as a reddish orange solid. MS: MH+ = 303.1.
The solution of nitromethylaniline in methanol was treated with 5% palladium on carbon and stirred under hydrogen atmosphere for 15 min. (until the disappearance of yellow coloration) at room temperature. The mixture was filtered and the filtrate was concentrated to provide 0.36 g of the diamine 4-{[3-amino-4-(methylamino)phenyl]oxy}-
N-methylpyridine-2-carboxamide. MS: MH+ = 273.3.
Step 2. Synthesis of 4-({2-[(4-bromophenyl)amino]-l-methyl-lH-benzimidazol- 5-yl} oxy)-N-methylpyridine-2-carboxamide: A solution of the diamine 4-{[3-amino-4-(methylamino)phenyl]oxy}-N- methylpyridine-2-carboxamide (leq) in methanol was treated with 4-bromophenyl- isothiocyanate (leq) and stirred at 60°C-65°C for 2 hours. The reaction mixture was cooled down to room temperature and methyl iodide (leq) was added and stirred overnight at 60°C. The reaction was cooled to room temperature, evaporated, taken up in ethyl acetate, and washed with water and brine, dried, and evaporated under reduced pressure. Column chromatography using a gradient solvent system of hexanes and ethyl acetate and either 1:1 methylene chloride and acetone or 5% methanol in methylene chloride yielded the product as a half white powder. MS: MH+=452.3
Example 120b Alternative Synthesis of 4-({2-[(4-bromophenyl amino]-l-methyl- 1 H-benzimidazol-5-yl) oxyVN-methylpyridine-2-carboxamide Step 1. Synthesis of N-methyl{4-[4-(methylamino)-3-aminophenoxy](2- pyridyl) } carboxamide:
Figure imgf000049_0001
5
C13H 12N4O4 M ol. Wt.: 288.26
Figure imgf000049_0002
7 C14H14N4O4
' Mol. Wt.: 302.29
Figure imgf000049_0003
8 C 1 H 16 4θ2 Mol. Wt.: 272.30
A mixture containing 4-amino-3-nitrophenol 5 (1.0 g, 6.4 mmol), potassium bis(trimethylsilyl)amide (2.58 g, 12.8mmol) was stirred in DMF (50 ml) for 2 hours at rt. To this mixture was added (4-chloro(2-pyridyl))-N-methylcarboxamide 4 (1.09 g, 6.4 mmol) and potassium carbonate (0.5 g, 7.6 mmol) and stirred at 90°C overnight. The reaction mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was separated and washed with brine (2 X 10 ml), dried, filtered and concentrated in vacuum to give brown solid. Purification on silica gel with 2% triethyl amine in 50% ethyl acetate in hexane gave 1.3 g (yield, 72%) of [4-(4-amino-3- nitrophenoxy)(2-pyridyl)]-N-methylcarboxamide 6 as an orange solid: H ΝMR (300 MHz, CDC13) δ 8.40 (d, J= 5.6 Hz, 1 H), 7.99 (br s, 1 H), 7.90 (d, J= 2.7 Hz, 1 H), 7.64 (d, J= 2.7 Hz, 1 H), 7.17 (dd, J= 2.7, 9.0 Hz, 1 H), 6.95 (ddd, J= 0.7, 2.5, 5.6 Hz, 1 H), 6.89 (d, J= 9.0 Hz, 1 H), 6.18 (br s, 2 H), 3.00 (d, J= 5.1 Hz, 3 H); mp 208-210 °C dec; LCMS m/z 289.2 (MH+), tR = 1.92 min.
A 500 mL three neck round bottom flask fitted with a mechanical stirrer was charged with nitroaniline 6 (10.0 g, 34.8 mmol) and CH2C12 (175 ml). The resulting suspension was cooled to 0°C and TFAA (9.5 mL, 14.1 g, 67.0 mmol) was added over 16 h while allowing the cooling bath to expire.2 After the reaction was judged complete by TLC,3 TBAC1 (5.2 g, 17.5 mmol)4 and dimethyl sulfate (6.7 mL, 8.9 g, 70.0 mmol) were added followed by 50% aqueous ΝaOH solution (140 mL). The resulting reaction mixture was cooled with an ice bath, and stirred vigorously for 1.5 h at rt.3'5'6 The reaction was then poured over ice water and the resulting phases were partitioned and separated. The aqueous phase was extracted with CH2C12 (3 X 100 mL) and the combined organic layers were washed with brine (2 X 100 mL), dried (MgSO4), and concentrated. The crude residue was purified by recrystallization (1:3 ethanol- water) to give 8.36 g (27.7 mmol, 79%) of 7 as fine red needles: 1H ΝMR (300 MHz, CDC13) δ 8.40 (dd, J= 0.5, 4.9 Hz, 1 H), 8.07 (br d, J= 3.7 Hz, 1 H), 7.98 (br s, 1 H), 7.95 (d, J = 2.9 Hz, 1 H), 7.62 (dd, J= 0.5, 2.9 Hz, 1 H), 7.27 (ddd, J= 0.5, 2.9, 9.3 Hz, 1 H), 6.98 (dd, J= 2.7, 5.6 Hz, 1 H), 6.92 (d, J= 9.3 Hz, 1 H), 3.07 (d, J= 5.1 MHz, 3 H), 3.00 (d, J = 5.1 Hz, 3 H); 13C ΝMR (75 MHz, CDC13) δ 166.6, 164.6, 152.6, 150.0, 144.8, 142.2, 130.6, 118.9, 115.5, 114.2, 109.7, 30.2, 26.4; mp 164-166 °C. LCMS m/z 303.4 (MH+), t = 2.37 min.
A suspension of nitroaniline 7 (5.0 g, 16.5 mmol) in methanol was sparged with Ν2 for 20 min after which 10% Pd/C (0.88 g, 0.8 mmol) was added. The reaction was purged with H2 and maintained under a H2 atmosphere overnight at room temperature. The reaction was purged with N2 and filtered through Celite. The collected solids were washed with EtOAc (3 X 50 mL), and the combined organic layers were dried (MgSO ) and concentrated to afford 4.35 g (16.0 mmol, 97%) of an off white solid as 8: 1H NMR (300 MHz, CDC13) δ 8.30 (d, J= 5.5 Hz, 1 H), 7.99 (br s, 1 H), 7.67 (d, J= 2.5 Hz, 1 H), 6.91 (dd, J= 2.5, 5.5 Hz, 1 H), 6.62 (d, J= 8.5 Hz, 1 H), 6.53 (dd, J= 2.5, 8.5 Hz, 1 H), 6.44 (d, J = 2.5 Hz, 1 H), 2.98 (d, J= 5.2 Hz, 3 H), 2.86 (s, 3 H); 13C NMR (75 MHz, CDC13) δ 167.4, 164.9, 152.2, 149.6, 146.0, 136.6, 136.3, 114.0, 112.3, 112.0, 110.2, 109.0, 31.6, 26.5; mp 153-156°C dec; LCMS m/z 273.3 (MH+), tR = 1.66 min.
Step 2. Synthesis of (4-{2-[(4-bromophenyl)amino]-l-methylbenzimidazol-5- yloxy} (2-pyridyl))-N-methylcarboxamide:
Figure imgf000051_0001
A 250 mL round bottom flask was charged with 4-bromophenylisothiocyanate1 (2.17 g, 10.1 mmol), diamine 8 (2.74 g, 10.1 mmol), and MeOH (40 mL) and the reaction was maintained at rt overnight. Ferric chloride (2.43 g, 15 mmol) was added and the resulting red reaction mixture was stirred overnight. The reaction was partitioned with EtOAc (100 mL) and water (100 mL), and filtered through Celite. The layers were separated and the aqueous phase was neutralized (pH = 7) with saturated Na2CO3 solution. The resulting aqueous phase was extracted with EtOAc (100 mL) and the mixture was filtered through Celite. The phases were separated and the aqueous phase was again extracted and filtered. The combined organic layers were washed with brine (250 mL), dried (MgSO4), and concentrated to give a brown solid. The crude residue was purified by trituration in hot toluene to furnish 2.22 g (4.95 mmol, 49%) of a tan solid as 1: 1H NMR (300 MHz, CDC13) δ 8.38 (d, J= 5.8 Hz, 1 H), 8.07 (br d, J= 4.7 Hz, 1 H), 7.61 (d, J= 2.5 Hz, 1 H), 7.44 (app dd, J= 8.8, 20.6 Hz, 4 H), 7.05 (m, 3 H), 6.78 (dd, J = 2.2, 8.5 Hz, 1 H), 3.51 (s, 3 H), 3.00 (d, J= 5.2 Hz, 3 H); mp 251-254 °C dec; LCMS m/z 452.2 (MH+), tR = 2.17 min.
Examples 121-384 The compounds shown in the following Table 3 (Examples 121-384) were prepared from following the procedure described for Example 120a.
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Example Structure Name MH+
234 N-methyl-4-( { 1 -methyl-2-[(3- 446.5 thien-2-yl-lH-pyrazol-5-yl)- amino]- 1 H-benzimidazol-5- yl } oxy)pyridine-2-carboxamide
235 4- {[2-(l ,3-benzodioxol-5-yl- 418.4 amino)- 1 -methyl- 1 H-benz- imidazol-5-yl]oxy} -N-methyl- pyridine-2-carboxamide
236 4-( {2-[(2-iodophenyl)amino]- 1 - 500.3 methyl- 1 H-benzimidazol-5-yl} - oxy)-N-methylpyridine-2- carboxamide
237 4-( {2-[(2,6-diethylphenyl)- 430.5 amino]- 1 -methyl- 1 H-b enz- imidazol-5-yl} oxy)-N-methyl- pyridine-2-carboxamide
238 4-[(2- { [3-( 1 -hydroxyethyl)- 418.5 phenyl] amino } - 1 -methyl- 1 H- benzimidazol-5-yl)oxy]-N- methylpyridine-2-carboxamide
Figure imgf000064_0001
239 ■CH, 4-[(2- {[4-(lH-imidazol-l -yl)- 440.5 phenyl] amino } - 1 -methyl- 1 Hr
CH, benzimidazol-5-yl)oxy]-N- methylpyridine-2-carboxamide
240 N-methyl-4-[(l-methyl-2-{[2- 466.5
M (phenyloxy)phenyl] amino } - 1 H-
H.C benzimidazol-5-yl)oxy]pyridine- 2-carboxamide
CH3
241 O P-CH, 4-[(2-{[3,4-bis(methyloxy)- 434.5 phenyl] amino } - 1 -methyl- 1 H- r , benzimidazol-5-yl)oxy]-N- methylpyridine-2-carboxamide
H,CCCr CH
242 N-methyl-4-[( 1 -methyl-2- { [2- 527.5 morpholin-4-yl-5-(trifluoro- methyl)phenyl] amino } - 1 H- benzimidazol-5-yl)oxy]pyridine-
Figure imgf000064_0002
2-carboxamide
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Example Structure Name MH+
342 4-{[2-({3-chloro-4-[(trifluoro- 492.9
O Cl meithyl)oxy]phenyl } amino)- 1 -
,-CH, methyl-lH-benzimidazol-5-yl]- tr-CCr oxy } -N-methylpyridine-2-
H.c carboxamide
343 N-methyl-4-( { 1 -methyl-2-[(4- 451.5 pyridin-3-ylphenyl)amino]- 1 H- benzimidazol-5-yl} oxy)pyridine- 2-carboxamide
344 4-[(2- {[3-chloro-4-(trifluoro- 476.9 methyl)phenyl] amino } - 1 - methyl- 1 H-benzimidazol-5-yl)- oxy]-N-methylpyridine-2- carboxamide
345 4-({2-[(4-chloro-3-fluoro- 426.8 phenyl)amino] - 1 -methyl- 1 H- benzimidazol-5-yl} oxy)-N- methylpyridine-2-carboxamide
346 4-( {2-[(2-bromo-4-methyl- 467.3 phenyl)amino]- 1 -methyl- 1 H- benzimidazol-5-yl} oxy)-N- methylpyridine-2-carboxamide
347 N-methyl-4-( { 1 -methyl-2- 428.4 [(2,3,5-trifluorophenyl)amino]- lH-benzimidazol-5-yl}oxy)- pyridine-2-carboxamide
348 4-({2-[(2,4-dibromophenyl)- 532.2 amino]- 1 -methyl- 1 H- benzimidazol-5-yl} oxy)-N- methylpyridine-2-carboxamide
349 4-( {2-[(2-chloro-5-fluoro- 426.8 phenyl)amino] - 1 -methyl- 1 H- benzimidazol-5-yl}oxy)-N- methylpyridine-2-carboxamide
350 4-{[2-({3-chloro-4-[(trifluoro- 508.9 methyl)thio]phenyl} amino)- 1 - methyl- 1 H-benzimidazol-5-yl]- oxy } -N-methylpyridine-2-
Figure imgf000076_0001
carboxamide 'ftj-
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0002
Example 372 Synthesis of 4-( {2-[(4-bromophenvDamino]- 1 -methyl- 1 H-benzimidazol-5-yl} oxy -N-ethylpyridine-2-carboxamide The compound 4-({2-[(4-bromophenyl)amino]-l-methyl-lH-benzimidazol-5- yl}oxy)-N-ethylpyridine-2-carboxamide was synthesized as follows:
Figure imgf000079_0001
Step 1. Synthesis of tert-butyl 4-chloropyridine-2-carboxylate:
4-chloropyridine-2-carbonyl chloride (leq) was suspended in anhydrous tetrahydrofuran. Then 2 equivalents of a solution of 1 M potassium ,tert-butoxide was added dropwise to the reaction slowly as the reaction was stirring under nitrogen. After
3-4 hours or when the reaction was determined to be complete by HPLC, the reaction was evaporated under reduced pressure and diluted with ethyl acetate. The organic layer was washed with water followed by brine and dried over anhydrous sodium sulfate. The organic extracts were evaporated under reduced pressure to yield the tert-butyl ester as a yellow oil. MS: MH+ = 214.0. Step 2. Synthesis of tert-butyl 4-(4-amino-3-nitrophenoxy)pyridine-2- carboxylate:
Solid anhydrous white powdered KHMDS (2eq) was suspended in a solution of dimethylformamide. Red crystalline 4-amino-3-nitrophenol (leq) was charged to the rapidly stirring solution under an inert atmosphere and the heterogeneous solution was allowed to stir for 2 hours. Then a dimethylformamide solution of tert-butyl 4- chloropyridine-2-carboxylate (leq) was added dropwise. Anhydrous powdered potassium carbonate (1.2eq) was charged to the reaction as an acid scavenger. The purple colored viscous mixture was heated to 80°C for 12-15 hours until when it was determined to be complete by HPLC. The reaction was evaporated under reduced pressure and diluted with excess ethyl acetate and water. An extraction of the aqueous layer was made with ethyl acetate. The organic layers were combined and washed 4 times with water followed by brine. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude material was purified by flash silica gel chromatography using an eluent of 1:1 mixture of hexanes to ethyl acetate to give the desired product. MS: MH+ = 332.
Step 3. Synthesis of tert-butyl 4-[3-nitro-4-(2,2,2-trifluoroacetylamino) phenoxy] pyridine-2-carboxylate:
Trifluoroacetic anhydride (leq) was slowly added dropwise to a solution of the above amine in anhydrous methylene chloride under nitrogen. After 10-15 minutes or until the reaction was complete as determined by HPLC, the reaction was quenched with excess saturated aqueous sodium bicarbonate. The product was extracted with methylene chloride from the aqueous layer and washed with water and brine. The extracts were dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the title product as a yellow solid. MS: MH+ = 428. Step 4. Synthesis of tert-butyl 4-[3-nitro-4-(2,2,2-trifluoro-N-methylacetylamino) phenoxy] pyridine-2-carboxylate:
A solution of tert-butyl 4-[3-nitro-4-(2,2,2-trifluoroacetylamino) phenoxy] pyridine-2-carboxylate (leq) and sodium carbonate (4eq) in dimethylformamide was stirred at 20°C under nitrogen for thirty minutes before 2 equivalents of iodomethane (2eq) was charged slowly dropwise to the reaction. After 2-3 hours or until it was determined to be complete by HPLC, the reaction was evaporated under reduced pressure. The crude mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the title product as an orange solid. MS: MH+= 442.
Step 5. Synthesis of tert-butyl 4-[4-(methylamino)-3-nitrophenoxy]pyridine-2- carboxylate:
A solution of tert-butyl 4-[3-nifro-4-(2,2,2- fluoro-N-memylacetylamino) phenoxy] pyridine-2-carboxylate in ethanol was stirred at room temperature. IN sodium hydroxide was slowly dropped into the reaction until the conversion was complete by HPLC. The reaction was evaporated under reduced conditions and then extracted with ethyl acetate and washed with a saturated aqueous solution of ammonium chloride followed by water and brine. The organic extracts were dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the product as an orange solid. MS: MH+ = 346
Step 6. Synthesis of tert-butyl 4-[3-amino-4-(methylamino)phenoxy]pyridine-2- carboxylate:
A solution of tert-butyl 4-[4-(methylamino)-3-nitrophenoxy]pyridine-2- carboxylate (leq) and 10% palladium on carbon (O.leq) in methanol was stirred at room temperature and flushed with nitrogen. Hydrogen was flushed through the reaction for 1-2 hours or until the reaction was determined to be complete by HPLC. Nitrogen was flushed through the reaction for 15 minutes before the reaction was filtered through a celite pad. The celite pad was washed with excess methanol followed by concentration under reduced pressure to afford the product as a light yellow solid. MS: MH+ = 316.
Step 7. Synthesis of tert-butyl 4-{2-[(4-bromophenyl)amino]-l-methyl- benzimidazol-5-yloxy}pyridine-2-carboxylate:
A solution of the diamine from step 6 (leq) and 4-bromophenyl isothiocyanate (leq) in anhydrous tetrahydrofuran under nitrogen was stirred at 20°C for 2-3 hours or when determined to be complete by HPLC. The solution was treated with 3 equivalents of l-ethyl-(3-dimethylaminopropyl) carbodiimide HCI. The stirred solution was heated to 50°C under nitrogen for 2-3 hrs or until the reaction is determined to be complete by HPLC. The reaction was evaporated under reduced pressure and then diluted with ethyl acetate and water. The aqueous layer was back extracted with ethyl acetate. The combined organic layers were washed with water and brine. The organic layer was dried over anhydrous sodium. sulfate and later evaporated under reduced pressure. The crude material was purified by reverse high-pressure liquid chromatography to afford the product as a brown powder after lyophlization. MS: MH+= 495.
Step 8. Synthesis of 4-{2-[(4-bromophenyl)amino]-l-methylbenzimidazol-5-yl- oxy}pyridine-2-carboxylic acid
A solution of the product of step 7 in trifluoroacetic acid was treated with two drops of water at room temperature for 3-4 hours or until the reaction was determined to be complete by HPLC. The reaction was evaporated under reduced pressure to afford the product as a red-orange oil in quantitative yield. MS: MH+ = 439.
Step 9. Synthesis of 4-({2-[(4-bromophenyl)amino]-l-methyl-lH-benzimidazol- 5-yl}oxy)-N-ethylpyridine-2-carboxamide:
A solution of above (leq) in anhydrous tetrahydrofuran (0.5 ml) was treated with O-benzotriazol-1-yl N,N,N',N'-tetramethyl uronium hexafluorophosphate (2eq), excess diisopropylethyl amine, and ethyl amine (leq). The reaction was left stirring under nitrogen for 12-15 hours. The reaction was evaporated under reduced pressure and diluted with ethyl acetate. The ethyl acetate layer was washed once with water and then evaporated under reduced pressure. The crude material was purified by reverse high- pressure liquid chromatography and recovered as TFA salt after lyophilization. MS: MH+= 466.
Examples 373-447
The compounds shown in the following Table 4 (Examples 373-447) were prepared from following the procedure described for Example 372.
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Example 450 Preparation of (4-Chloro-phenyl)-{5-[2-(4,5-dihydro-lH-imidazol-2-yl)- pyridin-4-yloxy]-l-methyl-lH-benzoimidazol-2-yl|-amine Step 1. Synthesis of 4-(4-Amino-3-nitro-phenoxy)=puridine-2-carbonitrile:
Figure imgf000091_0001
Potassium carbonate (9.00g) was dried in vacuo with heating, cooled to RT under nitrogen. 4-amino-3-ntrophenol (3.355 g), 4-chioro-2-cyanopyridine (3.00 g) and DMSAO (30 mL, anhydrous) were added. The system was stirred under nitrogen as it was heated to 103°C, and held at this temperature 1 hr. The reaction was then cooled to RT, poured onto ice/H2O (500 mL) the precipitate was collected, washed (H2O), dissolved (EtOAc), dried (Na2SO4), filtered and stripped to a solid. This was suspended (Et2O), collected, air-dried 4.1015 g (73.5%) a second crop was collected (0.5467 gm, 10%). M/z=257 (M+l) Step 2. Synthesis of N-[4-(2-Cyano-pyridin-4-yloxy)-2-nitro-phenyl]-2,2,2- trifluoro-N-methyl-acetamide:
Potassium carbonate (1.6g) was dried in vacuo with heating, cooled to RT and suspended in dichloromethane (30 mL) with 4-(4-amino-3-nitro-phenoxy)=puridine-2- carbonitrile (2.005 gm) under nitrogen. This was cooled to 0°C and TFAA (2.2mL) was added, neat. The starting material goes into solution rapidly as addition is made. After 10 min at 0°C, the mixture was diluted with dichloromethane, washed (H2O, aq NaCl), dried (K2CO3), filtered and stripped to a yellow foam. M/z=353 (M+l) The product was used without purification. Iodomethane (0.53 mL) was added to a suspension of potassium carbonate
(1.858 g) in DMF (30 mL containing compound 2 (-7.8 mmole) under nitrogen. The suspension stirred at RT overnight, then poured onto H2O (300 mL), extracted (Et2O, 3x 150 mL), the combined extracts were washed (H2O, aq. NaCl), dried (potassium carbonate), filtered and stripped to an orange oil (7.4922 g). M/z=367 (M+l)
Step 3. Synthesis of 4-(4-Methylamino-3-nitro-phenoxy)-pyri.dine-2-carbonitrile:
Figure imgf000092_0001
NaOH (1 mL, IN aq) was added dropwise to a solution of N-[4-(2-cyano-pyridin- 4-yloxy)-2-nitro-phenyl]-2,2,2-trifluoro-N-methyl-acetamide (440 mg) in ethanol (6 mL) at RT. After 40 min, the mixture was diluted with H2O (20 mL) and cooled to 0°C. Bright orange crystals were collected, washed (H2O) and air-dried 311.1 mg. (94%). M/z=271 (M+l)
Step 4. Synthesis of 4-[2-(4-Chloro-phenylamino)-l -methyl- lH-benzoimidazol- 5-yloxy]-pyridine-2-carbonitrile:
Figure imgf000092_0002
Palladium on carbon (46 mg 10% w/w) was suspended in MeOH (2 mL) under nitrogen. The resulting suspension was added, under nitrogen, to a suspension of 4-(4- methylamino-3-nitro-phenoxy)-pyridine-2-carbonitrile (311 mg) in MeOH (3mL) at RT.
The atmosphere was exchanged with hydrogen, and the system stirred vigorously under
1 arm hydrogen for 1 hr. The atmosphere was then exchanged for nitrogen, the mixture was filtered (celite) and the filtrate was used without further purification in the next reaction. M/z=2421 (M+l). 4-chlorophenylisothiocyanate (200 mg) was added to a solution of compound 5 in MeOH (10 mL). The solution was stirred at reflux for 2 hrs. Iodomethane (71 microliters) was added, and stirring continued at 67°C, overnight. The mixture was then cooled to RT evaporated to dryness, and the residue chromatographed (0.5% NH4OH, 5% MeOH, 94.5% dichloromethane on silica gel) to isolate a compound of Rf=0.29 (325 mg). This was crystallized from dichloromethane/ether to give 127 mg. M/z=376 (M+l)
1HNMR (MeOH-d4) 9.40ppm s(b) (IH)
8.55ppm d,d H=5.7, 0.6Hz (IH)
7.62ppm m (2 h)
7.42 ppm d, J=2.5, 0.6Hz (IH)
7.43 ppm d (IH)
7.37 ppm m (2 h)
7.21 ppm d J=2.0Hz (IH)
7.15 ppm d,d J=5.9, 2.5Hz (IH)
6.97 ppm d,d J=8.4,2.2 hz (IH)
3.80 ppm s (3H) Step 5. Synthesis of (4-Chloro-phenyl)-{5-[2-(4,5-dihydro-lH-imidazol-2-yl)- pyridin-4-yloxy]- 1 -methyl- 1 H-benzoimidazol-2-yl} -amine:
Figure imgf000093_0001
H2SO4 (454 mg) was added cautiously to a suspension of 4-[2-(4-chloro- phenylamino)-l-memyl-lH-benzoimidazol-5-yloxy]-pyridine-2-carbonitrile (60.0 mg) in ethylenediamine (0.50 mL). The system was shaken at room temperature for 72 hrs, then poured onto ice/NaHCO3. The solid product was collected, washed (H2O) air-dried
59.8 mg. M/z=419 (M+l).
Example 451 Synthesis of (4- {2-[(4-bromophenyl)amino]benzoxazol- , 5-yloxy|-(2-pyridyl -N-methylcarboxamide
Step 1. Synthesis of 2-amino-4-methoxyphenol The mixture containing 4-methoxy-2-nitrophenol in methanol with catalytic amount of 10%Pd/C was hydrogenated until disappearance of yellow color to yield 2- amino-4-methoxyphenol. MS: MH+ = 140.
Step 2. Synthesis of 5-methoxybenzoxazole-2-thiol The mixture containing 2-amino-4-methoxyphenol(leq) and O-ethylxanthic acid, potassium salt (l.leq) in pyridine was refluxed for two hours. The resultant mixture was poured in to ice/water containing hydrochloric acid to yield a 5-methoxybenzoxazole-2- thiol as a tan solid. MS: MH+ = 182
Step 3. Synthesis of 2-chloro-5-methoxybenzoxazole The mixture containing 5-methoxybenzoxazole-2-thiol was heated in thionyl chloride with a drop of DMF. The resultant mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was washed with brine and dried and concentrated. Purification on a silica gel column gave 2-chloro-5-methoxybenzoxazole ' as a white solid. MS: MH+ = 184. Step 4. Synthesis of (4-bromophenyl)(5-methoxybenzoxazol-2-yl)amine
The mixture containing 2-chloro-5-methoxybenzoxazole(leq), 4-bromoaniline
(2eq) and diisopropylethylamine was refluxed in dimethylformamide. The resultant mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was washed with brine and dried. Purification on silica gel gave (4-bromo- phenyl)(5-methoxybenzoxazol-2-yl)amine. MS: MH+ = 318
Step 5. Synthesis of 2-[(4-bromophenyl)amino]benzoxazol-5-ol The mixture of (4-bromophenyl)(5-methoxybenzoxazol-2-yl)amine and hydro- bromic acid (48%) was subjected to the microwave at 150°C for 6mins to yield 2-[(4- bromophenyl)amino]benzoxazol-5-ol. MS: MH+ = 305 Step 6. Synthesis of (4-{2-[(4-bromophenyl)amino]benzoxazol-5-yloxy}-(2- pyridyl))-N-methylcarboxamide
The mixture containing 2-[(4-bromophenyl)amino]benzoxazol-5-ol (leq), potassium bis(trimethylsilyl)amide (4eq), was stirred in dimethylformamide for 30 min at room temperature. To this mixture was added (4-chloro(2-pyridyl)-N-methyl- carboxamide (leq) and Potassium carbonate (1.2eq) and microwaved for 6 mins at 150°C. The reaction mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was separated and washed with brine, dried, filtered and concentrated. Purification on Prep LC yielded the desired product. MS: MH+ = 439. The compounds shown in the following Table 5 (Examples 452-481) were prepared from following the procedure described for Examples 449-451.
Table 5
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Example 482
Synthesis of [4-(2-{[4-(dimethylamino phenyn amino -1 -methyl benzimidazol-5-yloxy (2-pyridyl)1-N-(2-pyrrolidinylethyl)carboxamide
Step 1. Synthesis of 4-(2-{[4-(dimethylamino)phenylamino)-l-methyl- benzimidazol-5-yloxy)pyridinr-2-carboxylic acid
To tert-butyl4-[3-amino-4-(methylamino)phenoxy]pyridine-2-carboxylate (leq) in methanol was added 4-(dimethylamino)benzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS. The mixture was then concentrated and to it was added tetrahydrofuran and l-ethyl-(3- dimethylaminopropyl)carbodimidehydrochloride (2eq) and stir at ambient temperature for 16 h. tert-butyl4-(2-{[4-dimethylamino)phenyl]amino)-l-methylbenzimidazol-5- yloxy)pyridine-2-carboxylate crashes out of the reaction mixture. To it in methylene chloride was added trifluroacetic acid and stirred at ambient temperature overnight. Resulting 4-(2- { [4-dimet ylamino)phenylamino)- 1 -methylbenzimidazol-5-yloxy)- pyridine-2-carboxylic acid was purified by preparative chromatography. MS: MET*" = 403. Step 2. Synthesis of [4-(2-{[4-(dimethylamino)phenylamino-l-methyl- benzimidazol-5-yloxy)(2-pyridyl)]-N-(2-pyrrolidinylethyl)carboxamide:
To 4-(2- { [4-(dimethylamino)pheylamino)- 1 -methylbenzimidazol-5-yloxy)- pyridine-2-carboxylic acid (leq) in tetrahydrofuran was added 2-pyrrolidinylethylamine (2eq), HBTU (2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative chromatography yielded [4- (2-{[4-(dimethylamino)phenyl]amino -l-methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-(2- pyrrolidinylethyl)carboxamide. MS: MH+ = 498. Example 483
Synthesis of [4-(2- ( r4-bromo-3-methylphenyDamino- 1 -methyl benzimidazol-5-yloxy)(2-pyridyl ]-N-(2-pyrrolidinylethyl)carboxamide
Step 1. Synthesis of 4-{2-[(4-bromo-3-methylphenyl)amino]-l-methyl- benzimidazol-5-yloxy)pyridine-2-carboxylic acid To tert-butyl4-[3-amino-4-(methylamino)phenoxy]pyridine-2-carboxylate (leq) in methanol was added 4-bromo-3-methylbenzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS. To it was then added iodomethane (leq) and heated to 60°C for 2 h. Formation of tert- butyl4-(2-{[4-bromo-3-memylphenyl]amino)-l-methylbenzimidazol-5-yloxy)pyridine -2- carboxylate was followed by LC/MS. To it in methylene chloride was added trifluroacetic acid and stirred at ambient temperature overnight. Resulting 4-(2-{[4- bromo-3-methylphenylamino)- 1 -methylbenzimidazol-5-yloxy)pyridine-2-carboxylic acid was purified by preparative chromatography. MS: MH+ = 452
Step 2. Synthesis of [4-(2-{[4-bromo-3-methylphenyl)amino-l-methyl- benzimidazol-5-yloxy)(2-pyridyl)]-N-(2-pyrrolidinylethyl)carboxamide
To 4-(2-{[4-bromo-3-methylpheylamino)-l-methylbenzimidazol-5-yloxy)- pyridine-2-carboxylic acid(leq) in tetrahydrofuran was added 2-pyrrolidinylethylamine (2eq), HBTU (2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative chromatography yielded [4- (2-{[4bromo-3-methylphenyl]amino -l-methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-(2- pyrrolidinylethyl)carboxamide. MS: MH+ = 549. Example 484
Synthesis of 4-(2- { [2-fluro-5-(trifluromethyl)phenyl amino- 1 -methyl- benzimidazol-5-yloxy)(2-pyridyl 1-N-(2-pyπOlidinylethyl)carboxamide
Step 1. Synthesis of 4-{2-[(2-fluro-5-(trifluromethyl)phenyl)amino]-l- methylbenzimidazol-5-yloxy)pyridine-2-carboxylic acid
To tert-butyl4-[3-amino-4-(methylamino)phenoxy]pyridine-2-carboxylate (leq) in methanol was added 2-fluro-5-(trifluromethyl)benzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS. To it was then added iodomethane (leq) and heated to 60°C for 2 h. Formation of tert-butyl4-(2-{[2-fluro-5-( fluromethyl)phenyl]amino)-l-methylbenzimidazol-5- yloxy)pyridine-2-carboxylate was followed by LC/MS. To it in methylene chloride was added trifluroacetic acid and stirred at ambient temperature overnight. Resulting 4-(2- { [2-fluro-5-(trifluromethyl)phenylamino)- 1 -methylbenzimidazol-5-yloxy)pyridine-2- carboxylic acid was purified by preparative chromatography. MS: MH+ = 446. Step 2. Synthesis of [4-(2-{[2-fluro-5-(trifluromethyl)phenyl)ammo-l- memylbenzimidazol-5-yloxy)(2-pyridyl)]-N-(2-pyrrolidinylethyl)carboxamide:
To 4-(2-{[2-fluro-5-(trifluromethyl)phenylamino)-l-methylbenzimidazol-5-yl- oxy)pyridine-2-carboxylic acid (leq) in tetrahydrofuran was added 2-pyrrolidinylethylamine (2eq), HBTU (2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative chromatography yielded [4-(2- { [2-fluro-5-(trifluromethyl)phenyl] amino-1 -methylbenzimidazol-5-yloxy)- (2-pyridyl)]-N-(2-pyrrolidinylethyl)carboxamide. MS: MH+ = 542.
Example 485 Synthesis of [4-(2-|[4-bromo-3-flurophenyl amino-l-methyl- benzimidazol-5-yloxyX2-pyridyl)]-N-(2-piperidylethyl)carboxamide
Step 1. Synthesis of 4-{2-[(4-bromo-3-flurophenyl)amino]-l-methyl- benzimidazol-5-yloxy)pyridine-2-carboxylic acid
To tert-butyl4-[3-amino-4-(methylamino)phenoxy]pyridine-2-carboxylate (leq) in methanol was added 4-bromo-3-flurobenzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS.
To it was then added iodomethane (leq) and heated to 60°C for 2 h. Formation of tert- butyl4-(2-{[4-bromo-3-flurophenyl]amino)-l-methylbenzimidazol-5-yloxy)pyridine -2- carboxylate was followed by LC/MS. To it in methylene chloride was added trifluroacetic acid and stirred at ambient temperature overnight. Resulting 4-(2-{[4- bromo-3-flurophenylamino)-l-methylbenzimidazol-5-yloxy)pyridine-2-carboxylic acid was purified by preparative chromatography. MS: MH+ = 456.
Step 2. Synthesis of [4-(2-{[4-bromo-3-flurophenyl)amino-l-methyl- benzimidazol-5-yloxy)(2-pyridyl)]-N-(2-piperidylethyl)carboxamide:
To 4-(2-{[4-bromo-3-fluropheylamino)-l-methylbenzimidazol-5-yloxy)pyridine- 2-carboxylic acid (leq) in tetrahydrofuran was added 2-piperidylethylamine (2eq), HBTU (2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative chromatography yielded [4-(2-{[4-bromo- 3-flurophenyl]amino-l-memylbenzimidazol-5-yloxy)(2-pyridyl)]-N-(2-piperidylethyl)- carboxamide. MS: MH+ = 567. Example 486
Synthesis of 4- { 1 -methyl-2- [(4-methylphenyl amino- 1 -methyl- benzimidazol-5-yloxy (2-pyridyl')1-N- (2-pyrrolidinylethyl')carboxamide
Step 1. Synthesis of 4-{l-methyl-2-[(4-methylphenyl)amino]benzimidazol-5- yloxy)pyridine-2-carboxylic acid To tert-butyl-4-[3-amino-4-(methylamino)phenoxy]pyridine-2-carboxylate (leq) in methanol was added 4-methylbenzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS. To it was then added iodomethane (leq) and heated to 60°C for 2 h. Formation of tert- butyl-4- { 1 -methyl-2-[(4-methylphenyl)amino)benzimidazol-5-yloxy)pyridine -2- carboxylate was followed by LC/MS. To it in methylene chloride was added trifluroacetic acid and stirred at ambient temperature overnight. Resulting 4-{l-methyl-2-[(4- methylphenyl)amino]benzimidazol-5-yloxy)pyridine-2-carboxylic acid was purified by preparative chromatography. MS: MH+ = 374.
Step 2. Synthesis of 4-{l-methyl-2-[(4-methylphenyl)amino-l-methyl- benzimidazol-5-yloxy)(2-pyridyl)]-N- (2-pyrrolidinylethyl)carboxamide
To 4- { 1 -methyl-2-[(4-methylphenyl)amino]benzimidazol-5-yloxy)pyridine-2- carboxylic acid (leq) in tetrahydrofuran was added 2-pyrrolidinylethylamine (2eq), HBTU (2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and. preparative chromatography yielded 4-{l- methyl-2-[(4-methylphenyl)amino-l-methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-2(2- pyrrolidinylethyl)carboxamide. MS: MH = 470.
Example 487
Synthesis of [4-(2- { [4-ethylphenyl amino- 1 -methyl benzimidazol-5-yloxy (2-pyridyl)]-N-(2-pyrrolidinylethyl)carboxamide
Step 1. Synthesis of 4-{2-[(4-ethylphenyl)amino]-l-methylbenzimidazol-5- yloxy)pyridine-2-carboxylic acid
To tert-butyl4-[3-amino-4-(methylamino)phenoxy]pyridine-2-carboxylate (leq) in methanol was added 4-ethylbenzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS. To it was then added iodomethane (leq) and heated to 60°C for 2 h. Formation of tert-butyl4-(2- {[4-ethylphenyl]amino)-l-methylbenzimidazol-5-yloxy)pyridine -2-carboxylate was followed by LC/MS. To it in methylene chloride was added trifluroacetic acid and stirred at ambient temperature overnight. Resulting 4-(2-{[4-ethylphenylamino)-l- methylbenzimidazol-5-yloxy)pyridine-2-carboxylic acid was purified by preparative chromatography. MS: MH+ = 388. Step 2. Synthesis of [4-(2-{[4-ethylphenyl)amino-l-methylbenzimidazol-5- yloxy)(2-pyridyl)]-N-(2-pyrrolidinylethyl)carboxamide
To 4-(2- { [4-ethylpheylamino)- 1 -methylbenzimidazol-5-yloxy)pyridine-2- carboxylic acid (leq) in tetrahydrofuran was added 2-pyrrolidinylethylamine (2eq), HBTU (2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative chromatography yielded [4- (2-{[4-ethylphenyl]amino-l-methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-(2-pyrrolidinyl- ethyl)carboxamide. MS: MH+ = 484. . Example 488 Synthesis of [4-(2-{[3-(tert-butyl phenyl amino-l-methyl- benzimidazol-5-yloxy (2-pyridyl)1-N-(2-piperidylethyl')carboxamide
Step 1. Synthesis of 4-{2-[(3-(tert-butyl)phenyl)amino]-l-methylbenzimidazol-5- yloxy)pyridme-2-carboxylic acid
To tert-butyl4-[3-amino-4-(methylamino)phenoxy]pyridine-2-carboxylate (leq) in methanol was added 3-(tert-butyl)benzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS. To it was then added iodomethane (leq) and heated to 60°C for 2 h. Formation of tert- butyl4-(2- { [3-(tert-butyl)phenyl]amino)- 1 -methylbenzimidazol-5-yloxy)pyridine -2- carboxylate was followed by LC/MS. To it in methylene chloride was added trifluroacetic acid and stirred at ambient temperature overnight. Resulting 4-(2-{[3-(tert- butyl)phenylammo)-l-memylbenzimidazol-5-yloxy)pyridine-2-carboxylic acid was purified by preparative chromatography. MS: MH = 416. Step 2. Synthesis of [4-(2-{[3-(tert-butyl)phenyl)amino-l-methylbenzimidazol-5- yloxy)(2-pyridyl)]-N-(2-piperidylethyl)carboxamide
To 4-(2-{[3-(tert-butyl)phenylamino)-l-methylbenzimidazol-5-yloxy)pyridine-2- carboxylic acid (leq) in tetrahydrofuran was added 2-piperidylethylamine (2eq), HBTU (2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative chromatography yielded [4-(2-{[3-(tert- butyl)phenyl]amino-l-methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-(2-piperidylethyl)- carboxamide. MS: MH+ = 512.
Example 489 Synthesis of r4-(2-{[4-chloro-3-(trifluromethyl)phenyl amino-l-methyl- benzimidazol-5-yloxy')(2-pyridyl ]-N-(2-piperidylethyl')carboxamide
Step 1. Synthesis of 4-{2-[(4-cUoro-3-(trifluromethyl)phenyl)amino]-l-methyl- benzimidazol-5-yloxy)pyridine-2-carboxylic acid
To tert-butyl4-[3-amino-4-(methylamino)phenoxyipyridine-2-.carboxylate (leq) in methanol was added 4-chloro-3-(trifluromethyl)berizeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by
LC/MS. To it was then added iodomethane (leq) and heated to 60°C for 2 h. Formation of tert-butyl4-(2- { [4-cUoro-3-(trifluromethyl)phenyl]amino)- 1 -methylbenzimidazol-5- yloxy)pyridine -2-carboxylate was followed by LC/MS. To it in methylene chloride was added trifluroacetic acid and stirred at ambient temperature overnight. Resulting 4-(2- { [4-chloro-3 -(trifluromethyl)phenylamino)- 1 -methylbenzimidazol-5-yloxy)pyridine-2- carboxylic acid was purified by preparative chromatography. MS: MH+ = 462.
Step 2. Synthesis of [4-(2-{[4-chloro-3-(trifluromethyl)phenyl)amino-l-methyl- benzimidazol-5-yloxy)(2-pyridyl)]-N-(2-piperidylethyl)carboxamide
To 4-(2-{[4-chlro-3-(trifluromethyl)pheylamino)-l-methylbeiizimidazol-5-yloxy)- pyridine-2-carboxylic acid(leq) in tetrahydrofuran was added 2-piperidylethylamine (2eq), HBTU (2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative chromatography yielded [4- (2-{[4-cUoro-3-1rifluromethylphenyl]amino-l-methylbenzimidazol-5-yloxy)(2-pyridyl)]- N-(2-piperidylethyl)carboxamide. MS: MH+ = 558.
Each of the compounds 490-626 listed below in Table 6, were synthesized as indicated in the right hand column by the method described in one of the Examples 482- 489.
Table 6
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Synthesized as in
Example Molecular Structure Name MH+ Example:
620 4-[(2-{[4-chloro-3- 520.9 489 (trifluoromethyl)phenyl] ami no} -1 -methyl- 1H-
Figure imgf000124_0001
benzimidazol-5-yl)oxy]-N- [2-(methyloxy)ethyl]- pyridine-2-carboxamide
621 4-[(2-{[4-chloro-3- 574.0 489 (trifluoromethyl)phenyl] ami H,c o no}-l-methyl-lH- benzimidazol-5-yl)oxy]-N- (2-piperidin- 1 -ylethyl)- pyridine-2-carboxamide
622 4-[(2-{[4-chloro-3- 588.0 489 xχy°χτ» (trifluoromethyl)phenyl] ami no} -1 -methyl- 1H- benzimidazol-5-yl)oxy]-N- (3 -piperidin- 1 -yl- propyl)pyridine-2-carbox- amide
623 4-[(2-{[4-chloro-3-(tri- 568.0 489 fluoromethyl)phenyl] - amino } - 1 -methyl- 1 H-
Figure imgf000124_0002
benzimidazol-5-yl)oxy]-N- (2-pyridin-4-ylethyl)- pyridine-2-carhoxamide
624 4-[(2-{[4-chloro-3- 575.0 489 (trifluoromethyl)phenyl] ami no} -1 -methyl- 1H-
Figure imgf000124_0003
benzimidazol-5-yl)oxy]-N- (2-piperazin- 1 -ylethyl)- pyridine-2-carboxamide
625 4-[(2-{[4-chloro-3- 531.9 489 (trifluoromethyl)phenyl] ami no} -1 -methyl- 1H-
Figure imgf000124_0004
benzimidazol-5-yl)oxy]-N- [(3R)-ρyrrolidin-3-yl]- pyridine-2-carboxamide
Figure imgf000125_0001
Example 627 Step 1. Synthesis of [4-(2-{[4-(chloromethyl)phenyl] carbonylamino)- 1- methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-methylcarboxamide A solution of sodium thiocyanate (leq) in acetone was added slowly in to a solution of 4-(chloromethyl)benzoylchloride (leq) in acetone at 0°C. The mixture was then filtered in to a solution of {4-[3-amino-4-(methylamino)phenoxy](2-pyridyl)}-N- methylcarboxamide (leq) in acetone. Formation of N-acylthiourea was followed by LC/MS. The mixture was concentrated and taken in tetrahydrofuran and to it was added l-ethyl-(3-dimethylaminopropyl)carbodimidehydrochloride (2eq) and stirred at ambient temperature for 16 h. The mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was then dried and concentrated to yield [4-(2-{[4- (chloromethyl)phenyl]carbonylamino)-l-methylbenzimidazol-5-yloxy)(2-pyridyl)]-N- methylcarboxamide. MS: MH+ = 449. , Step 2. Synthesis of N-methyl{4-[l-methyl-2-({4-[(4methylpiperazinyl) methyl]phenyl} carbonylamino) benzimidazol-5-yloxy] (2-pyridyl)} carboxamide.
To a solution of [4-(2-{[4-(chloromethyl)phenyl] carbonylamino)- 1- methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-methylcarboxamide (leq) in tetrahydrofuran was added methylpiperazine (4eq) and stiired at ambient temperature for 16 h. The reaction mixture was concentrated and purified on preparative chromatography to yield N-methyl {4-[l -methyl-2-( {4-[(4methylpiperazinyl) methyl]phenyl} carbonylamino) benzimidazol-5-yloxy](2-pyridyl)}carboxamide. MS: MH+ = 512.
Example 628 Step 1. Synthesis of N-methyl[4-(l -methyl-2- {2- {4-[(4-methylpiperazinyl)- methylphenyl} -benzimidazol-5-yloxy)(2-pyridyl)] carboxamide To a solution of {4-[3-amino-4-(methylamino)phenoxy](2-pyridyl)}-N- methylcarboxamide (leq) in tetrhydrofuran was added 4-(chloromethyl)benzoylchloride (leq) and triethylamine (2eq). N-acylation is completed in 0.5 h. The reaction mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and to the crude product was added methylpiperazine (4eq) and tetrahydrofuran and stir for 16 h at ambient temperature. The reaction mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and taken in acetic acid and heated to 60°C for 3 h. Preparative chromatography yielded N-methyl[4-(l -methyl-2- {2- {4-[(4-methylpiperazinyl)methyl- phenyl} -benzimidazol-5-yloxy)(2-pyridyl)]carboxamide. MS: MH+ - 470.
Example 629 Step 1. Synthesis of 2-chloro-4-(3-pyridyl)pyrimidine
Nitrogen was bubbled through a solution of 2,4-dichloropyrimidine (leq) in tetrahydrofuran and water (3:1) for 0.5 h. Bis(diphenylphosphino)ferrocene Palladium(II)chloride (0.05eq) followed by pyridine-3-boronic acid (leq) and sodium carbonate (3eq) was added and the mixture was heated to 60°C for 16 h under nitrogen. The reaction mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was washed with brine and dried with sodium sulfate and concentrated. Purification on silica gel gave 2-chloro-4-(3-pyridyl)pyrimidine. MS: MH+ =190. Step 2. Synthesis of 2-nitro-4-(4-(3-pyridyl)pyrimidin-2-yloxy)phenylamine
A solution of 4-amino-3-nitro-phenol (leq) and 2-chloro-4-(3-pyridyl)pyrimidine
(leq) in N,N-dimethylformamide was microwaved at 150°C for 10 mins. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was concentrated and purified on silica gel to yield 2-nitro-4-(4-(3-pyridyl)pyrimidin-2- yloxy)phenylamine. MS: MH+ =309.
Step 3. Synthesis of 4-(4-(3-pyridyl)pyrimidin-2-yloxy)benzene-l,2-diamine The mixture containing 2-nitro-4-(4-(3-ρyridyl)pyrimidin-2-yloxy)phenylamine in methanol with catalytic amount of 10% Pd/C was hydrogenated until disappearance of yellow color to yield 4-(4-(3-pyridyl)pyrimidin-2-yloxy)benzene-l,2-diamine. MS: MH + =279.
Step 3. Synthesis of {4-[(4-methylpiperazinyl)methyl]phenyl}-N-[5-(4-(3- pyridyl)pyrimidin-2-yloxy)benzimidazol-2-yl]carboxamide. A solution of sodium thiocyanate (leq) in acetone was added slowly in to a solution of 4-(chloromethyl)benzoylchloride (leq) in acetone at 0°C. The mixture was then filtered in to a solution of 4-(4-(3-pyridyl)pyrimidin-2-yloxy)benzene-l,2-diamine (leq) in acetone. Formation of N-acylthiourea was followed by LC/MS. The mixture was concentrated and taken in tetrahydrofuran and to it was added l-ethyl-(3- dimethylaminopropyl)carbodimidehydrochloride (2eq) and stirred at ambient temperature for 16 h. The mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was then dried and concentrated to yield [4-(chloromethyl)phenyl]-N- [5-(4-(3-pyridyl)pyrimidin-2-yloxy)benzimidazol-2-yl]carboxamide. It was taken in tetrahydrofuran and added methylpiperazine (4eq) and stirred at ambient temperature for 16 h. The reaction mixture was concentrated and purified on preparative chromatography to yield {4-[(4-methylpiperazinyl) memyl]phenyl}-N-[5-(4-(3-pyridyl)pyrimidin-2- yloxy)benzimidazol-2-yl]carboxamide. MS: MH + =520.
Example 630 Step 1. Synthesis of 4-ethyl-l-[(4-nitrophenyl)methylpiperazine
To 4-(chloromethyl)-l-nitrobenzene(leq) in tetrahydrofuran was added Ethylpiperazine (3eq) and stir for 16 h at ambient temperature. Concentrating and passing through a plug of silica gave 4-ethyl-l-[(4-nitrophenyl)methylpiperazine. MS: MH+ = 249 Step 2. Synthesis of 4-[(4-ethylpiperazinyl)methyl]phenylamine
The mixture containing .4-ethyl-l-[(nitrophenyl)methylpiperazine in methanol with catalytic amount of 10% Pd/C was hydrogenated to yield 4-[(4-ethyl- piperazinyl)methyl]phenylamine. MS: MH+ = 219.
Step 3. Synthesis of 4-[(4-ethylpiperazinyl)methyl]benzeneisothiocyanate To 4-[(4-ethylpiperazinyl)methyl]phenylamine in acetone at 0°C was added sodium bicarbonate (2eq) and thiophosgene (2eq). The mixture was brought to ambient temperature and concentrated and partitioned between ethyl acetate and water. The organic layer was dried with sodium bicarbonate and sodium sulfate and concentrated to yield 4-[(4-ethylpiperazinyl)methyl]benzeneisotlιiocyanate. MS: MH = 261. Step 4. Synthesis of [4-[(2-{[4-ethylpiperazinyl)methyl]phenyl] amino)- 1- methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-methylcarboxamide To 4-[(4-ethylpiperazinyl)methyl]benzeneisothiocyanate(leq) in methanol was added {4- [3 -amino-4-(methylamino)phenoxy] (2-pyridyl) } -N-methylcarboxamide ( 1 eq) and heated to 60°C for 16 h. Preparative chromatography yielded [4-[(2-{[4- ethylpiperazinyl)methyl]phenyl]amino)-l-methylbenzimidazol-5-yloxy)(2-pyridyl)]-N- methylcarboxamide. MS: MH+ = 499.
Example 631 Step 1. Synthesis of 4-Ethyl-l-(4-nitrophenyl)piperazine
To 4-fluro-l-nitrobenzene(leq) in N,N-dimethylformamide was added Ethyl piperazine (2eq) and N,N-diisopropylethyl amine (2eq) and heated at 80°C for 16 h. Concentrated the resultant mixture and partitioned between ethyl acetate and water. The organic layer was then washed with brine and dried with sodium sulfate and concentrated. Passed through a plug of silica to yield 4-Ethyl-l-(4-nitrophenyl)piperazine. MS: MH+ = 235. Step 2. Synthesis of 4-(4-ethylpiperazinyl)phenylamine
The mixture containing 4-ethyl-l-(4-nitrophenyl)piperazine in methanol with catalytic amount of 10%Pd/C was hydrogenated to yield 4-(4-ethylpiperazinyl)phenyl- amine. MS: MH+ = 205.
Step 3. Synthesis of 4-(4-ethylpiperazinyl)benzeneisothiocyanate To 4-(4-ethylpiperazinyl)phenylamine in acetone at 0°C was added sodium bicarbonate (2eq) and thiophosgene (2eq). The mixture was brought to ambient temperature and concentrated and partitioned between ethyl acetate and water. The organic layer was dried with sodium bicarbonate and sodium sulfate and concentrated to yield 4-(4-ethylpiperazinyl)benzeneisothiocyanate. MS: MH+ = 247. Step 3. Synthesis of [4-(2-{[4-ethylpiperazinyl)phenyl] amino)- 1-methyl- benzimidazol-5-yloxy)(2-pyridyl)]-N-methylcarboxamide
To 4-(4-ethylpiperazinyl)benzeneisothiocyanate (leq) in methanol was added {4-
[3-amino-4-(methylamino)phenoxy](2-pyridyl)}-N-methylcarboxamide (leq) and heated to 60°C for 16 h. Preparative purification yielded [4-(2-{[4-ethylpiperazinyl)phenyl]- amino)-l-methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-methylcarboxamide. MS: MH+ =
485. Example 632
Step 1. Synthesis of 4-(2-bromoethyl)-l -nitrobenzene
To 4-(2-bromoethyl)-l-nitrobenzene(leq) in tetrahydrofuran was added morpholine (3eq) and stir for 16 h at ambient temperature. Concentrating and passing through a plug of silica gave 4-[2-(4-nitrophenyl)ethylmorpholine. MS: MH+ = 236.
Step 2. Synthesis of 4-(2-morpholin-4-ylethyl)phenylamine
The mixture containing 4-[2-(4-nitrophenyl)ethyl]morpholine in methanol with catalytic amount of 10%Pd/C was hydrogenated to yield 4-(2-morpholin-4- ylethyl)phenylamine. MS: MH+ = 206. Step 3. Synthesis of 4-(2-morpholin-4-ylethyl)benzeneisothiocyanate
To 4-(2-morpholin-4-ylethyl)phenylamine in acetone at 0°C was added sodium bicarbonate (2eq) and thiophosgene (2eq). The mixture was brought to ambient temperature and concentrated and partitioned between ethyl acetate and water. The organic layer was dried with sodium bicarbonate and sodium sulfate and concentrated to yield 4(2-morpholin-4-ylethyl)benzeneisothiocyanate. MS: MH+ = 252.
Step 4. Synthesis of N-methyl[4-(l -methyl-2- {[4-(2-morpholin-4- ylethyl)phenyl]amino}-benzimidazol-5-oxy)(2-pyridyl)]carboxamide
To 4(2-morpholin-4-ylethyl)benzeneisothiocyanate (leq) in methanol was added
{4-[3-amino-4-(methylamino)phenoxy](2-pyridyl)}-N-methylcarboxamide (1 eq) and stirred at ambient temperature for 16 h. The corresponding thiourea formation was followed by LC/MS. To it was the added iodomethane(leq) and heated to 60°C for 3h.
Concentration followed by preparative chromatography yielded N-methyl[4-(l-methyl-2- j {[4-(2-morpholin-4-ylethyl)phenyl]amino}-benzimidazol-5-oxy)(2-pyridyl)]carbox- amide. MS: MH+ = 486.
Example 633 Step 1. Synthesis of [(4-mtrophenyl)ethyl]benzylamine
To a solution of l-(4-nitrophenyl)ethan-l-one (leq) and phenylmethylamine
(leq) in methanol was added sodiumtriacetoxyborohydride (1.2eq). The resulting mixture was stirred at ambient temperature for 16 h. The mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative purification yielded [(4-nitrophenyl) ethyl]benzylamine. MS: MH+ =256. Step 2. Synthesis of [(4-aminophenyl)ethyl]benzylamine
The mixture containing [(4-nitrophenyl) ethyl]benzylamine in methanol with catalytic amount of 10%Pd/C was hydrogenated until disappearance of yellow color to yield [(4-aminophenyl)ethyl]benzylamine. MS: MH + =226. Step 3. Synthesis of 4-{[ben2ylamino]ethyl}benzeneisothiocyanate
To [(4-nitrophenyl) ethyl]benzylamine in acetone at 0°C was added sodium bicarbonate (2eq) and thiophosgene (2eq). The mixture was brought to ambient temperature and concentrated and partitioned between ethyl acetate and water. The organic layer was dried with sodium bicarbonate and sodium sulfate and concentrated to yield 4-{[benzylamino]ethyl}benzeneisothiocyanate. MS: MH+ =268.
Step 4. Synthesis of N-methyl(4-{l-methyl-2-2[(4-{[benzylamino]ethyl}- phenyl)amino)benzimidazol-5-yloxy)-(2-pyridyl))carboxamide
To a solution of [4-(3,4-diammophenoxy)(2-pyridyl))]-N-methylcarbox- amide(leq) in methanol was added 4-{[benzylamino]ethyl}benzeneisothiocyanate (leq) and heated to 60°C for 3h. Preparative chromatography yielded N-methyl(4-{l -methyl-
2-2-[(4-{[benzylamino] ethyl}phenyl) amino)benzimidazol-5-yloxy)-(2-pyridyl))- carboxamide. MS: MH+ =506.
Example 634 ' Step 1. Synthesis of (5-fluro-2-nitrophenyl)methylamine
A solution of 5-fluro-2-nitrophenylamine (leq) in methylenechloride was treated with trifluoroacetic anhydride (leq) and stirred for 10 minutes at 0°C. The mixture was quenched with saturated sodium bicarbonate solution. The organic layer was separated and washed with water , brine, dried and evaporated. To the solution of the trifluroacetamide (leq) in a mixture of toluene, acetonitrile and sodium hydroxide solution (50%) was added benzyltrimethylammonium chloride (leq) and dimethyl sulfate (1.2eq). The biphasic mixture was stirred overnight at room temperature and evaporated. The mixture was taken up in ethyl acetate, washed with water, brine, dried and evaporated. The crude was purified by column chromatography eluting with 1 : 1 hexanes and ethyl acetate to afford (5-fluro-2-nitrophenyl)methylamine. MS: MH + =170.
Step 2. Synthesis of {4-[4-amino-3-(methylamino)phenoxy](2-pyridyl)}-N- methylcarboxamide The mixture containing 5-fluro-2-nitrophenylamine (leq), Potassium bis(trimethylsilyl)amide (2eq) was stirred in dimethylformamide for 2 hours at room temperature. To this mixture was added (3-hydroxyphenyl)-N-methylcarboxamide (leq) and Potassium carbonate (1.2eq) and stirred at 90°C for 16 h. The reaction mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was separated and washed with brine, dried, filtered and concentrated in vacuum to give brown solid. Purification on silica gel gave N-methyl{4-[3-(methylamino)-4-nitro- phenoxy](2-pyridyl))carboxamide. It was taken in methanol and hydrogenated with catalytic amount of 10%Pd/C to give {4-[4-aminb-3-(methylamino)phenoxy](2- pyridyl)} -N-methylcarboxamide. MS: MH+ =272.
Step 3. Synthesis of (4-{2-[(4-bromophenyl)amino]-l-methylbenzimidazol-6- yloxy)-(2-pyridyl)-N-methylcarboxamide
A solution of the {4-[4-amino-3-(methylamino)phenoxy](2-pyridyl)}-N-methyl- carboxamide(leq) in methanol was treated with 4 -bromophenylisotbiocyanate (leq) and stirred at 60°C for 2 hours. The reaction mixture was cooled down to room temperature and iodomethane (leq) was added and stirred overnight at 60°C. The reaction was concentrated and preparative chromatography gave (4-{2-[(4-bromophenyl)amino]-l- me ylbenzimidazol-6-yloxy)-(2-pyridyl)-N-methylcarboxamide. MS: MH+ =452.
Example 635
Step 1. Synthesis of ((5-aminobenzimidazol-2-yl)(4-bromophenylamine) A solution of the 4-nitrobenzene-l,2-diamine in methanol was treated with 4- bromo phenyl isothiocyanate (leq) and stirred at 60°C for 2 hours. The reaction mixture was cooled down to room temperature and iodomethane (leq) was added and stirred overnight at 60°C. The reaction was concentrated and purified on silica gel to yield (4- bromophenyl)(5-nitrobenzimidazol-2-yl)amine. The product was taken in methanol and hydrogenated with catalytic amount of 10%Pd/C to give ((5-aminobenzimidazol-2-yl)(4- bromophenylamine). MS: MH+ =302.
Step 2. Synthesis of [4-({2-[(4-bromophenyl)amino}benzimidazol-5τyl}amino)- (2-pyridyl_-N-methylcarboxamide
To a solution of ((5-aminobenzimidazol-2-yl)(4-bromophenylamine(leq) in N,N- dimethylformamide was added sodium hydride (2eq) and the mixture was microwaved for 8mins at 220°C. The reaction mixture was partitioned between ethyl acetate and water and the organic layer was dried with sodium sulfate and concentrated. Preparative chromatography - yielded [4-( {2-[(4-bromophenyl)amino}benzimidazol-5-yl} amino)(2- pyridyl_-N-methylcarboxamide. MS: MH+ =437.
Example 636 Step 1. Synthesis of (4-{2-[(4-bromophenyl)methyl]-l-methylbenzimidazol-5- yloxy)-(2-pyridyl))-N-methylcarboxamide
To 4-bromophenyl acetic acid (leq) in dichoromethane containing a drop of N,N- dimethyl formamide at 0°C was added oxalyl chloride (1.2eq). The resulting mixture was then brought to ambient temperature and stirred for 2 h. The mixture was concentrated and to it was added tetrahydrofuran and [4-(3,4-diaminophenoxy)(2-pyridyl)]-N- methylcarboxamide (leq) and triethyl amine (leq) and stirred for 2 h. Formation of the N-acylated product was followed by LC/MS. The mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was dried with sodium sulfate and concentrated and taken in acetic acid and heated to 60°C for 2 h. Preparative chromatography yielded (4- {2-[(4-bromophenyl)methyl]-l-methylbenzimidazol-5- yloxy)-(2-pyridyl))-N-methylcarboxamide. MS: MH+ = 451.
Example 637
Step 1. Synthesis of 4-({l-methyl-5-[2-(N-methylcarbamoyl)(4-pyridyl- oxy))]benzimidazol-2-yl } amino)benzoic acid
To {4-[3-amino-4-(methylamino)phenoxy](2-pyridyl)}-N-methylcarboxamide
(leq) in methanol was added 4-isothiocyanatobenzoic acid (leq) and stirred at 60°C for 3h. To it was then added iodomethane (leq) and heated to 60°C for 3h. and concentrated the solvent and purified on silica gel to yield 4-({l-methyl-5-[2-(N-methylcarbamoyl)(4- pyridyloxy))]benzimidazol-2-yl}amino)benzoic acid. MS: MH = 417..
Step 2. Synthesis of N-methyl[4-(l-methyl-2-{[4-(2-morpholin-4-ylethyl)phenyl]- amino-benzimidazol-5-oxy)(2-pyridyl)] carboxamide CHIR- 164277 To 4-( { 1 -methyl-5-[2-(N-methylcarbamoyl)(4-pyridyloxy))]benzimidazol-2-yl}- amino)benzoic acid (leq) in tetrahydrofuran was added morpholine (2eq) and N,N- diisopropylethylamine(4eq) and HBTU(2eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was washed with brine and dried with sodium sulfate. Preparative chromatography gave N-methyl[4-(l-methyl-2-{[4-(2-morpholin-4-ylethyl)phenyl]- amino-benzimidazol-5-oxy)(2-pyridyl)]carboxamide. MS: MH+ = 529.
Example 638 Step 1. Synthesis of 3-({l-methyl-5- [2-(N-methylcarbamoyl)(4-pyridyloxy))] benzimidazol-2-yl} amino) benzoic acid
To 4-[3-amino-4- (methylamino) phenoxy] (2-pyridyl)} -N-methylcarboxamide (leq) in methanol was added 3-isothiocyanatobenzoic acid (leq) and stirred at 60°C for
3h. To it was then added iodomethane (leq) and heated to 60°C for 3h and concentrated the solvent and purified on silica gel to yield 3-({l-methyl-5- [2-(N-methylcarbamoyl)(4- pyridyloxy))] benzimidazol-2-yl} amino)benzoic acid. MS: MH+ = 417.
Step 2. Synthesis of N-methyl[3-(l-methyl-2-{[4-(2-morpholin-4-ylethyl)ρhenyl]- amino-benzimidazol-5-oxy)(2-pyridyl)]carboxamide
To 3-({l-methyl-5-[2-(N-methylcarbamoyl)(4-pyridyloxy))]benzimidazol-2-yl}- amino)benzoic acid (leq) in tetrahydrofuran was added morpholine (2eq) and N,N- diisopropylethylamine (4eq), EDCI (2eq), HOAT(1.2eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was washed with brine and dried with sodium sulfate. Preparative chromatography gave N-methyl[3-(l-methyl-2-{[4-(2-morpholin-4-ylethyl)- phenyl]amino-benzimidazol-5-oxy)(2-pyridyl)]carboxamide. MS: MH+ = 529.
Each of the compounds 639-698, listed in Table 7 were synthesized as indicated in the right hand column by the method described in one of the Examples 627-638 or as otherwise indicated.
Table 7
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Synthesis as in
Example Structure Name MH+ Example:
654 N-methyl-4-( { 1 -methyl-2- 528.6 637 [(4- {['(2-piperidin-l -ylethyl)- amino]carbonyl}phenyl)amin
Figure imgf000136_0001
o]- 1 H-benzimidazol-5-yl} - oxy)pyridine-2-carboxamide
655 4-[(2-{[4-({[3-(lH-imidazol- 525.6 637 l-yl)propyl]amino}carbonyl)- u v phenyl] amino } - 1 -methyl- 1 H- benzimidazol-5-yl)oxy]-N- methylpyridine-2-carbox- amide
656 4-[(2-{[4-({[(l-ethyl- 528.6 637 Λ σ -1 pyrrolidin-2-yl)methyl]- amino} carbonyl)phenyl]- amino } - 1 -methyl- 1 H- benzimidazol-5-yl)oxy]-N- methylpyridine-2-carbox- amide
657 N-methyl-4-( { 1 -methyl-2- 514.6 637 [(4- { [(2-pyrrolidin- 1 -yl- ethyl)amino]carbonyl}- phenyl)amino] - 1 H- benzimidazol-5-yl} oxy)- pyridine-2-carboxamide
658 N-methyl-4-( { 1 -methyl-2- 508.6 637 cr x tcr [(4- { [(pyridin-4-ylmethyl)- amino]carbonyl}phenyl)- amino]- 1 H-benzimidazol-5- yl } oxy)pyridine-2- carboxamide
659 N-methyl-4-{[l-methyl-2- 500.6 637 ({4-[(l,3-thiazol-2-yl- amino)carbonyl]phenyl} amin
Figure imgf000136_0002
o)-lH-benzimidazol-5-yl]- oxy } pyridine-2-carboxamide
660 N-methyl-4-[(l-methyl-2-' 557.7 637 rγ Λa { [4-( { [3 -(4-methylpiperazin-
Λ-O° 1 -yl)propyl] amino } carbonyl)- phenyl]amino } - 1 H- benzimidazol-5-yl)oxy]- pyridine-2-carboxamide
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Example 699
Step 1. Synthesis of {4-[2-methoxy-4-(methylamino)-5-nitrophenoxy](2- pyridyl) } -N-methylcarboxamide
To a stirred solution of concentrated nitric acid (22eq) was added 2 h- benzo[d]l,3-dioxolane(leq) at 0-10 °C for 0.5h and stirred for another 0.5h. To this reaction mixture was then added concentrated sulfuric acid (0.06eq) drop- wise at 0-10C° for 0.5h and stirred at 20C° for 0.5h. It was then poured on to crushed ice, and the separated solid was filtered washed with water and dried to give 5,6-dinitro-2 h- benzol[d]l,3-dioxalane. MS:MH+ 212
Step 2. Synthesis of methyl(6-nitro(2 h-benzo[3,4-d]l,3-dioxalan-5-yl)amine
To a stirred solution of methyl amine in ether and ethanol (1.5:1) was added 5,6- dinitro-2 h-benzol[d]l,3-dioxalane and stirred at ambient temperature for 24h. The solvent was evaporated under vacuum and the solid was washed with water and dried to give methyl(6-nitro(2 h-benzo[3.4-d]l,3-dioxaln-5-yl))amine. MS: MH+ 196
Step 3. Synthesis of 2-methoxy-4-(methylamino)-5-nitrophenol
To a stirred solution of methanol was added sodium metal (4.8 eq) slowly at ambient temperature followed by methyl(6-nitro(2 h-benzo[3,4-d]l,3-dioxalan-5- yl))amine (1 eq) and stirred for 2 h. The mixture was then refluxed for 0.5h and diluted with water. After cooling it to ambient temperature the separated solid was filtered and dried to give 2-methoxy-4-(methylamino)-5-nitrophenol as a red solid. MS:MH+ 198
Step 4. Synthesis of {4-[2-methoxy-4-(methylamino)-5-nitrophenoxy](2- pyridyl) } -N-methylcarboxamide
To a stirred solution of 2-methoxy-4-(methylamino)-5-nitrophenol(leq) in N,N- dimethylacetamide was added potassium-t-butoxide (1.2eq) and continued stirring at ambient temperature untilit solidified. To it was then added (3-chlorophenyl)-N- methylcarboxamide (leq) and anhydrous potassium carbonate (leq) and the resulting mixture was heated to 50°C whereby the solid liquified. It was then heated to 110°C for 12 h. After cooling to ambient temperature the solvent was distilled off and the resulting solid was extracted using ethyl acetate in a soxhlet apparatus for 48h. the organic layer was cooled to 0°C , when the product crystallized from the ethyl acetate to give {4-[2- methoxy-4-(methylamino)-5-nitrophenoxy](2-pyridyl)}-N-methylcarboxamide. MS:MH+ 332
Step 5. Synthesis of 4-{2-[(4-chlrophenyl)amino]-6-methoxy~l-methyl- benzimidazol-5-yloxy)pyridine-2-carboxylic acid
To tert-butyl4-[3-amino-6-methoxy-4-(methylamino)phenoxy]pyridine-2- carboxylate(leq) in methanol was added 4-chlorobenzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS. To it was then added iodomethane (leq) and heated to 60°C for 2 h. Formation of tert-butyl4-(2-{[4-chlorophenyl]amino)-l-methylbenzimidazol-5-yloxy)pyridine -2- carboxylate was followed by LC/MS. To it in methylene chloride was added trifluroacetic acid and stirred at ambient temperature overnight. Resulting 4-(2-{[4- chlorophenylamino)-6-methoxy~l-methylbenzimidazol-5-yloxy)pyridine-2-carboxylic acid was purified by preparative chromatography. MS: MH+ = 424.
Step 6. Synthesis of [4-(2-{[4-chlorophenyl)amino-6-methoxy-l- methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-(2-pyrrolidinylethyl)carboxamide
To 4-(2- { [4-chloropheylamino)-6-methoxy- 1 -methylbenzimidazol-5-yloxy)- pyridine-2-carboxylic acid(leq) in tetrahydrofuran was added 2-pyrrolidinylethylamine (2eq), HBTU (2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative chromatography yielded [4- (2-{[4-chlorophenyl]amino-6-methoxy-l-methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-(2- pyrrolidinylethyl)carboxamide. MS: MH+ = 522.
Example 700 Step 1. Synthesis of 4-{2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-l- methylbenzimidazol-5-yloxy)pyridine-2-carboxylic acid
To tert-butyl4-[3-amino-6-methoxy-4-(memylamino)phenoxy]pyridine-2- carboxylate(leq) in methanol was added 4-bromo-3-methylbenzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS. To it was then added iodomethane (leq) and heated to 60°C for 2 h. Formation of tert-butyl4-(2-{[4-bromo-3-methylphenyl] amino)- 1- methylbenzimidazol-5-yloxy)pyridine -2-carboxylate was followed by LC/MS. To it in methylene chloride was added trifluroacetic acid and stirred at ambient temperature overnight. Resulting 4-(2- { [4-bromo-3 -methylphenylamino)-6-methoxy~ 1 - methylbenzimidazol-5-yloxy)pyridine-2-carboxylic acid was purified by preparative chromatography. MS: MH+ = 482.
Step 2. Synthesis of [4-(2-{[4-bromo-3-methylphenyl)amino-6-methoxy-l- memylbenzimidazol-5-yloxy)(2-pyridyl)]-N-(2-pyrrolidinylethyl)carboxamide
To 4-(2-{[4-bromo-3-methylpheylamino)-6-methoxy-l-methylbenzimidazol-5- yloxy)pyridine-2-carboxylic acid(leq) in tetrahydrofuran was added 2- pyrrolidinylethylamine (2eq), HBTU (2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative chromatography yielded [4-(2- { [4-bromo-3 -methylphenyl] amino-6-methoxy- 1 - methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-(2-pyrrolidinylethyl)carboxamide. MS:
MH+ = 579.
Example 701 Step 1. Synthesis of 4-{3-[3-(3-Isopropyl-phenyl)-thioureaido]-4-methylamino- phenoxy } -pyridine-2-carboxylic acid
To tert-butyl4- [3-amino-4- (methylamino) phenoxy] pyridine-2-carboxylate (leq) in methanol was added 3-isopropylbenzeneisothiocyanate (leq) and stir at ambient temperature for 16 h. Formation of the corresponding thiourea was followed by LC/MS. To it was then added iodomethane (leq) and heated to 60°C for 2 h. Formation of 4-{3- [3 -(3 -Isopropyl-phenyl)-thioureaido] -4-methylamino-phenoxy } -pyridine-2-carboxylate was followed by LC/MS. To it in methylene chloride was added trifluoroacetic acid and stirred at ambient temperature overnight. Resulting 4-(2-{[4-bromo-3-methylphenyl- amino)-l-methylbenzimidazol-5-yloxy) pyridine-2-carboxylic acid was purified by preparative chromatography. MS: MH+ = 437
Step 2. Synthesis of 4-[2-(3-Isopropyl-phenylamino)-l-methyl-lH- benzoimidazol-5-yloxy]-pyridine-2-carboxylicacid) 2-pyrrolidin- 1 -yl-ethyl)-amide
To 4-{3-[3-(3-Isopropyl-phenyl)-thioureaido]-4-methylamino-phenoxy}-pyridine- 2-carboxylic acid (leq) in tetrahydrofuran was . added 2-pyrrolidinylethylamine (2eq), EDCI (2eq), HO AT (1.2eq) and N,N-diisopropylethylamine (4eq) and stir at ambient temperature for 16 h. The mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was concentrated and preparative chromatography yielded 4-[2-(3-Isopropyl-phenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]-pyridine- 2-carboxylicacid) 2-pyrrolidin- l-yl-ethyl)-amide. MS: MH+ = 499. Example 702
Step 1. Synthesis of 3-chloro-4-(2-methyl-5-nitrophenyl)pyridine Nitrogen was. bubbled through a solution of 2-bromo-l-methyl-4-nitrobenzene (leq) in dimethoxyethane and water (3:1) for 0.5h. Bis(diphenylphosphino)ferrocene Palladium(II)chloride (0.05eq) followed by 3-chloro-4-pyridine boronic acid hydrate (leq) and sodium carbonate (3eq) was added and the mixture was heated to 90°C for 16 h under nitrogen. The reaction mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was washed with brine and dried with sodium sulfate and concentrated. Purification on silica gel gave 3-chloro-4-(2-methyl-5- nitrophenyl)pyridine. MS: MH+ =248.
Note: The same procedure was used for Suzuki reaction between the halopyridines and the nitrophenylboronic acids. Boronic acids were synthesized using the following procedure if commercially unavailable.
Step la. Synthesis of 2-fluropyridine boronic acid
A flame-dried flask was charged with toluene and tetrahydrofuran (4:1) and then with 4-bromo-2-fluropyridine(leq) and triisopropylborate (1.2eq) and the flask was cooled to -70°C. Then n-butyllithium (1.2eq) was added dropwise over 0.5h and the mixture was stirred for 0.5h at -70°C. The reaction mixture was then brought to -20°C and 2N hydrochloric acid was added to it. Formation of 2-fluropyridine boronic acid was seen by LC/MS on warming the mixture to ambient temperature. The mixture was partitioned between ethyl acetate and water. The organic layer was dried with sodium sulfate and concentrated to yield 2-fluropyridine boronic acid. MS: MH+ =141.
Step 2. Synthesis of 3-(3-chloro(4-pyridyl)-4-methylphenylamine
To the mixture containing 3-chloro-4-(2-methyl-5-nitrophenyl)pyridine in acetic acid was added Fe dust (5eq) and the resulting mixture was stirred at ambient temperature for 6h. To it was then added saturated sodium carbonate to bring it to neutral pH and extracted with ethyl acetate. The organic layer was washed with brine and dried with sodium sulfate and concentrated and passed through a plug of silica to yield 3-(3- chloro(4-pyridyl))-4-methylphenylamine. MS: MH+ = 218.
Step 3. Synthesis of 3-(3-chlro(4-pyridyl))-4-methylbenzeneisothiocyanate
To 3-(3-chloro(4-pyridyl))-4-methylphenylamine in acetone at 0°C was added sodium bicarbonate (2eq) and thiophosgene (2eq). The mixture was brought to ambient temperature and concentrated and partitioned between ethyl acetate and water. The organic layer was dried with sodium bicarbonate and sodium sulfate and concentrated to yield 3-(3-chloro(4-pyridyl))-4-methylbenzeneisothiocyanate. MS: MH+ = 260.
Step 4. Synthesis of {4-(2-{[3-(3-chloro(4-pyridyl))-4-methylphenyl]amino)-l- methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-methylcarboxamide
To 3-(3-chloro(4-pyridyl))-4-methylbenzeneisothiocyanate(leq) in methanol was added {4-[3-amino-4-(me ylamino)phenoxy](2-pyridyl)}-N-memylcarboxamide (leq) and the resulting mixture was stirred at ambient temperature for 16 h. LC/MS shows formation of the corresponding thiourea. To it in methanol was then added anhydrous ferric chloride (1.5eq) and stirred for 3h. The reaction mixture was then concentrated to half its volume and brought to neutral pH with IN sodium hydroxide. It was then extracted with ethyl acetate and the organic layer was washed with brine and dried with sodium sulfate. The crude was then titurated with hot methanol to yield {4-(2-{[3-(3- cMoro(4-pyridyl))-4-methylphenyl]amino)-l-methylbenzimidazol-5-yloxy)(2-pyridyl)]- N-methylcarboxamide. MS: MH+ = 498.
Example 703 1. Synthesis of {4-[2-methoxy-4-(methylamino)-5-nitrophenoxy](2-pyridyl)}-N- methylcarboxamide
To a stirred solution of concentrated nitric acid (22eq) was added 2 h- benzo[d]l,3-dioxolane(leq) at 0-10 °C for 0.5h and stirred for another 0.5h. To this reaction mixture was then added concentrated sulfuric acid (0.06eq) drop-wise at 0-10C° for 0.5h and stirred at 20C° for 0.5h. It was then poured on to crushed ice, and the separated solid was filtered washed with water and dried to give 5,6-dinitro-2 h- benzol[d]l,3-dioxalane. MS:MH+ 212
Step 2. Synthesis of methyl(6-nitro(2 h-benzo[3,4-d]l,3-dioxalan-5-yl)amine To a stirred solution of methyl amine in ether and ethanol (1.5:1) was added 5,6- dinitro-2 h-benzol[d]l,3-dioxalane and stirred at ambient temperature for 24h. The solvent was evaporated under vacuum and the solid was washed with water and dried to give methyl(6-nitro(2 h-benzo[3.4-d]l,3-dioxaln-5-yl))amine. MS: MH+ 196 Step 3. Synthesis of 2-methoxy-4-(methylamino)-5-nitrophenol To a stirred solution of methanol was added sodium metal (4.8 eq) slowly at ambient temperature followed by methyl(6-nitro(2 h-benzo[3,4-d]l,3-dioxalan-5- yl))amine (1 eq) and stirred for 2 h. The mixture was then refluxed for 0.5h and diluted with water. After cooling it to ambient temperature the separated solid was filtered and dried to give 2-methoxy-4-(methylamino)-5-nitrophenol as a red solid. MS:MH+ 198
Step 4. Synthesis of {4-[2-methoxy-4-(methylamino)-5-nitrophenoxy](2- pyridyl) } -N-methylcarboxamide To a stirred solution of 2-methoxy-4-(methylamino)-5-nitrophenol(leq) in N,N- dimethylacetamide was added potassium-t-butoxide (1.2eq) and continued stirring at ambient temperature untilit solidified. To it was then added (3-chlorophenyl)-N- methylcarboxamide (leq) and anhydrous potassium carbonate (leq) and the resulting mixture was heated to 50°C whereby the solid liquified. It was then heated to 110°C for 12 h. After cooling to ambient temperature the solvent was distilled off and the resulting solid was extracted using ethyl acetate in a soxhlet apparatus for 48h. The organic layer was cooled to 0°C, when the product crystallized from the ethyl acetate to give {4-[2- methoxy-4-(methylamino)-5-nitrophenoxy](2-pyridyl)}-N-methylcarboxamide. MS:MH+ 332
Step 5. Synthesis of {4-[3-amino-6-methoxy-4-(methylamino)phenoxy](2- pyridyl) } -N-methylcarboxamide A solution of {4-[2-methoxy-4-(methylamino)-5-nitrophenoxy](2-pyridyl)}-N- methylcarboxamide. In methanol was hydrogenated with 10%Pd/C. The catalyst was filtered off and the solvent was concentrated to yield {4-[3-amino-6-methoxy-4- (methylamino)phenoxy] (2-pyridyl)} -N-methylcarboxamide. MS:MH+: 302.
Step 6. Synthesis of (4-{2-[(4-bromo-3-methylphenyl)amino)]-6-methoxy-l- methylbenzimidazol-5-yloxy}-(2-pyridyl))-N-methylcarboxamide
To a solution of {4-[3-amino-6-methoxy-4-(methylamino)phenoxy](2-pyridyl)}- N-methylcarboxamide (leq) in methanol was added 4-bromo-3- methylbenzeneisothiocyanate (leq) and stirred at 60°C for 2 h. Formation of thiourea was followed by LC/MS. To it was added iodomethane (leq) and heated to 60°C for 3h. The mixture was concentrated and purified on preparative chromatography to yield (4- {2- [(4-bromo-3-methylphenyl)amino)]-6-methoxy-l-methylbenzimidazol-5-yloxy}-(2- pyridyl))-N-methylcarboxamide. MS:MH+ 496.
Example 704 Synthesis of (5-{2-[(4-bromophenyl)amino]-l-methylbenzimidazol-5-yloxy)-(3- pyridyl))-N-methylcarboxamide
Figure imgf000148_0001
Step 1. Synthesis of methyl-5-(4-nitrophenoxy)pyridine-3-carboxylate
The mixture containing methyl-5-hydroxypyridine-3-carboxylate (leq), Potassium bis(trimethylsilyl)amide (1.2eq) was stirred in N,N-dimethylformamide for 2 hours at room temperature. To this mixture was added >l-fluro-4-nitrobenzene (l.leq) and Potassium carbonate (1.2eq) and stirred at 80°C for 16 h. The reaction mixture was then concentrated and partitioned between ethyl acetate and water. The organic layer was separated and washed with brine, dried, filtered and concentrated in vacuum to give brown solid. Purification on silica gel methyl-5-(4-nitrophenoxy)pyridine-3-carboxylate. MS: MH+ = 274.
Step 2. Synthesis of methyl5-[4-aminophenoxy]pyridine-3 -carboxylate
The mixture containing methyl-5-(4-nitrophenoxy)pyridine-3-carboxylate in methanol with catalytic amount of 10%Pd/C was hydrogenated to yield methyl5-[4~ aminophenoxy]pyridine-3-carboxylate. MS: MH+ = 244.
Step 3. Synthesis of methyl-5-[4-(2,2,2-trifluroacetamino)phenoxy]pyridine-3- carboxylate
A solution of methyl-5-[4-aminophenoxy]pyridine-3-carboxylate (leq) in methylene chloride was treated with trifluoroacetic anhydride (leq) and stirred for 10 minutes at 0 °C. The mixture was quenched with saturated sodium bicarbonate solution. The organic layer was separated and washed with water , brine, dried and evaporated to yield methyl-5-[4-(2,2,2-trifluroacetamino)phenoxy]pyridine-3-carboxylate. MS: MH+ = 340.
Step 4. Synthesis of methyl5-[3-nitro-4-(2,2,2-trifluroacetylamino)phenoxy]- pyridine-3-carboxylate
To a solution of methyl-5-[4-(2,2,2-trifluroacetamino)phenoxy]pyridine-3- carboxylate in acetic acid and acetic anhydride(l:l) at 0°C was added nitric acid followed by sulfuric acid. Followed the reaction by LC and once complete it was partitioned between ethyl acetate. The organic layer was washed with brine and dried with sodium sulfate and concentrated to yield methyl5-[3-nitro-4-(2,2,2-trifluroacetylamino)phenoxy]- pyridine-3-carboxylate. MS: MH+ = 385.
Step 5. Synthesis of methyl4-[4-(methylamino)-3-nitrophenoxy]pyridine-3- carboxylate
To the solution of the methyl5-[3-nitro-4-(2,2,2-trifluroacetylamino)phenoxy]- pyridine-3-carboxylate (leq) in a mixture of toluene, acetonitrile and sodium hydroxide solution (50%) was added benzyltrimethylammonium chloride (leq) and dimethyl sulfate
(1.2eq). The biphasic mixture was stirred overnight at room temperature and evaporated.
The mixture was taken up in ethyl acetate, washed with water, brine, dried and evaporated. The crude was purified by column chromatography to afford methyl4-[4- (methylamino)-3-nitrophenoxy]pyridine-3-carboxylate. MS: MH+ = 303.
Step 6. Synthesis of methyl5-[3-amino-4-(methylamino)phenoxy]pyridine-3- carboxylate The mixture containing methyl4-[4-(amethylamino)-3-nitrophenoxy]pyridine-3- carboxylate was hydrogenated with 10%Pd/C to yield methyl5-[3-amino-4- (methylamino)phenoxy]pyridine-3 -carboxylate. MS: MH+ = 273.
Step 7. Synthesis of methyl5-{2-[(4-bromophenyl)amino]-l-methylbenzimidazol- 5-yloxy} pyridine-3 -carboxylate A solution of the methyl5-[3-amino-4-(methylamino)phenoxy]pyridine-3- carboxylate (leq) in methanol (8 ml) was treated with 4-bromophenylisothiocyanate (leq) and stirred at 60°C - 65°C for 2 hours. The reaction mixture was cooled down to room temperature and methyl iodide (leq) was added and stirred overnight at 60°C. The reaction was cooled down to room temperature, evaporated, taken up in ethyl acetate and washed with water and brine, dried, evaporated under reduced pressure. Column chromatography yielded methyl5- {2-[(4-bromophenyl)amino]- 1 -methylbenzimidazol-5- yloxy}pyridine-3-carboxylate. MS: MH+ = 452
Step 8. Synthesis of (5-{2-[(4-bromophenyl)amino]-l-methylbenzimidazol-5- yloxy)-(3-pyridyl))-N-methylcarboxamide To a solution of methyl5-{2-[(4-bromophenyl)amino]-l-methylbenzimidazόl-5- yloxy}pyridine-3-carboxylate in added methylamine and the resulting mixture was stirred at ambient temperature for 16 h. It was then concentrated and purified by preparative chromatography to yield (5-{2-[(4-bromophenyl)amino]-l-methylbenzimidazol-5-yloxy)- (3-pyridyl))-N-methylcarboxamide. MS: MH+ = 452.
Each of the compounds 705-746, listed in Table 8 were synthesized as indicated in the right hand column by the method described in one of the Examples 699 or 700. Table 8
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Each of the compounds 747-782, listed in the below table were synthesized as indicated in the right hand column by the method described in one of the Examples 702 or 703 unless indicated otherwise.
Table 9
Synthesized as in
Exampld Structure Name MH+ Example:
747 4- {[2-[(4-chlorophenyl)amino]- 438.9 703 1 -methyl-6-(methyloxy)- 1 H- benzimidazol-5-yl]oxy } -N- methylpyridine-2-carboxamide
748 4- {[2-[(3-chlorophenyl)amino]- 438.9 703 1 -methyl-6-(methyloxy)- 1 H- benzimidazol-5-yl]oxy } -N-
Figure imgf000157_0001
methylpyridine-2-carboxamide~
749 4- {[2-[(4-bromo-3-methyl- 497.4 703 phenyl)amino]- 1 -methyl-6- (methyloxy)- 1 H-benzimidazol-
Figure imgf000157_0002
yl]oxy } -N-methylpyridine-2- cafboxamide
750 N-methyl-4-( { 1 -methyl-6- 418.5 703 (methyloxy)-2- [(4-methyl- phenyl)amino] - 1 H-
Figure imgf000157_0003
benzimidazol-5-yl}oxy)- P3τidine-2-carboxamide
751 4-{[2-(2,3-dihydro-lH-inden-5- 444.5 703 ylamino)- 1 -methyl-6-(methyl- oxy)- lH-benzimidazol-5-yl]-
Figure imgf000157_0004
oxy } -N-methylpyridine-2- carboxamide
752 N-methyl-4- { [ 1 -methyl-6- 405.4 703 (methyloxy)-2-(pyridin-3-yl- amino)-lH-benzimidazol-5-yl]-
Figure imgf000157_0005
oxy } pyridine-2-carboxamide
753 4-{[2-{[4-(l,l-dimethylethyl)- 460.5 703 phenyl] amino } - 1 -methyl-6- (methyloxy)- 1 H-benzimidazol-
Figure imgf000157_0006
5-yl]oxy } -N-methylpyridine-2- carboxamide Synthesized as in
Exampld Structure Name MH+ Example:
754 4-{[2-[(2,5-dichlorophenyl)- 473.3 703 amino]- 1 -methyl-6-(methyl- oxy)-lH-benzimidazol-5-yl]-
Figure imgf000158_0001
oxy } -N-methylpyridine-2- carboxamide
755 4-{[2-(l,3-benzodioxol-5- 448.4 703 ylamino)- 1 -methyl-6-(methyl- oxy)- 1 H-benzimidazol-5-yl]-
Figure imgf000158_0002
oxy } -N-methylpyridine-2- carboxamide
756 4- {[2-[(3-chloro-2-methyl- 452.9 703 phenyl)amino] - 1 -methyl-6- (methyloxy)- 1 H-b enzimidazol-
Figure imgf000158_0003
yl] oxy} -N-methylpyridine-2- carboxamide
757 4- {[2-[(4-ethylphenyl)amino]- 432.5 703 1 -methyl-6-(methyloxy)- 1 H- benzimidazol-5-yl]oxy} -N-
Figure imgf000158_0004
methylpyridine-2-carboxamide
758 4-{[2-[(4-bromophenyl)amino]- 483.3 703 1 -methyl-6-(methyloxy)- 1 H- benzimidazol-5-yl]oxy} -N-
Figure imgf000158_0005
methylpyridine-2-carboxamide
759 N-methyl-4- { [ 1 -methyl-6- . 488.4 703 (methyloxy)-2-( {4-[(trifluoro- methyl)oxy]phenyl}amino)-lH-
Figure imgf000158_0006
benzimidazol-5-yl]oxy} - pyridine-2-carboxamide
760 4- {[2-[(2,4-dimethylphenyl)- 432.5 703 amino]- 1 -methyl-6-(methyl- oxy)- 1 H-benzimidazol-5 -yl] -
Figure imgf000158_0007
oxy } -N-methylpyridine-2- carboxamide
761 N-methyl-4-(3-{[l-methyl-5- 508.6 703 ( {2-[(methylamino)carbonyl]- pyridin-4-yl} oxy)- 1 H-
Figure imgf000158_0008
benzimidazol-2-yl] amino } - phenyl)pyridine-2-carboxamide
Figure imgf000159_0001
Figure imgf000160_0001
Synthesized as in
|Example| Structure Name MH+ Example:
778 N-methyl-4-({l-methyl-2-[(3- 452.5 702
CH, pyrimidin-5-ylphenyl)amino]- 1 H-benzimidazol-5-yl} oxy)-
H,C pyridine-2-carboxamide
779 4-{[2-({3-(2-fluoroρyridin-4- 553.5 702 yl)-4- [(trifluoromethyl)oxy] - phenyl } amino)- 1 -methyl- 1 H- benzimidazol-5-yl]oxy } -N- methylpyridine-2-carboxamide
780 4- {[2-( {3-(3-fluoroρyridin-4- 553.5 702 yl)-4- [(trifluoromethyl)oxy] - phenyl} amino)- 1 -methyl- 1 H- benzimidazol-5-yl]oxy} -N- methylpyridine-2-carboxamide
781 N-methyl-4-( { 1 -methyl-2- [(3- 456.5 702 thien-2-ylphenyl)amino] - 1 H- benzimidazol-5-yl} oxy)- pyridine-2-carboxamide
782 N-methyl-4-( { 1 -methyl-2-[(3 - 501.6 702 quinolin-3 -ylphenyl)amino] - 1 H-benzimidazol-5-yl} oxy)- pyridine-2-carboxamide
Figure imgf000161_0001
Example 783
Synthesis of [4-(2- { [6-(dimethylamino)(3 -pyridyl)] amino } - 1 -methylbenzimidazol-5- yloxy)(2-pyridyl)] -N-methylcarboxamide
Figure imgf000161_0002
c) Mel, 60°C Step 1. Synthesis of 2-(Dimethylamino-5-nitropyridine:
2-Chloro-5-nitropyridine (1.0 eq) and dimethylamine (2 M in EtOH, 4.6 eq) in NMP were heated for 2 h at 100°C. The solution was then poured slowly into H2O. The filtrate that formed was filtered and dried to give 2-(dimethylamino)-5-nitropyridine. Step 2. Synthesis of 2-(Dimethylamino-5-aminopyridine:
A mixture of 2-(dimethylamino)-5-nitropyridine (leq) and 5% palladium on carbon (0.3eq) in ethanol was stirred at room temperature and flushed with nitrogen. The reaction vessel was evacuated and purged with hydrogen three times. The reaction mixture was left under an atmosphere of hydrogen overnight. Nitrogen was flushed through the reaction and then the reaction was filtered through a celite pad. The celite pad was washed with excess ethanol before the solvent was removed by evaporation under reduced pressure to afford 2-(dimethylamino)-5-aminopyridine.
Figure imgf000162_0001
Step 3. Synthesis of 2-(Dimethylamino)-5-isothiocynanate pyridine: 2-(Dimethylamino)-5-aminopyridine (1.0 eq) was taken up in acetone and cooled to 0C. Thiophosgene (1.6 eq) was added dropwise and the reaction was stirred for 30 minutes at 0C before the excess thiophosgene and acetone were removed by evaporation under reduced pressure.
Step 4. Synthesis of [4-(2-{[6-(dimethylamino)(3-pyridyl)]amino}-l- methylbenzimidazol-5-yloxy)(2-pyridyl)]-N-methylcarboxamide
A solution of the {4- [3 -amino-4-(methylamino)phenoxy] (2-pyridyl)} -N-methylcarboxamide (1.1 eq) in methanol was treated with 2-(dimethylamino)-5-isothiocynanate pyridine (1.0 eq) and stirred at 60°C for 2 hours. Methyl iodide (leq) was added and stirred overnight at 60°C. The reaction was cooled down to room temperature, evaporated and purified by reverse phase HPLC. MS : MH+= 418.3 Example 784
Step l
Figure imgf000163_0001
A solution of 1 (leq) and 10% palladium on carbon (O.leq) in ethyl acetate was stirred at room temperature and flushed with nitrogen. Hydrogen was flushed through the reaction for 2-3 hours or until the reaction was- determined to be complete by HPLC. Nitrogen was flushed through the reaction for 15 minutes before the reaction was filtered through a celite pad. The celite pad was washed with excess ethyl acetate and methylene chloride before the combined organic solution was removed by evaporation under reduced pressure to afford the product as a solid 2. MS: MH+ = 207
Step 2
Figure imgf000163_0002
A solution of 2 (leq) and sodium carbonate (1.5eq) in acetone was stirred under nitrogen in an ice bath. Thiophosgene (1.5eq) was added drop wise over 30 minutes. The reaction was stirred for another 30 minutes in the ice bath before being removed and allowed to warm to RT. The reaction was stirred at RT for 1.5h before the reaction solution was concentrated under vacuum. Toluene was added to the crude product and removed under vacuum to azetrope off any residual thiophoisgene and afford the product 3. MS: MH+ = 249 Step 3
Figure imgf000164_0001
A solution of 3 (l.Oeq) and 4 (l.Oeq) in MeOH was stirred at RT overnight. Ferric chloride (1.2eq) was added and the resulting reaction mixture was stirred overnight at RT. The reaction mixture was concentrated under vacuum. The crude product was partitioned with EtOAc and water and filtered. The layers were separated and the aqueous phase was neutralized (pH = 7) with saturated Na2CO3 solution. The resulting aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried (Na2SO4), and concentrated to give the desired product 5. MS: MH+ = 487
Step 4
Figure imgf000164_0002
A solution of 5 (leq), 6 (leq), and sodium carbonate (1.2eq) in DME/H2O (3:1) was degassed by bubbling argon through the solution for 10 minutes. Pd(II)(dppf)C12- MeC12 (O.leq) was added to the reaction solution and the reaction was sealed. The reaction was heated at 100°C overnight. The reaction was cooled to RT and ethyl acetate and water were added. The organic layer was separated from the aqueous layer. The aqueous layer was washed once more with ethyl acetate. The organic layers were combined, dried (Na2SO4), and concentrated under vacuum to yield the desired product 7. MS: MH+ = 469 Step 5
Figure imgf000165_0001
The reaction flask was flame dried and cooled under nitrogen. A solution of 8 (l.Oeq) in THF was added to the reaction flask followed by triisopropyl borate (1.2eq). The reaction solution was placed in a dry ice/acetone bath to stir at approximately -72°C. N-butyl lithium (1.5eq, 2.5M solution in hexane) was added drop wise over 40 minutes. The reaction solution was stirred for another 30 minutes in the dry ice/acetone bath. The reaction solution was then transferred to a saturated NaCl/dry ice bath to stir at approx. -25°C and stirred for 20 minutes before 2N HCI (2.0eq) was added. The reaction solution was then removed from the bath to stir and warm to RT. The organic and aqueous layers were separated. The aqueous layer was washed once with ethyl acetate. The organic layers were combined, dried (Na2SO4), and concentrated under vacuum to yield the desired product 9. MS: MH+ = 141
Each of the compounds 785-802, listed in the below table were synthesized as indicated in the right hand column by the method described in one of the Examples 783 or 784.
Table 10
Figure imgf000165_0002
Synthesized as in
Example Structure Name MH" Example:
787 4-( {2-[(4-chloro-3-pyridin-4- 485.9 784 ylphenyl)amino]- 1 -methyl- 1 H- benzimidazol-5-yl} oxy)-N- methylpyridine-2-carboxamide
788 4-[(2-{[4-chloro-3-(2- 503.9 784 fluoropyridin-4-yl)phenyl] - amino } - 1 -methyl- 1 H-benz- imidazol-5-yl)oxy]-N-methyl- pyridine-2-carboxamide
789 4-({2-[(4-chloro-3-pyridin-2- 485.9 784 ylphenyl)amino]- 1 -methyl- 1 H- benzimidazol-5-yl} oxy)-N- methylpyridine-2-carboxamide
790 4-({2-[(4-chloro-3-pyridin-3- 485.9 784 ylphenyl)amino] - 1 -methyl- 1 H- benzimidazol-5-yl}oxy)-N- methylpyridine-2-carboxamide
791 4-[(2-{[4-chloro-3-(3- 503.9 784 fluoropyridin-4-yl)phenyl] - amino } - 1 -methyl- 1 H-benz- imidazol-5-yl)oxy]-N-methyl- pyridine-2-carboxamide
792 4-[(2-{[4-chloro-3-(6- 503.9 784 fluoropyridin-3 -yl)phenyl] - amino } - 1 -methyl- 1 H-benz- imidazol-5-yl)oxy]-N- methylpyridine-2-carboxamide
793 4-{[2-({4-chloro-3-[6- 516 784 (methyloxy)pyridin-3 -yl] - phenyl } amino)- 1 -methyl- 1 H- benzimidazol-5-yl]oxy} -N- methylpyridine-2-carboxamide
794 4-[(2- {[3-(6-fluoropyridin-3-yl)- 537.5 784
(trifluoromethyl)phenyl] - amino }- 1 -methyl- 1 H-benz- imidazol-5-yl)oxy]-N-methyl-
Figure imgf000166_0001
pyridine-2-carboxamide Synthesized as in
Example Structure Name MH+ Example:
795 4-[(2- { [3-(3-fluoropyridin-4-yl> 537.5 784
(trifluoromethyl)phenyl]- amino } - 1 -methyl- 1 H-benz- imidazol-5-yl)oxy]-N-methyl- pyridine-2-carboxamide
796 4-[(2-{[3-(2-fluoropyridin-4-yl 537.5 784
(trifluoromethyl)phenyl] - amino }- 1 -methyl- 1 H-benz- imidazol-5-yl)oxy]-N-methyl- pyridine-2-carboxamide
797 N-methyl-4-[(l-methyl-2- {[3- 549.5 784 [6-(methyloxy)pyridin-3-yl]-5- (trifluoromethyl)phenyl] amino } • lH-benzimidazol-5-yl)oxy]- pyridine-2-carboxamide
798 N-methyl-4-[( 1 -methyl-2- { [3- 519.5 784 pyridin-2-yl-5-(trifluoromethyl)- phenyl] amino } - 1 H-b enz- imidazol-5-yl)oxy]pyridine-2- carboxamide
799 N-methyl-4-[(l-methyl-2- {[3- 519.5 784 pyridin-3-yl-5-(trifluoromethyl)- phenyl] amino } - 1 H-b enz- imidazol-5-yl)oxy]pyridine-2- carboxamide
800 N-methyl-4-[(l-methyl-2-{[3- 519.5 784 pyridin-4-yl-5-(trifluoromethyl)- phenyl]amino}-lH-benz- imidazόl-5-yl)oxy]pyridine-2- carboxamide
801 [(2- { [6-(dimethylamino)- 418.5 783 pyridin-3 -yl] amino } - 1 -methyl- 1 H-benzimidazol-5 -yl)oxy] -N- methylpyridine-2-carboxamide
802 N-methyl-4-( { 1 -methyl-2-[(6- 444.5 783 pyrrolidin- 1 -ylpyridin-3 -yl)- amino]-lH-benzimidazol-5-yl}- oxy)pyridine-2-carboxamide
Figure imgf000167_0001
Example 803
Figure imgf000168_0001
Step 1. 4-[2-(3-Isopropyl-phenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]- pyridine-2-carboxylic acid (2-phenylmethanesulfonylamino-ethyl)-amide
To a mixture containing 4-[2-(3-Isopropyl-phenylamino)-l-methyl-lH-benzo- imidazol-5-yloxy]-pyridine-2-carboxylic acid (2-amino-ethyl)-amide (leq) (prepared using previously described example 3), K2CO3 (5eq), (0.2 M in a 5:1 mixture of acetonitrile and water) were added α-toluenesulfonyl chloride (1 eq) via syringe. The resulting heterogeneous mixture was allowed to stir for 1 hour at room temperature. The mixture was then diluted with water and extracted with dichloromethane. The organics were washed with water and a saturated solution of sodium chloride, dried with sodium sulfate and concentrated in vacuo to viscous oil. Purification by chromatography yielded 4-[2-(3-Isopropyl-phenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]-pyridine-2- carboxylic acid (2-phenylmethanesulfonylamino-ethyl)-amide. MS: MH+ 599
The compounds shown in the following Table (Examples 804-812) were prepared from following the procedure described for Example 803.
Table 11
Figure imgf000168_0002
Figure imgf000169_0001
Example 813
Figure imgf000170_0001
Step 1. 4-{2-(3-(l-Benzyl-lH- [1,2,3] triazol-4-yl)-phenyl amino] -1 -methyl- 1H- benzoimidazol-5-yloxy}-pyridine-2-carboxylic acid methyl amide To a mixture of 4-[2-(3-Ethynl-phenylamino)-l-methyl-lH-benzoimidazol-5-yl- oxy]-pyridine-2-carboxylic acid methylamide (leq)(prepared using previously described example 2), benzyl azide (leq) in t-butanol (0.1M) was added sodium ascorbate (0.05eq), and copper (II) sulfate pentahydrate (O.Oleq). The resulting mixture was allowed to stir for 1 hour at room temperature. The mixture was then diluted with water and the solid collect via suction filtration. MS: MH+ 531
Example 814
di-t-butyl dicarbonate
Figure imgf000170_0003
Figure imgf000170_0002
Step 1. Synthesis of 6-Nitro-indole-l -carboxylic acid t-butyl ester
To a stirring solution of 6-nitroindole (leq) in dichloromethane (0.3M) and DMF (3.1M), was added di-t-butyl dicarbonate (2eq) followed by the addition of 4-(dimethyl amino) pyridine (leq). Resulting solution was allowed to stir overnight at room temperature. The dichloromethane was then removed on a rotovap and remaining solution diluted with water and extracted with ethyl acetate. Organics were washed with
10% citric acid solution, saturated solution of sodium chloride, saturated solution of sodium bicarbonate, saturated solution of sodium chloride and dried with sodium sulfate.
Ethyl acetate was then removed in vacuo. Ethyl ether was then added and a brown solid was collected by suction filtration to yield 6-Nitro-indole-l -carboxylic acid t-butyl ester. MS: MH+ 263
Figure imgf000171_0001
Step 2. Synthesis of 6-Amino-2, 3 -dihdro-indole-1 -carboxylic acid t-butyl ester 6-Nitro-indole-l -carboxylic acid t-butyl ester (leq) was dissolved in methanol
(0.1M), to this solution was added palladium on carbon (O.leq) in methanol under nitrogen. A hydrogen atmosphere was then inserted and resulting mixture allowed to stir for 3 hours at room temperature. The reaction mixture was then filtered through celite and solvent removed in vacuo to afford.6-Amino-2, 3-dihdro-ind'ole-l -carboxylic acid t- butyl ester as a white solid. MS: MH+ 235
Figure imgf000171_0002
Step 3. Synthesis of 6-Isothiocyanate-2, 3 -dihydro-indole-1 -carboxylic acid t- butyl ester
Thiophosgene (1.1 eq) was added to a stirred suspension of 6-Amino-2, 3-dihdro- indole-1 -carboxylic acid t-butyl ester (leq), sodium carbonate (lOeq), and dichloromethane: water 3:1 by volume at OoC. The resulting mixture was allowed to stir for 2 hours at OoC. The mixture was diluted with water and organics separated and washed with water, saturated solution of sodium chloride and dried with sodium sulfate, solvent removed in vacuo to afford 6-Isothiocyanate-2, 3-dihydro-indole-l -carboxylic acid t-butyl ester as orange oil.
Figure imgf000172_0001
Step 4. Synthesis of 4-[2-(2,3-Dihydro-lH-indol-6-ylamino)-l-methyl-lH- benzoimidazol-5-yloxy]-pyridine-2-carboxylic acid methylamide.
To a solution of 4-(4-Methylamino3-nitro-phenoxy)-pyridine-2-carboxylic acid methylamide (leq) in methanol (0.1M) was added palladium on carbon (O.leq) under nitrogen. The atmosphere was exchanged for hydrogen (1 arm) and the resulting suspension allowed to stir for 2 hours at room temperature: The mixture was filtered through celite and added to 6-Isothiocyanate-2, 3-dihydro-indole-l -carboxylic acid t- butyl ester (1 eq). The resulting solution was allowed to stir overnight. Iron (III) chloride(2 eq) in methanol was added and the solution turns deep red in color. This solution was allowed to stir for 3 hours at room temperature. Methanol was then removed in vacuo; the resulting oil was diluted with water and extracted with dichloromethane. Organics were washed with saturated sodium bicarbonate solution, water, and saturated sodium chloride solution and dried with sodium sulfate. Solvent was removed iii vacuo. To the resulting oil was added toluene and heated to reflux, solution was cooled to room temperature and a solid was collected after 3 days by suction filtration to afford 4-[2-(2,3-Dihydro-lH-indol-6-ylamino)-l-methyl-lH-benzoimidazol- 5-yloxy]-pyridine-2-carboxylic acid methylamide. MS: MH+ 415
Example 815
Figure imgf000172_0002
Step 1. Synthesis of 4- {1 -Methyl-2- [l-(4-morpholin-4-yl-butylryl)-2,3-dihydro- lH-indol-6-ylamino]-lH-benzoimidazol-5-yloxy}-pyridine-2-carboxylic acid methylamide To . mixture containing 4-[2-(2,3-Dihydro-lH-indol-6-ylamino)-l-methyl-lH- benzoimidazol-5-yloxy]-pyridine-2-carboxylic acid methylamide (leq)(previously prepared using example 1), EDCI (2eq), HO AT (1.2eq), DIEA (4eq) was added THF. The mixture was- allowed to stir overnight at room temperature under nitrogen. The mixture was then diluted with water, extracted with ethyl acetate. Organics were washed with water, then saturated solution of sodium chloride and dried with sodium sulfate, filtered and the solvent was removed in vacuo. Purification by chromatography yielded 4- { 1 -Methyl-2- [ 1 -(4-morpholin-4-yl-butylryl)-2,3-dihydro- 1 H-indol-6-ylamino]- 1 H- benzoimidazol-5-yloxy}-pyridine-2-carboxylic acid methylamide. MS: MH+ 570
The compounds shown in the following table (Examples 816-819) were prepared from following the procedure described for Example 815.
Table 12
Figure imgf000173_0001
Example 820
Figure imgf000174_0001
Step 1. Synthesis of 4-(4-Methylamino-3-nitro-phenoxy)-pyridine-2-carboxylic acid: A stirring solution of 4-(4-Methylamino-3-nitro-phenoxy)-pyridine-2-carboxylic acid tert-butyl ester in trifluoroacetic acid was treated with two drops of water at room temperature for 3-4 hours or when the reaction was determined to be complete by HPLC. The reaction was evaporated under reduced pressure to afford the product as a red-orange oil. Addition of ethyl ether, sonication, and filtration captures the product as a light pink solid. LCMS m z 290.1 (MH+), tR = 1.71 min.
Step 2. Synthesis of 4-(4-Methylamino-3-nitro-phenoxy)-pyridine-2-carboxylic acid (2-hydroxy-ethyl)-amide:
To a suspension of the 4-(4-methylamino-3-nitro-phenoxy)-pyridine-2-carboxylic acid (leq) in dry THF, EDC-HC1 (1.2eq), HOAT (1.2eq), and diisopropylethylamine (3 eq) were added. The suspension was stirred for 10 minutes whereupon 2,2-dimethyl- oxazolidine (l.leq) was added and the solution is allowed to stir overnight. The mixture was then diluted with ethyl acetate and washed with water. The aqueous layer was washed with ethyl acetate, the organic layers combined, dried over MgSO4, filtered, and concentrated. LCMS m/z 333.2 (MH+), tR = 2.1 min. Step 3. 4-(3-Amino-4-methylamino-phenoxy)-pyridine-2-carboxylic acid (2- hydroxy-ethyl)-amide: A solution of 4-(4-methylamino-3-nitro-phenoxy)-pyridine-2-carboxylic acid (2- hydroxy-ethyl)-amide (leq) and 10% palladium on carbon (O.leq) in methanol was stirred at room temperature and flushed with nitrogen. Hydrogen was flushed through the reaction for 1-2 hours or until the reaction was determined to be complete by HPLC. Nitrogen was flushed through the reaction for 15 minutes before the reaction was filtered through a celite pad. The celite pad was washed with excess methanol before it was all removed by evaporation under reduced pressure to afford the product as a light yellow solid. LCMS m/z 303.2 (MH+), tR - 1.5 min.
Step 4. 4-[l-Methyl-2-(3-trifluoromethylsulfanyl-phenylamino)-lH- benzoimidazol-5-yloxy]-pyridine-2-carboxylic acid (2-hydroxy-ethyl)-amide:
A flask was charged with 3-(trifluoromethylthio)phenylisothiocyanate (leq), 4-(3- amino-4-memylamino-phenoxy)-pyridine-2-carboxylic acid (2-hydroxy-ethyl)-amide (leq), and MeOH. The reaction was maintained at rt overnight. Ferric chloride, (1.5eq) was added and the resulting red reaction mixture was stirred overnight. The reaction was partitioned with EtOAc and water, and filtered through Celite. The layers were separated and the aqueous phase was neutralized with saturated Na2CO3 solution. The resulting aqueous phase was extracted with EtOAc and the mixture was filtered through Celite. The phases were separated and the aqueous phase was again extracted and filtered. The combined organic layers were washed with brine, dried (MgSO4), filtered, and concentrated to give a brown solid. The crude residue was purified by reverse phase HPLC. LCMS m z 504.1 (MH+), tR = 3.7 min.
Example 821
Figure imgf000175_0001
Step 1. Synthesis of 4-[2-(4-Fluoro-phenylamino)-l-methyl-lH-benzoimidazol-5- yloxy]-ρyridine-2-carboxylic acid tert-butyl ester: A round bottom flask was charged with 4-fluorophenylisothiocyanate (leq), 4-(3- Amino-4-methylamino-phenoxy)-pyridine-2-carboxylic acid tert-butyl ester (leq), and MeOH. The reaction was maintained stirring at room temperature overnight. Ferric chloride, (1.5eq) was added and the resulting mixture was stirred overnight. The reaction was partitioned with EtOAc and water, and filtered through Celite. The layers were separated and the aqueous phase was neutralized with saturated Na2CO3 solution. The resulting aqueous phase was extracted with EtOAc and the mixture was filtered through Celite. The phases were separated and the aqueous phase was again extracted and filtered. The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to give a brown solid. The crude residue was purified by triruration in hot toluene to furnish the desired product. LCMS m/z 435.6 (MH+), tR = 2.12 min.
Step 2. Synthesis of 4-[2-(4-Fluoro-phenylamino)-l-methyl-lH-benzoimidazol-5- yloxy]-pyridine-2-carboxylic acid: A stirring solution of 4-[2-(4-Fluoro-phenylamino)-l-methyl-lH-benzoimidazol-
5-yloxy]-pyridine-2-carboxylic acid tert-butyl ester in trifluoroacetic acid was treated with two drops of water at room temperature for 3-4 hours or when the reaction was determined to be complete by HPLC. The reaction was evaporated under reduced pressure and then ether was added to the residue, which was then sonicated for 30 minutes. Filtration and washing with ether yields the desired acid in quantitative yield. LCMS m z 379.4 (MH+), tR = 1.74 min.
Step3. Synthesis of {5-[2-(lH-Benzoimidazol-2-yl)-pyridin-4-yloxy]-l-methyl- 1 H-benzoimidazol-2-yl} -(4-fluoro-phenyl)-amine:
To a suspension of 4-[2-(4-Fluoro-phenylamino)-l-methyl-lH-benzoimidazol-5- yloxy]-ρyridine-2-carboxylic acid (leq) in dry THF, EDC-HC1 (1.2eq), HOAT (1.2eq), and diisopropylethylamine (3 eq) were added. The suspension was stirred for 10 minutes whereupon phenylenediamine (1.1 eq) was added and the solution is allowed to stir overnight. The mixture was then diluted with ethyl acetate and washed with water. The aqueous layer was washed with ethyl acetate, the organic layers combined, dried over MgSO4, filtered, and concentrated. Acetic acid was added to the residue followed by sodium acetate (1.1 eq). The mixture was heated for 3 hours at 70°C, whereupon the solution is concentrated and the residue purified by reverse phase HPLC to afford the desired product. LCMS m/z 451.5 (MH+), tR = 1.92 min. SYNTHESIS OF SIDE CHAINS Ether Substituted phenylenediamines:
Figure imgf000177_0001
4-(3-Bromopropoxy)-2-nitrophenylamπιe:
A flask is charged with 4-amino-3-nitrophenol 1 (1 eq), K2CO (2 eq), and 2-butanone. 1,3-dibromopropane 2 (1.5 eq) is added and the mixture is heated at 80°C for 18 hours. After cooling, the mixture is filtered concentrated and water is added. The solution is then extracted with CH2C12 (x3), the organic layer concentrated, and the solid recovered washed with pentane to yield the desired product 3. LCMS m/z 275.1 (MH+), R^ 2.74 minutes.
Figure imgf000177_0002
2-Nitro-4-(3-pyrrolidinylpropoxy)phenylamine: ,
4-(3-bromopropoxy)-2-nitrophenylamine 1 (1 eq) was heated to 70°C with pyrrolidine 2 (5 eq) in MeCN with Cs2CO3 (2 eq) and Bi^ I (0.1 eq) for 48 hours. The reaction mixture was cooled, filtered, and concentrated. The residue is dissolved in CH2C12, and washed with water. The organic layer is concentrated yielding the desired product 3. LCMS m/z 266.2 (MH+), R, 1.51 minutes.
Figure imgf000178_0001
4-(3-Pyrrolidinylpropoxy)benzene-l,2-diamine:
To a solution 2-Nitro-4-(3-pyrrolidinylpropoxy)phenylamine 1 in EtOH, Pd/C
(O.leq) is added. The reaction vessel is repeatedly purged (x3) with nitrogen, and then stirred under a hydrogen atmosphere for 18 h. The product is filtered through a Celite plug, and the plug washed with 25 mL of EtOH, to yield 2. LCMS 236.2 Rt 0.94 min.
3-Fluoro-4-amino substituted phenylenediamines:
Figure imgf000178_0002
1 2
1. Synthesis of 2-Fluoro-3-(4-methyl-piperazin- 1 -yl)-6-nitro-phenylamine.
A solution of N-methylpiperazine (1.0 eq), NMP, triethylamine (3.0 eq) and 5,6- difluoro-2-nitroaniline (1.0 eq) were heated at 90oC for 1 hour. The reaction was allowed to cool to room temperature and then poured into water and let stand for 1 hour. The resulting solid was collected and dried and utilized without further purification. MH+ —
255.3
2. Synthesis of 3-Fluoro-4-(4-methyl-piperazin-l-yl)-benzene-l,2-diamine. To a solution Synthesis of 2-fluoro-3-(4-methyl-piperazin-l-yl)-6-nitro- phenylamine in EtOH, Pd/C (O.leq) is added. The reaction vessel is repeatedly purged (x3) with nitrogen, and then stirred under a hydrogen atmosphere for 18 h. The product is filtered through a Celite plug, the plug washed with 25 mL of EtOH, to yield the desired diamine. LCMS 225.3 Rt 0.45 min. 4- Amino substituted phenylenediamines (a):
Figure imgf000179_0001
Synthesis of 5-(4-Methyl-piperazin-l-yl)-2-nitro-phenylamine
A solution of N-methylpiperazine (1.0 eq), NMP, triethylamine (3.0 eq) and 5- fluoro-2-nitrophenylamine (1.0 eq) were heated at 90°C for 1 hours. The reaction was allowed to cool to room temperature and then poured into water and let stand for 12 hours. The resulting solid was collected and dried and utilized without further purification. MH+ = 237.3.
Synthesis of 4-(4-Methyl-piperazin- 1 -yl)-benzene- 1 ,2-diamine: To a solution 5-(4-Methyl-piperazin-l-yl)-2-nitro-phenylamine in EtOH, Pd/C (O.leq) is added. The reaction vessel is repeatedly purged (x3) with nitrogen, then stirred under a hydrogen atmosphere for 18 h. The product is filtered through a Celite plug, the plug washed with 25 mL of EtOH, to yield the desired diamine. LCMS 207.3 Rt 0.25 min.
4- Amino substituted phenylenediamines (b):
Figure imgf000179_0002
Synthesis of 5-(4-Cyclopentyl-piperazin- 1 -yl)-2-nitro-phenylamine 1. A solution of N-cyclopentylpiperazine (1.0 eq), NMP, triethylamine (3.0 eq) and 5-fluoro-2-nitrophenylamine (1.0 eq) were heated at 90°C for 1 hours. The reaction was allowed to cool to room temperature and then poured into water and let stand for 12 hours. The resulting solid was collected and dried and utilized without further purification. MH+ = 291.4.
2. Synthesis of 4-(4-Cyclopentyl-piperazin-l-yl)-benzene-l,2-diamine: To a solution 5-(4-Cyclopentyl-piperazin-l-yl)-2-nitro-phenylamine in EtOH, Pd/C (O.leq) is added. The reaction vessel is repeatedly purged (x3) with nitrogen, then stirred under a hydrogen atmosphere for 18 h. The product is filtered through a Celite plug, the plug washed with 25 mL of EtOH, to yield the desired diamine. MH+ = 261.3.
Example 822
Figure imgf000180_0001
KHMDS, DMF, 80° C K2C03, 3 days
Figure imgf000180_0002
Figure imgf000180_0003
Figure imgf000180_0004
Step 1. Synthesis of 4-Chloro-pyridine-2-carboxylic acid dimethylamide:
A solution of 4-chloro-pyridme-2-carbonyl chloride (leq) in dichloromethane was cooled to 0°C, whereupon triethylamine (2eq) was added followed by dimethylamine (2eq, 2M solution in THF). The solution was allowed to warm to room temperature and let stir overnight. It was then washed with IM NaOH. The separated organic layer is dried over MgSO4, filtered, and concentrated to yield the desired product. HPLC, 1.82 min; MS: MH+ = 185.6
Step 2. Synthesis of 4-(4-Amino-3-nitro-phenoxy)-pyridine-2-carboxylic acid dimethylamide:
A mixture containing 4-amino-3-nitrophenol (leq) and potassium bis(trimethylsilyl)amide (2eq) was stirred in dimethylformamide for 2 hours at room temperature. To this mixture was added 4-Chloro-pyridine-2-carboxylic acid dimethylamide (leq) and potassium carbonate (1.2eq) and then it was stirred at 90oC for
3 days. The reaction mixture was then concentrated before partitioning between ethyl acetate and water. The organic layer was separated, washed with brine, dried, filtered and concentrated in vacuum to give brown solid. Purification by flash chromatography with ethyl acetate and hexane (1:1) gave the desired product as a yellow syrup. HPLC, 1.69 min; MS: MH+ = 303.1. Step 3. Synthesis of 4-(4-Methylamino-3-nitro-phenoxy)-pyridine-2-carboxylic acid dimethylamide:
A solution of 4-(4-Amino-3-nitro-phenoxy)-pyridine-2-carboxylic acid dimethylamide (leq) in methylene chloride was treated with trifluoroacetic anhydride
(leq) and stirred for 10 minutes at 0°C. The mixture was quenched with satd. NaHCO3 solution. The organic layer was separated and washed with water, brine, dried, filtered and evaporated. MS: MH+=399.0
To the solution of the trifluroacetamide (leq) in a mixture of toluene, acetonitrile and sodium hydroxide solution (50%) was added benzyltrimethylammonium chloride (leq) and dimethyl sulfate (1.2eq). The biphasic mixture was stirred overnight at room temperature. The mixture was taken up in ethyl acetate, washed with water, brine, dried and evaporated. The crude was purified by flash chromatography eluting with 5% methanol in dichloromethane to afford the desired product. HPLC, 2.14 min; MS: MH+ = 317.3
Step 4. Synthesis of 4-(3-Amino-4-methylamino-phenoxy)-pyridine-2-carboxylic acid dimethylamide:
The solution of 4-(4-Methylamino-3-nitro-phenoxy)-pyridine-2-carboxylic acid dimethylamide in methanol was treated with 10% palladium on carbon and stirred under hydrogen atmosphere for 3 hours, at room temperature. The mixture was purged with nitrogen and then was filtered through celite and the filtrate was concentrated to provide the diamine. HPLC, 1.17 min; MS: MH+ = 287.1
Step 5. Synthesis of 4-[2-(2,6-Difluoro-phenylamino)-l -methyl- 1H- benzoimidazol-5-yloxy]-pyridine-2-carboxylic acid dimethylamide:
A solution of the 4-(3-Amino-4-methylamino-phenoxy)-pyridine-2-carboxylic acid dimethylamide (leq) in methanol was treated with 2,6-difluorophenylisothiocyanate (leq) and stirred overnight. To the reaction mixture, methyl iodide (leq) was added and stirred overnight at 60°C. The reaction was cooled down to room temperature, evaporated, and the residue purified by reverse phase HPLC. HPLC, 1.66 min; MS: MH+ = 424.1 Each of the compounds 823-984, listed in the below table were synthesized as indicated in the right hand column by the method described herein.
Table 13
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Synthesized
Example Structure Name MH+ as in Ex.:
N-[3-(4-methylpiperazin- 1 -yl)- 568.4 372 propyl]-4-[(l-methyl-2-{[3-(tri- fluoromethyl)phenyl] amino } - lH-benzimidazol-5-yl)oxy]-
934 pyridine-2-carboxamide
4-[(l-methyl-2-{[3-(trifluoro- 511.2 372 methyl)phenyl] amino } - 1 H- benzimidazol-5-yl)oxy]-N-l ,3- thiazol-2-ylpyridine-2-carbox-
935 amide
N-[2-(l -methylpyrrolidin-2-yl)- 539.3 372 ethyl]-4-[(l-methyl-2-{[3-(tri- fluoromethyl)phenyl]amino } - 1 H-benzimidazol-5-yl)oxy]-
936 pyridine-2-carboxamide
4-[(l -methyl-2- {[3-(trifluoro- 540.3 372 methyl)phenyl] amino } - 1 H- benzimidazol-5-yl)oxy]-N-[2-(2- oxoimidazolidin- 1 -yl)ethyl]-
937 pyridine-2-carboxamide
4-[(l-methyl-2-{[3-(trifluoro- 525.3 372 methyl)phenyli amino } - 1 H- benzimidazol-5-yl)oxy]-N-(2- pyrrolidin- 1 -ylethyl)pyridine-2-
938 carboxamide
N-[3 -( 1 H-imidazol- 1 -yl)propyl] - 536.3 372 4-[(l-methyl-2-{[3-(trifluoro- methyl)phenyl]amino} - 1 H- benzimidazol-5-yl)oxy]pyridine-
939 2-carboxamide
N-[2-(methyloxy)ethyl]-4-[(l - 486.3 372 methyl-2- { [3 -(trifluoromethyl)- phenyl] amino } - 1 H-benz- imidazol-5-yl)oxy]pyridine-2-
940 carboxamide
N-(2-hydroxyethyl)-4-[(l - 472.2 372 methyl-2- {[3-(trifluoromethyl)- phenyl]amino} - 1 H-benz- imidazol-5-yl)oxy]pyridine-2-
941
Figure imgf000196_0001
carboxamide
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Example 985: Synthesis of Oxime Series: 4-[2-(4-Bromo-phenylamino')-l -methyl- 1H- benzoimidazol-5-yloxy] -pyridine-2-carbaldehyde oxime
Step 1. Synthesis of [4-(4-Methylamino-3-nitro-phenoxy)-pyridin-2-yl]-methanol
Figure imgf000202_0002
A flame dried 500 mL three-necked round bottom flask purged with N2 was charged with LAH (2.32 g, 58.0 mmol) and dry THF (60 mL). The resulting suspension was cooled to 0 °C and a suspension of t-butyl ester 1 (10.0 g, 29.0 mmol) in dry THF (60 mL) was slowly added while keeping the internal reaction temperature under 5 °C. The reaction was stirred at 0 °C for 30 min then at rt for 30 min. After the reaction was judged complete, the mixture was treated with successive dropwise addition of water (2.3 mL), 10 % NaOH (2.3 mL), and water (7.2 mL). The resulting suspension was filtered through Celite, washed with ethyl acetate and methanol, and the collected organics concentrated. The crude product was absorbed onto silica gel and purified by flash chromatography (97: 3 CH2Cl2/MeOH) to give 2 as an orange solid: 1H NMR (300 MHz, CDC13) δ 8.40 (d, J= 5.5 Hz, 1 H), 8.05 (br s, IH), 7.96 (d, J= 2.75 Hz, 1 H), 7.29 (d, J = 2.75 Hz, 1 H), 6.92 (d, J= 9.35 Hz, 1 H), 6.75 ( , 2 H), 4.68 (s, 2 H), 3.07 (d, J= 5.23 Hz, 3 H).
Step 2. Synthesis of 4-(4-Methylamino-3-nitro-phenoxy)-pyridine-2- carbaldehyde
Figure imgf000203_0001
A 250 mL reaction tube was charged with benzyl alcohol 1 (1.0 g, 3.6 mmol), MnO2 (4.7 g, 54 mmol) and EtOAc (20 mL). The reaction tube was sealed was heated to 120 °C with stirring for 2 h. The reaction was allowed to cool to rt, then filtered through Celite and washed successively with EtOAc, MeOH, and EtOH. The combine organics were concentrated to give 936 mg (3.4 mmol, 94%) of 2 as an orange solid: 1H NMR (300 MHz, CDC13) δ 10.01 (s, 1 H), 8.64 (d, J= 5.5 Hz, 1 H), 8.09 (br s, 1 H), 7.96 (d, J = 2.75 Hz, 1 H), 7.37 (d, J= 2.48 Hz, 1 H), 7.29 (d, J= 2.75 Hz, 1 H), 7.08 (dd, J= 2.47, 5.5 Hz, 1 H), 6.94 (d, J= 9.35 Hz, 1 H), 3.08 (d, J= 5.23 Hz, 3 H).
Step 3. Synthesis of 4-(4-Methylamino-3-nitro-phenoxy)-pyridine-2- carbaldehyde oxime
Figure imgf000203_0002
A 50 mL round bottom flask was charged with 1 (680 mg, 2.5 mmol), hydroxylamine HCI (191 mg, 2.75 mmol), pyridine (0.25 mL, 3.0 mmol) and ethanol (10 L). The resulting reaction mixture was stirred at rt overnight. The crude product was concentrated, absorbed onto silica gel, and purified by flash chromatography ( 97: 3 CH2Cl2/MeOH to give 2 as an orange solid. LCMS m/z 289.2 (MH+), tR = 2.06 min. Step 4. Synthesis of 4-(3-Amino-4-methylamino-phenoxy)-pyridine-2- carbaldehyde oxime
Figure imgf000204_0001
A reaction tube was charged with suspension of 1 (330 mg, 1.15 mmol) and Lindlar catalyst (245 mg, 10 mol %) in methanol (5 mL), sealed, and placed on a Parr shaker. The reaction was pressurized with H2 (60 psi) and maintained for 1 h. The reaction was filtered through Celite and the remaining solids were washed with MeOH. The combined organics were concentrated to give 2 as a brown semi-solid which was taken on without further purification.
Step 5. Synthesis of 4-[2-(4-Bromo-phenylamino)-l-methyl-lH-benzoimidazol- 5-yloxy]-pyridine-2-carbaldehyde oxime
Figure imgf000204_0002
A 5 mL round bottom flask was charged with 4-bromophenylisothiocyanate (54 mg, 0.25 mmol), diamine 1 (65 mg, 0.25 mmol), and MeOH (1 mL). The resulting reaction was maintained at rt overnight. Methyl iodide (20 μL, 0.33 mmol) was added to the reaction and stirred overnight. The reaction was concentrated and the resulting residue was purified by reverse-phase HPLC. LCMS m/z 438.1 (MH+), tR = 1.87 min.
Example 986: Synthesis of O-methyl-oxime Series: 4- [ 1 -Methyl-2-(4- tofluoromethylsulfanyl-phenylamino)-lH-benzoimidazol-5-yloxy]-pyridine-2- carbaldehyde O-methyl-oxime
Step 1. Synthesis of 4-(4-Methylamino-3-nitro-phenoxy)-pyridine-2- carbaldehyde O-methyl-oxime
Figure imgf000205_0001
A 25 mL round bottom flask was charged with a suspension of 1 (600 mg, 2.2 mmol), methoxylamine HCI (202 mg, 2.42 mmol), and pyridine (0.22 mL, 2.6 mmol) in ethanol (9 mL). The resulting reaction mixture was stirred at rt overnight. The crude product was concentrated, absorbed onto silica gel, and purified by flash chromatography (97: 3 CH2Cl2/MeOH) to give 2 as an orange solid. LCMS m/z 303.2 (MH+), tR = 2.40 min.
Step 2. Synthesis of 4-(3-Amino-4-methylamino-phenoxy)-pyridine-2- carbaldehyde O-methyl-oxime
Figure imgf000205_0002
A reaction tube was charged with a suspension of 1 (270 mg, 0.9 mmol) and Lindlar catalyst (192 mg, 10 mol %) in methanol (5 mL), and was then placed on a Parr shaker. The was reaction pressurized with H2 (60 psi) and maintained for 1 h. The reaction was filtered through Celite and the remained solids were washed with methanol. The combined organics were concentrated to give 2 as a brown semi-solid which was carried forward without further purification LCMS m/z 273.3 (MH+), t = 1.56 min.
Step 3. Synthesis of 4- [ 1 -Methyl-2-(4-trifluoromethylsulfanyl-phenylamino)- 1 H- benzoimidazol-5-yloxy]-pyridine-2-carbaldehyde O-methyl-oxime
Figure imgf000205_0003
A 5 mL round bottom flask was charged with 4-trifluoromethylthio- phenylisothiocyanate (24 mg, 0.1 mmol), diamine 1 (27 mg, 0.1 mmol), and MeOH (0.5 mL). The reaction was maintained at rt overnight, after which methyl iodide (8 μL, 0.13 mmol) was added. After 16 h, the reaction was concentrated and the resulting residue was purified by reverse-phase HPLC. LCMS m/z 474.3 (MH+), tR = 2.42 min.
Example 987
Figure imgf000206_0001
Synthesized as described in Example 986 step 3 using 4-bromophenyl isothiocyanate. LCMS m/z 402.4 (MH+), tR = 2.15 min.
Example 988
Figure imgf000206_0002
Synthesized as described in Example 986 step 3 using 4- ethylphenylisiothiocyanate. LCMS m/z 402.4 (MH*), tR = 2.15 min.
Example 989
Figure imgf000206_0003
Synthesized as described in Example 986 step 3 using 4-bromo-2-trifluoro- methoxyphenylisothiocyanate. LCMS m/z 536.2 (MH+), tR = 2.38 min.
Example 990
Figure imgf000206_0004
Synthesized as described in Example 986 step 3 using 2,4- dimethylphenylisothiocyanate. LCMS m/z 402, (MH1"), tR = 2.07 min.
Example 991: Synthesis of Benzyl Alcohol Series: {4- [2-(4-Chloro-phenylamino)- 1 - methyl- 1 H-benzoimidazol-5-yloxy] -pyridin-2-yl } -methanol Step 1. Synthesis of [4-(3-Amino-4-methylamino-phenoxy)-pyridin-2-yl]- methanol
Figure imgf000207_0001
A suspension of nitroaniline 1 (550 mg, 2.0 mmol) in methanol was sparged with N2 for 20 min after which 10% Pd/C (106 mg, 0.1 mmol) was added. The reaction was charged with H2 and maintained under a H2 atmosphere overnight at rt. The reaction was sparged with N2 and filtered through Celite. The collected solids were washed with EtOAc (3 X 50 mL), and the combined organic layers were dried (MgSO4) and concentrated to afford 2, which was taken on without further purification.
Step 2. Synthesis of {4-[2-(4-Chloro-phenylamino)- 1 -methyl- 1 H-benzoimidazol- 5-yloxy]-pyridin-2-yl}-methanol.
Figure imgf000207_0002
A 5 mL round bottom flask was charged with 4-chlorophenylisothiocyanate (34 g, 0.2 mmol), diamine 1 (49 mg, 0.2 mmol), and MeOH (1 mL) and the resulting reaction was maintained at rt overnight. Ferric chloride (16 mg, 0.1 mmol) was added and the red reaction mixture was stirred overnight. The reaction was partitioned with EtOAc and water, the layers were separated and the aqueous phase was neutralized (pH = 7) with saturated aqueous Na2CO3 solution. The aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried, and concentrated to give a brown solid. The reaction was concentrated and the resulting residue purified on reverse-phase HPLC. LCMS m/z 381.3 (MH+), tR = 2.27 min. Example 992.
Figure imgf000208_0001
Synthesized as described in Example 1058 step 2 using fluorophenylisiothiocyanate. LCMS m/z 365.4 (MH+), tR = 2.04 min. Example 993
Figure imgf000208_0002
Synthesized as described in Example 991 step 2 using 4-bromo-3- methylphenylisiothiocyanate. LCMS m/z 439.3 (MH+), tR = 2.79 min.
Example 994
Figure imgf000208_0003
Synthesized as described in Example 991 step 2 using 4-bromo-2- trifluoromethoxyphenylisothiocyanate. LCMS m/z 511.3 (MH+), t = 3.08 min.
Example 995
Figure imgf000208_0004
Synthesized as described in Example 991 step 2 using 4- methylthiophenylisiothiocyanate. LCMS m/z 393.4 (MH+), tR = 2.46 min. Example 995
Figure imgf000209_0001
Synthesized as described in Example 991 step 2 using ethylphenylisiothiocyanate. LCMS m/z 375.4 (MH+), tR = 2.57 min. Example 996
Figure imgf000209_0002
Synthesized as described in Example 991 step 2 using 4-trifluoromethylthio- phenylisiothiocyanate. LCMS m/z 447.3 (MH+), tR = 3.21 min.
Example 997
Figure imgf000209_0003
Synthesized as described in Example 991 step 2 using iodophenylisiothiocyanate. LCMS m/z 473.2 (MH+), tR = 2.57 min.
Example 998
Figure imgf000209_0004
Synthesized as described in Example 991 step 2 using 3- trifluoromethylthiophenylisothiocyanate. LCMS m/z 447.3 (MH+), tR = 3.08 min. Example 999: 4-[2-(4-Bromo-phenvlamino)-l-methvl-lH-benzoimidazol-5-vloxy1- pyridine-2-carboxylic acid phenylamide. Procedure for Synthesis of Anilide Series (4-Br and 3-iPr west-ends) Synthesis of 4-[2-(4-Bromo-phenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]- pyridine-2-carboxylic acid phenylamide.
Figure imgf000210_0001
A suspension of 1 (44 mg, 0.1 mmol), HBTU (46 mg, 0.12 mmol), and DIEA (43 uL, 0.25 mmol) in NMP (0.5 mL) was shaken for 30 min at rt. Aniline was added and the reaction was shaken overnight. The crude product purified on reverse-phase HPLC. LCMS m/z 515.2 (MH+), tR = 2.75 min.
Example 1000
Figure imgf000210_0002
Synthesized as described in Example 999 using N, O-dimethylhydroxylamine HCI. LCMS m/z 483.3 (MH+), tR = 2.07 min. Example 1001
Figure imgf000210_0003
Synthesized as described in Example 999 using 4-bromoaniline. LCMS m/z 594.0 (MH+), tR = 5.39 min. Example 1002
Figure imgf000211_0001
Synthesized as described in Example 999 using 3,4-dimethylaniline. LCMS m/z 543.2 (MH+), tR = 5.39 min. Example 1003
Figure imgf000211_0002
Synthesized as described in Example 999 using 3-trifluoromethylaniline. LCMS m/z 583.1 (MH+), tR = 3.12 min.
Example 1004
Figure imgf000211_0003
Synthesized as described in Example 999 using 3-chloroaniline. LCMS m/z 550.1 (MH+), tR = 5.28 min.
Example 1005
Figure imgf000211_0004
Synthesized as described in Example 999 using 3-ethylaniline. LCMS m/z 543.2
(MH+), tR = 3.16 min. Example 1006
Figure imgf000212_0001
Synthesized as described in Example 1067 using 4-methylaniline. LCMS m/z 529.2 (MH+), tR = 5.15 min. Example 1007
Figure imgf000212_0002
Synthesized as described in Example. 999 using 3-isopropylaniline. LCMS m/z 520.3 (MH+), tR = 5.98 min.
Example 1008
Figure imgf000212_0003
Synthesized as described in Example 999 using 3-tert-butylaniline. LCMS m/z 534.3 (MH+), tR = 3.32 min.
Example 1009
Figure imgf000212_0004
Synthesized as described in Example 999 using 3-trifluoromethoxyaniline.
LCMS m/z 562.2 (MH+), tR = 3.15 min.
Figure imgf000213_0001
Synthesized as described in Example 999 using 3-biphenylamine. LCMS m/z 554.3 (MH+), tR = 3.28 min.
Figure imgf000213_0002
Synthesized as described in Example 999 using 4-bromoaniline. LCMS m/z 557.2 (MH+), tR= 5.65 min.
Figure imgf000213_0003
Synthesized as described in Example 999 using 3-trifluoromethylaniline. LCMS m/z 546.3 (MH+), tR = 5.74 min.
Figure imgf000213_0004
Synthesized as described above in Example 999 using 3-iodoaniline. LCMS m/z
604.2 (MH+), tR = 5.81 min.
Example 1014 : 4- [ 1 -Methyl-2-(3 -phenoxy-phenylamino)- 1 H-benzoimidazol-5-yloxy]- pyridine-2-carboxylic acid methylamide Step 1. Synthesis of 3 -phenoxyphenylisothiocyanate
Figure imgf000213_0005
To a stirring solution of 3 -phenoxy aniline (185 mg, 1.0 mmol) in acetone (4.0 mL) at 0°C was added thiophosgene (0.23 mL, 3.0 mmol) and the resulting reaction maintained for 30 min. The reaction determined complete by TLC (4 : 1 hexane/EtOAc). The reaction was concentrated, azeotroped with toluene and taken on without further purification.
Step 2. Synthesis of 4- [l-Methyl-2-(3 -phenoxy-phenylamino)- 1H- benzoimidazol-5-yloxy]-pyridine-2-carboxylic acid methylamide
Figure imgf000214_0001
A 1 dram vial was charged with a solution of 3-phenoxyphenylisothiocyanate (23 mg, 0.1 mmol), diamine 1 (27 mg, 0.1 mmol), and MeOH (0.5 mL) and the reaction was shaken at rt overnight. Methyl iodide (8 uL, 0.13 mmol) was added and the mixture shaken overnight. The reaction was concentrated and the resulting residue purified on reverse phase HPLC. LCMS m/z 466.3 (MH*), tR = 2.40 min.
Example 1015
Figure imgf000214_0002
Synthesized as described in Example 1014 step 2 using trifluoromethylthiophenylisothiocyanate. LCMS m/z 474.5 (MH+), tR = 3.76 min.
Example 1016
Figure imgf000214_0003
Synthesized as described in Example 1014 step 2 using 3- trifiuoromethylthiophenylisothiocyanate. LCMS m/z 474.5 (MOHT), tR = 3.65 min.
\ Example 1017
HN
Synthesized as described in Example 1014 step 2 using 4-l-isothiocyanato-4- methanesulfonyl-benzene, prepared as in step 1. LCMS m/z 452.5 (MH+), tR = 2.86 min. Example 1018
Figure imgf000215_0001
Synthesized as described in Example 1014 step 2 using 4-(2-isothiocyanato-4- trifluoromethyl-phenoxy)-benzonitrile, prepared as in step 1. LCMS m/z 559.6 (MH+), tR = 4.22 min. Example 1019
Figure imgf000215_0002
Synthesized as described in Example 1014 step 2 using 2-(2-methoxy-phenoxy)- 5-trifluoromethyl-phenylisothiocyanate, prepared as in step 1. LCMS m/z 564.6 (MH+), tR = 4.42 min. Example 1020.
Figure imgf000215_0003
Synthesized as described in Example 1014 step 2 using 2-phenylsulfanyl- phenylisothiocyanate, prepared as in step 1. LCMS m/z 482.5 (MH4 , tR = 3.85 min.
Example 1021.
Figure imgf000216_0001
Synthesized as described in Example 1014 step 2 using 4-isothiocyanato-3- trifluoromethoxy-benzonitrile, prepared as in step 1. LCMS m/z 483.4 (MH+), tR = 2.35 min.
Example 1022.
Figure imgf000216_0002
Synthesized as described in Example 1014 step 2 using 2,4-dibromo-6- fluorophenylisotbiocyanate. LCMS m/z 550.3 (MH+), tR = 3.50 min.
Example 1023.
Figure imgf000216_0003
Synthesized as described in Example 1014 step 2 using 4-bromo-2- trifluoromethoxy-phenylisothiocyanate. LCMS m/z 537.3 (MH+), t = 3.89 min.
Example 1024.
Figure imgf000216_0004
Synthesized as described in Example 1014 step 2 using phenylisothiocyanate. LCMS m/z 374.5 (MH+), tR = 2.84 min. Example 1025.
Figure imgf000217_0001
Synthesized as described in Example 1014 step 2 using 2-phenoxy- phenylisothiocyanate, prepared as in step 1. LCMS m/z 466.5 (MH+), tR = 2.37 min. Example 1026.
Figure imgf000217_0002
Synthesized as described in Example 1014 step 2 using 2-methyl- phenylisothiocyanate. LCMS m/z 388.5 (MH+), tR = 2.99 min.
Example 1027.
Figure imgf000217_0003
Synthesized as described in Example 1014 step 2 using 2-difluoromethoxy- phenylisothiocyanate. LCMS m/z 440.5 (MH+), tR = 3.13 min.
Example 1028.
Figure imgf000217_0004
Synthesized as described in Example 1014 step 2 using 2-iodo- phenylisothiocyanate. LCMS m/z 500.4 (MH+), tR = 2.07 min. Example 1029.
Figure imgf000218_0001
Synthesized as described in Example 1014 step 2 using 2,6-diisopropyl- phenylisothiocyanate. LCMS m/z 430.5 (MH+), tR = 2.27 min. Example 1030.
4-[2-(4-Bromophenyl)-l-methyl-lH-benzimidazol-5-yloxy]-pyridine-2-carboxylic acid methylamide.
4-bromobenzaldehyde
Figure imgf000218_0002
dioxane, 100 °C
Figure imgf000218_0003
A mixture of diamine 1 (137 mg, 0.36 mmol) and 4-bromobenzaldehyde (66 mg, 0.50 mmol) in dry dioxane (2 mL) was heated to 100 °C for 16 h. The reaction mixture was allowed to cool to rt and was then concentrated. The resulting residue was purified by reverse phase HPLC to furnish 2 as the TFA salt: LCMS m/z 437.1, tR = 2.16 min.
Example 1031 4-[l-Methyl-2-(4-methylbenzylamino)-lH-benzoimidazol-5-yloxy]-pyridine-2- carboxylic acid methylamide.
Figure imgf000218_0004
Prepared as per Example 120b using 4-methylbenzyl thioisocyanate: LCMS m/z
Figure imgf000218_0005
Example 1032 4-[2-(4-Bromophenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]-pyridine-2- carboxylic acid (3 -pyrrolidin- l-yl-propyl)-amide.
Figure imgf000219_0001
Prepared as per Example 371 using amido-l-(3-aminopropyl)pyrrolidine: LCMS m/z 549.5 (MH+), tR = 2.97 min.
Example 1033. (4-Brombphenyl)-[l-methyl-5-(pyridin-4-yloxy)-lH-benzolimidazol-2-yl]-amine
Figure imgf000219_0002
A solution of acid 1 (44 mg, 0.1 mmol) in dry NMP (1 mL) was heated at 200 °C for 20 min. The reaction was allowed to cool to rt and the crude reaction mixture was directly purified on reverse-phase HPLC to provide 2 as a TFA salt: 1H NMR (300 MHz, CD3OD) δ 8.67 (d, J= 7.4 Hz, 2 H), 7.70 (d, J= 8.5 Hz, 1 H), 7.68 (d, J= 8.8 Hz, 2 H), 7.45 (d, J= 8.8 Hz, 2 H), 7.42 (d, J= IA Hz, 2 H), 7.32 (d, J= 2.2 Hz, 1 H), 7.26 (dd, J= 2.2, 8.5 Hz, 1 H), 3.86 (s, 3 H); LCMS m/z 395.0 (MH+), tR = 1.48 min.
Example 1034
Figure imgf000219_0003
LCMS m/z 359.3 (MH+), tR = 1.91 min.
Example 1035 {4-[2-(4-Bromophenylamino)-l-methyl-lH-benzolimidazol-5-yloxy]-pyridin-2- yl} -methanol
Figure imgf000220_0001
A suspension of t-butyl ester 1 (496 mg, 1.0 mmol) in dry THF (3 mL) was added to a stirring suspension of LAH (61 mg, 1.6 mmol) in dry THF (2 mL) at -78°C. The reaction was allowed to warm to rt over 3 h. After the reaction was judged complete by LCMS, water (30 ul, 1.7 mmol) and NaF (270 mg, 6.4 mmol) were added and the resulting mixture was stirred vigorously overnight at rt. The crude mixture was filtered through Celite and the remaining solids were rinsed with EtOAc. The combined organic portions were concentrated and a portion of the resulting residue was purified by reverse- phase HPLC to furnish alcohol 2 as a TFA salt: 1H NMR (300 MHz, CD3OD) δ 8.56 (d, J= 7.2 Hz, 1 H), 7.72 (d, J= 8.5 Hz, 1 H), 7.69 (d, J= 8.8 Hz, 2 H), 7.45 (d, J= 8.8 Hz, 2 H), 7.33 (m, 3 H), 7.28 (dd, J = 2.2, 8.5 Hz, 1 H), 4.86 (app s, 2 H), 3.87 (s, 3 H); LCMS m/z 425.1, tR = 1.49 min.
Example 1036: (4-Bromophenyl)-[l-methyl-5-(2-methylaminomethyl-pyridin-4-yloxy)- IH benzoimidazol-2-yl] -amine
General Preparation for Benzyl Amines Step 1. 4- [2-(4-Bromophenylamino)- 1 -methyl- 1 H-benzoimidazol-5-yloxy] - pyridine-2-carboxaldehyde
Figure imgf000220_0002
Dry DMSO (0.1 mL, ΛA mmol) was added to a solution of oxalyl chloride (0.11 mL, 1.3 mmol) in dry THF (2 mL) at -78 °C and the resulting solution was maintained at -78 °C for 30 min. A solution of alcohol 1 in dry THF (2 mL) was then introduced and the resulting reaction was maintained at -78 °C for 30 min, then at -50 °C for 45 min. Triethylamine (0.5 mL, 3.6 mmol) was added and the reaction was allowed to warm to rt over 1 h. The reaction was quenched with water and partitioned with EtOAc. The layers were separated and the aqueous portion was extracted with EtOAc (3 X). The combined organic phases were washed with brine, dried (MgSO4), and concentrated. The resulting residue was carried forward without further purification.
Step 2. (4-Bromophenyl)-[ 1 -methyl-5-(2-methylaminomethyl-pyridin-4-yloxy)- 1H benzoimidazol-2-yl]-amine.
Methyl amine (0.3 mL, 0.6 mmol, 2.0 M in MeOH) was added to a solution of aldehyde 1 in MeOH (1 mL) and the reaction was maintained at rt for 2 d. The reaction was acidified by addition of acetic acid (pH = 3-4), and an excess of NaBH3CN was added. The reaction was maintained for 2 d then concentrated. The crude reaction mixture was dissolved in EtOAc and partitioned with aqueous saturated NaHCO3 solution. The layers were separated and the aqueous phase was extracted with EtOAc (3 X). The combined organic portions were washed with brine, dried (MgSO4), and concentrated. The resulting residue was purified by reverse-phase HPLC to afford N- methyl amine 2 as a TFA salt: 1H ΝMR (300 MHz, CD3OD) δ 8.48 (d, J= 5.8 Hz, IH),
7.72 (d, J= 8.8 Hz, 2 H), 7÷67 (d, J= 9.4 Hz, 1 H), 7.43 (d, J= 8.8 Hz, 2 h), 7.20 (dd, J=
2.2, 9.4 Hz, 1 H), 7.19 (d, J= 2.2 Hz, IH), 7.02 (d, J= 2.2, 1 H), 6.90 (dd, J= 2.2, 5.8 Hz, 1 H), 4.27 (s, 2 H), 3.86 (s, 3 H), 2.76 (s, 3 H); LCMS m/z 438.5 (MH+), tR = 1.85 min.
The following tabulated benzyl amines were prepared by the above method as in Example 1036 using the appropriate amine.
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Example 1053 [5-(2-Aminomethyl-pyridin-4-yloxy)- 1 -methyl- 1 H-benzoimidazol-2~yl]-(4- bromophenyl)-amine.
Figure imgf000224_0002
LAH (98 mg, 2.5 mmol) was added portionwise to a stirring solution of oxime 1 (225 mg, 0.5 mmol) in dry THF (3 mL) at 0 °C. After addition, the cooling bath was removed and the reaction was allowed to warm to rt overnight. The reaction was quenched by addition of water (0.1 mL), 10% w/w aqueous NaOH solution (0.1 mL), and water (0.3 mL). The resulting slurry was stirred at rt for 1 h and filtered through Celite. The remaining solids were rinsed with EtOAc and the organic portions were combined and concentrated. The crude residue was purified by reverse-phase HPLC to provide benzyl amine 2 as a TFA salt: LCMS m/z 424.1 (MH+), tR = 1.87 min.
Example 1054 {4-[2-(4-Bromophenylamino)- 1 -methyl- 1 H-benzoimidazol-5-yloxy]-pyridin-2-yl- methyl]-carbamic acid methyl ester.
Figure imgf000224_0003
Methyl chloroformate (6 μL, 0.08 mmol) was added to a solution of benzyl amine 1 (21 mg, 0.05 mmol) and triethylamine (69 μL, 0.5 mmol) in dry THF (1 mL) at 0 °C. The reaction was maintained at 0°C for 20 min, then at rt for 2 h. The reaction mixture was concentrated and purified by reverse-phase HPLC to provide methyl carbamate 2 as a TFA salt: LCMS m/z 482.2 (MH+), tR = 1.96 min.
Example 1055 N-{4-[2-(4-Bromophenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]-pyridin-2- ylmethyl } acetamide.
Figure imgf000225_0001
To a solution of benzyl amine 1 (17 mg, 0.04 mmol) in dry NMP (2 mL) was added triethylamine (0.06 mL, 0.4 mmol) and acetic anhydride (0.04 mL, 0.4 mmol). The resulting reaction was maintained at rt overnight and purified directly by reverse- phase HPLC to furnish acetamide 2 as a TFA salt: LCMS m/z 466.3 (MH+), tR = 1.78 min. Example 1056: 4-[2-(3 -Ethylphenylamino)- 1 -methyl- 1 H-benzoimidazol-5-yloxy]- pryidine-2-carboxylic acid [3-(2-oxo-pyrrolidin-yι)-propyl]-amide.
General Preparation for N-(3-Aminopropyl)-pyrrolidinone Amides Step 1: 4-Chloro-pyridine-2-carboxylic acid [3-(2-oxo-pyrrolidin-l-yl)-propyl]- amide
Figure imgf000225_0002
1 2 3
Acid chloride 1 (2.12 g, 10 mmol) was treated with N-methylmorpholine (4.5 mL, 41 mmol) and N-(3-aminopropyl)-pyrrolidinone 2 (1.6 mL, 11 mmol) in dry THF (40 mL). The reaction was maintained overnight and concentrated. The residue was
I dissolved in EtOAc and partitioned with water. The aqueous portion was extracted with EtOAc (3 X) and the combined organic phases were washed with brine, dried (MgSO4), and concentrated. The crude residue was purified by Kugelrohr distillation (0.5 mmHg, 170-200°C) to provide 3.
Step 2: 4-(4-Methylamino-3-nitrophenoxy)-pyridine-2-carboxylic acid [3-(2-oxo- pyrrolidin-yl)-propyl]-amide
Figure imgf000226_0001
Prepared as per Example 120b with the appropriate substitutions. Amide 3 can be purified by flash chromatography (95:5 CH2Cl2-MeOH). It can also be further purified by recrystallization from MeCN.
Step 3: 4-(3-Amino-4-methylamino-phenoxy)-pyridine-2-carboxlic acid [3-(2- oxo-pyrrolidin-yl)-propyl]-amide
Figure imgf000226_0002
Prepared as per Example 120b .
Step 4: 4-[2-(3-Ethylphenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]- pryidine-2-carboxylic acid [3-(2-oxo-pyrrolidin-yl)-propyl]-amide.
Figure imgf000227_0001
Prepared as per Example 120b to provide benzimidazole 2 as a TFA salt: LCMS m/z 513.3 (MH+), tR = 2.22 min.
Example 1057
Figure imgf000227_0002
Prepared as per Example 1056: LCMS m/z 563.2 (MH+), tR = 2.15 min.
Example 1058
Figure imgf000227_0003
Prepared as per Example 1056: LCMS tR = 585.3 (MH+), tR = 2.55 min. Example 1059
Figure imgf000227_0004
Prepared as per Example 1056: LCMS m/z 563.2 (MH+), tR = 2.50 min. The following additional compounds were prepared following the procedures of the indicated Examples: Table 15
Figure imgf000228_0001
Figure imgf000229_0001
Figure imgf000230_0001
Figure imgf000231_0001
Figure imgf000232_0001
General Preparation for Phenolic Benzimidazoles 3 - Amino-4-methylaminophenol
10% Pd/C, H2 MeOH
Figure imgf000232_0003
Figure imgf000232_0002
Diamine 2 prepared as per Example 120b from nitroaniline 1.
Example 1095 2-(3 -Bromophenylamino)- 1 -methyl- 1 H-benzoimidazol-5-ol
Figure imgf000232_0004
Benzimidazole 2 was prepared as per Example 120b: LCMS m/z 318.1 (MH+), tR = 2.07 min.
Example 1096
Figure imgf000233_0001
LCMS m/z 332.1 (MH+), tR = 2.22 min
Example 1097
Figure imgf000233_0002
LCMS m/z 366.1 (MH4), tR = 2.13 min
Example 1098
Figure imgf000233_0003
■ LCMS m/z 340.2 (MH+), tR = 2.39 min
Example 1099
Preparation of Symmetrical bis-Benzimidazoles Step 1: 4,4'-dimethylamino-3,3'-dinitro diphenyl ether
Figure imgf000233_0004
Diphenyl ether 2 was prepared using the method described in Example 120b: 1H NMR (300 MHz, CDC13) δ 7.98 (br s, 2 H), 7.75 (d, J= 3.0 Hz, 2 H), 7.29 (app d, J= 3.0 Hz, 1 H), 6.87 (d, J= 9.5 Hz, 2 H), 3.05 (d, J= 5.2 Hz, 6 H).
Step 2: 4,4'-dimethylamino-3,3'-diamino diphenyl ether
Figure imgf000234_0001
Tetramine 2 was prepared as per Example 120b: 1H NMR (300 MHz, CDC13) δ 6.59 (d, J= 8.5 Hz, 2 H), 6.47 (dd, J= 2.8, 8.5 Hz, 2 H), 6.41 (d, J= 2.8 Hz, 2 H), 3.40 (br s, 4 H), 3.06 (br s, 2 H), 2.84 (d, J= 5.5 Hz, 6 H). Example 1100 bis-5- [2-(3 -Bromophenylamino)- 1 -methyl- 1 H-benzoimidazole] -ether.
Figure imgf000234_0002
Prepared as per Example 120b: LCMS m/z 617.1 (MET1"), tR = 2.27 min
Example 1101
Figure imgf000234_0003
Prepared as per Example 120b: LCMS m/z 573.4 (MH4"), tR = 2.78 min Example 1102
Figure imgf000235_0001
Prepared as per Example 120b: LCMS m/z 661.2 (MH+), tR = 2.83 min
Example 1103
Figure imgf000235_0002
Prepared as per Example 120b: LCMS m/z 545.4 (MH+), tR = 2.73 min
Example 1104
Figure imgf000235_0003
Prepared as per Example 120b: LCMS m/z 461.3 (MH+), tR = 1.98 min Example 1105
Preparation of Benzo Derivatives 2-(N-Phthalimido)-4-fluoronitrobenzene
F-x /ftϊj^ /F postassium phthalimide
Figure imgf000235_0005
Figure imgf000235_0004
A suspension of 2,4 difluoronitrobenzene (15.9 g, 100 mmol) and postassium phthalimide (16.5 g, 100 mmol) was stirred in dry NMP (50 mL) for 3 d. The reaction solution was poured into MTBE and the resulting precipitate was collected by filtration. The solids were washed with MTBE (3 X) and the mother liquor was extracted with MTBE (3 X). The combined organic portions were washed with water (3 X) and concentrated to furnish a yellow solid which was combined with the initial crop of precipitate. The combined crude solid was purified by recrystallization from hot toluene, and the crystals were washed with cold MTBE: 1H NMR (300 MHz, d6-DMSO) δ 8.31 (dd, J= 5.2, 9.1 Hz, 1 H), 7.98 (m, 4 H), 7.69 (dd, J= 2.8, 9.1 Hz, 1 H), 7.62 (ddd, J = 1.7, 2.8, 7.7 Hz, I H).
Example 1106 2-(N-Phthalimido)-4-phenoxynitrobenzene
Figure imgf000236_0001
2-(N-Phthalimido)-4-phenoxynitrobenzene 2 was prepared using a similar procedure employed in Example 120b.
Example 1107 2-(N-Phthalimido)-4-phenoxyaniline
Figure imgf000236_0002
2-(N-Phthalimido)-4-phenoxyaniline 2 was obtained through the reduction of 2- (N-phthalimido)-4-phenoxynitrobenzene 1 as described in Example 120b. Example 1108 N- [2-(N-Phthalimido)-4-phenoxy-phenyl] -formamide
Figure imgf000237_0001
A mixture of formic acid (0.12 mL, 5.3 mmol) and acetic anhydride (0.24 mL, 2.5 mmol) was heated to 60 °C for 2 h. After allowing to cool to rt, a solution of aniline 1
(387 mg, 1.0 mmol) in dry THF (1 mL) was added and the reaction was maintained overnight. The reaction was concentrated and the resulting crude residue was directly used in the next step.
Example 1109 N-Methyl- [2-(N-phthalimido)-4-phenoxy] -aniline
T I HHFr-
Figure imgf000237_0002
Figure imgf000237_0003
Figure imgf000237_0004
A solution of formamide 1 was treated with BH3-DMS solution (2.0 M in CH2C12, 0.5 mL, 1.0 mL) and the reaction was allowed to warm to rt overnight. The reaction was concentrated and the resulting residue was dissolved in EtOAc. The solution was partitioned with saturated aqueous NaHCO3 solution and the layers were separated. The aqueous phase was extracted with EtOAc (3 X) and the combined organics phases were washed with brine, dried (MgSO4), adsorbed onto SiO2 and purified by flash chromatography (4 : 1 hexanes-EtOAc) to furnish 2 as a colorless residue. Example 1110 NI -Methyl-4-phenoxybenzene- 1 ,2-diamine
Figure imgf000238_0001
Hydrazine monohydrate (0.13 mL, 2.7 mmol) was added to a solution of phthalimide 1 (134 mg, 0.39 mmol) in ethanol (4 mL). The reaction was maintained overnight at rt and then was filtered through Celite. The filter cake was rinse with EtOAc
(3 X) and the organic portions were combined and concentrated to give diamine 2 which was carried forward without further purification: LCMS m/z 215.1 (MH4), t = 1.77 min.
Example 1111 Synthesis of (4-Bromophenyl)-(l-'methyl-5-phenoxy-lH-benzoimidazol-2-yl)- amine.
Figure imgf000238_0002
Benzimidazole 2 was prepared as per Example 120b: !H NMR (300 MHz, CD3OD) δ 7.68 (app ddd, J= 2.9, 4.9, 8.8 Hz, 2 H), 7.53 (app d, /= 8.8 Hz, 1 H), 7.41 (app ddd, J= 2.9, 4.9, 8.8 Hz, 2 H), 7.40 (app ddd, J= 1.0, 2.0, 8.5 Hz, 2 h), 7.24 (app ddd, J- 1.0, 2.0, 8.5 Hz, 1 H), 7.07 (app dd, J=2.2, 8.8 Hz, 1 H), 7.00 (app d, J= 2.2 Hz, 1 H), 7.00 (app ddd, J= 1.0, 2.0, 8.5 Hz, 2 H), 3.82 (s, 3 H); LCMS m/z 394.0 (MH+), tR = 2.36 min. Example 1112
Figure imgf000239_0001
Example 371 1
A solution of 1 in MeCN was treated with aqueous 1 N HCI and freeze dried. The resulting residue was purified by reverse-phase HPLC to provide vinyl chloride 2 as a TFA salt: LCMS m/z 434.2 (MH4), tR = 2.48 min..
Example 1113 4-[2-(3-Furan-3-yl-phenylamino)-l-methyl-lH-benzoimidazol-5-yloxy]- pyrindine-2-carboxylic acid methyl amide.
Figure imgf000239_0002
NMP, 100 °C
Example 311 1
2. Pd(dppf)CH2CI2, /Pr2NEt
A solution of Pd(OAc)2 (4.5 mg, 0.02 mmol) and triphenylphosphine (13.1 mg
0.05 mmol) in dry NMP (1 mL) was stirred at rt for 20 min. Aryl iodide 1 (100 mg, 0.2 mmol), 3-furyl boronic acid (45 mg, 0.4 mmol), and triethylamine (0.11 mL, 0.8 mmol) were added and the resulting solution was degassed and purged with Ar. The reaction was heated to 100°C for 2 h; LCMS indicated no conversion. The reaction was allowed to cool to rt under Ar and Pd(dppf)Cl2CH2Cl2 and diisopropylethylamine (0.14 mL) were added. The reaction was heated to 100 °C and maintained overnight. The reaction was allowed to cool to rt and LCMS indicated complete conversion. The reaction was partitioned between saturated aqueous NaHCO3 solution and EtOAc and the resulting mixture filtered through Celite. The remaining solids were washed with water and EtOAc. The combined rinsings were partitioned and separated. The aqueous phase was extracted with EtOAc (3 X) and the combined organic portions were washed with saturated aqueous Na2CO3, brine, dried (MgSO4), and concentrated. The crude residue was purified by reverse-phase HPLC to furnish 2 as a TFA salt: LCMS m/z 440.3 (MH4), t = 2.35 min.
Example 1114
Figure imgf000240_0001
Prepared as per Example 120b.
Example 1115
Figure imgf000240_0002
Prepared as per Example 120b.
Example 1116
Raf/Mek Filtration Assay
Buffers
Assay buffer: 50 mM Tris, pH 7.5, 15 mM MgCl2, 0.1 mM EDTA, 1 mM DTT
Wash buffer: 25 mM Hepes, pH 7.4, 50 mM sodium pyrophosphate, 500 mM NaCl
Stop reagent: 30 mM EDTA Materials
Raf, active: Upstate Biotech #14-352
Mek, inactive: Upstate Biotech #14-205
33p-ATP: NEN Perkin Elmer #NEG 602 h
96 well assay plates: Falcon U-bottom polypropylene plates #35-1190
Filter apparatus: Millipore #MAVM 096 OR 96 well filtration plates: Millipore Immobilon 1 #MAIP NOB
Scintillation fluid: Wallac OptiPhase "SuperMix" #1200-439
Assay conditions
Raf approximately 120 pM Mek approximately 60 nM
33P-ATP 100 nM
Reaction time 45-60 minutes at room temperature Assay protocol
Raf and Mek were combined at 2X final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2. 0.1 mM EDTA and 1 mM DTT) and dispensed 15 μl per well in polypropylene assay plates (Falcon U-bottom polypropylene 96 well assay plates #35-1190. Background levels are determined in wells containing Mek and DMSO without Raf.
To the Raf/Mek containing wells was added 3 μl of 10X of a raf kinase inhibitor test compound diluted in 100% DMSO. The raf kinase activity reaction was started by the addition of 12 μl per well of 2.5X 33P-ATP diluted in assay buffer. After 45-60 minutes, the reactions were stopped with the addition of 70 μl of stop reagent (30 mM
EDTA). Filtration plates were pre-wetted for 5 min with 70% ethanol, and then rinsed by filtration with wash buffer. Samples (90 μl) from the reaction wells were then transferred to the filtration plates. The filtration plates were washed 6X with wash buffer using
Millipore filtration apparatus. The plates were dried and 100 μl per well of scintillation fluid (Wallac OptiPhase "SuperMix" #1200-439) was added. The CPM is then determined using a Wallac Microbeta 1450 reader.
Example 1117 ASSAY 2: Biotinylated Raf Screen
In Vitro Raf Screen
The activity of various isoforms of Raf serine/threonine kinases can be measured by providing ATP, MEK substrate, and assaying the transfer of phosphate moiety to the
MEK residue. Recombinant isoforms of Raf were obtained by purification from sf9 insect cells infected with a human Raf recombinant baculovirus expression vector. Recombinant kinase inactive MEK was expressed in E. coli and labeled with Biotin post purification. For each assay, test compounds were serially diluted in DMSO then mixed with Raf (0.50 nM) and kinase inactive biotin-MEK (50 nM) in reaction buffer plus ATP (1 uM). Reactions were subsequently incubated for 2 hours at room temperature and stopped by the addition of 0.5 M EDTA. Stopped reaction mixture was transferred to a neutradavin-coated plate (Pierce) and incubated for 1 hour. Phosphorylated product was measured with the DELFIA time-resolved fluorescence system (Wallac), using a rabbit anti-p-MEK (Cell Signaling) as the primary antibody and europium labeled anti-rabbit as the secondary antibody. Time resolved fluorescence was read on a Wallac 1232 DELFIA fluorometer. The concentration of each compound for 50% inhibition (IC50) was calculated by non-linear regression using XL Fit data analysis software.
Using the procedures of Examples 1116 or 1117, the compounds of Examples 1- 1094 were shown to have a raf kinase inhibitory activity at an IC50 of less than 5 μM. While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.

Claims

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
A compound of the formula (I):
Figure imgf000243_0001
wherein, X\ and X2 are independently selected from =N-, -NR4-, -O- or -S-, provided that if Xi is -NR4-, -O- or -S-, then X2 is =N-, or if X2 is -NR -, -O- or -S-, then X2 is =N-, and both X\ and X2 are not =N-;Y is O or S;
Y is O or S;
Ai is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;
A2 is substituted or unsubstituted heteroaryl;
Rl is O or H, and R2 is NR5 Rg or hydroxyl; or Rj is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl;
R5 and R are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and the pharmaceutically acceptable salts, esters and prodrugs thereof.
2. A compound of Claim 1 wherein X is j.
3. A compound of Claim 2 wherein i is hydrogen.
4. A compound of Claim 2 wherein t is methyl.
5. A compound of Claim 1 wherein Y is O.
6. A compound of Claim 1 wherein Aj is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclylcarbonylphenyl, heterocyclylphenyl, heterocyclylalkylphenyl, chlorophenyl, flourophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylflourophenyl, triflouromethylchlorophenyl, triflouromethylbromophenyl indenyl, 2,3-dihydroindenyl, tetralinyl, triflourophenyl, (triflouromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N- morpholinylalkyl, piperazinylalkyl, cyclόhexylalkyl, indolyl, 2,3-dihydroindolyl, 1- aceytl-2,3-dihydroindolyl, cycloheptyl, bicyclo[2.2.1]hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin- 1-yl, pyrrolidin- 1-ylalkyl, 4- amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-l-yl, piperidin-1-yl, piperidin- 1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-l-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, l,4'-bipiperidin-l'-yl, and (1,4'- bipiperidin- 1 '-ylcarbonyl)phenyl.
7. A compound of Claim 1 wherein A2 is substituted or unsubstituted pyridyl.
8. A compound of Claim 1 wherein Rj is O and the dashed line represents a single or double bond.
9. A compound of Claim 1 wherein R2 is NR5R6, R5 is hydrogen and R6 is selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl,
\ amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl.
10. A compound of Claim 1 wherein Rj is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group.
11. A compound of Claim 1 wherein R3 is loweralkoxy.
12. A compound of Claim 11 wherein R3 is methoxy.
13. A compound of Claim 1 wherein R4 is loweralkyl.
14. A compound of Claim 13 wherein R4 is methyl.
15. The compound of claim 1 wherein Rj is O, R2 is NR5R6, R5 is H, and Rg is methyl.
16. A compound of the formula (II) :
Figure imgf000245_0001
wherein and Y is O or S;
Ai is substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, heteroarylarylalkyl;
A2 is substituted or unsubstituted heteroaryl;
Rl is O and R2 is NR5 R6; or Ri is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen or loweralkyl; R5 and R6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and the pharmaceutically acceptable salts, esters, and prodrugs thereof.
17. A compound of Claim 16 wherein R4 is hydrogen.
18. A compound of Claim 16 wherein R4 is methyl.
19. A compound of Claim 16 wherein Y is O.
20. A compound of Claim 16 wherein Al is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclylcarbonylphenyl, heterocyclylphenyl, heterocyclylalkylphenyl, chlorophenyl, flourophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbeirzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylflourophenyl, triflouromethylchlorophenyl, triflouromethylbromophenyl indenyl, 2,3-dihydroindenyl, tetralinyl, triflourophenyl, (triflouromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N- morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, 1- aceytl-2,3-dihydroindolyl, cycloheptyl, bicyclo[2.2.1]hept-2-yl, hydroxyphenyl, hydroxy alkylphenyl, pyrrolidinyl, pyrrolidin- 1-yl, pyrrolidin- 1-ylalkyl, 4- amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonylj phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-l-yl, piperidin-1-yl, piperidin- 1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-l-yl,* hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, l,4'-bipiperidin-l'-yl, and (1,4'- bipiperidin- 1 '-ylcarbonyl)phenyl.
21. A compound of Claim 16 wherein A2 is substituted or unsubstituted pyridyl.
22. A compound of Claim 16 wherein Ri is O and the dashed line represents a single or double bond.
23. A compound of Claim 16 wherein R2 is NR5R6, R5 is hydrogen and R6 is selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl. .
24. A compound of Claim 16 wherein Ri is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group.
,
25. A compound of claim 16 wherein Ri is O, R2 is NR5R6, R5 is H, and R6 is methyl.
26. A compound of Claim 16 wherein R3 is loweralkoxy.
27. A compound of Claim 26 wherein R3 is methoxy.
28. A compound of Claim 16 wherein R4 is loweralkyl.
29. A compound of Claim 28 wherein R4 is methyl.
30. A compound of the formula (III):
Figure imgf000247_0001
wherein X is N ^, O or S;
Ai is substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, heteroarylarylalkyl;
A2 is substituted or unsubstituted heteroaryl;
Rl is O and R2 is NR5 Rβ, or Ri is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen or loweralkyl;
R5 and R6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and the pharmaceutically acceptable salts, esters and prodrugs thereof.
31. A compound of Claim 30 wherein X is NR4.
32. A compound of Claim 31 wherein R4 is hydrogen.
33. A compound of Claim 30 wherein R4 is methyl.
34. A compound of Claim 30 wherein Ai is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclylcarbonylphenyl, heterocyclylphenyl, heterocyclylalkylphenyl, chlorophenyl, flourophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylflourophenyl, triflouromethylchlorophenyl, triflouromethylbromophenyl indenyl, 2,3-dihydroindenyl, tetralinyl, triflourophenyl, (triflouromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N- morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, Y- aceytl-2,3-dihydroindolyl, cycloheptyl, bicyclo[2.2.1]hept-2-yl, hydroxyphenyl, hydroxy alkylphenyl, pyrrolidinyl, pyrrolidin- 1-yl, pyrrolidin- 1-ylalkyl, 4- amino(immo)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-l-yl, piperidin- 1-yl, piperidin- 1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-l-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, l,4'-bipiperidin-r-yl, and (1,4'- bipiperidin- 1 '-ylcarbonyl)phenyl.
35. A compound of Claim 30 wherein A2 is substituted or unsubstituted pyridyl.
36. A compound of Claim 30 wherein Ri is O and the dashed line represents a single or double bond.
37. A compound of Claim 30 wherein R2 is NR5R6, R5 is hydrogen and Rg is selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl.
38. A compound of Claim 30 wherein Ri is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group.
39. A compound of Claim 30 wherein R3 is loweralkoxy.
40. A compound of Claim 39 wherein R3 is methoxy.
41. A compound of Claim 30 wherein R4 is loweralkyl.
42. A compound of Claim 41 wherein R4 is methyl.
43. A compound of claim 30 wherein Ri is O, R2 is NR5R6, R5 is H, and R6 is methyl.
44. A compound of the formula (IN) :
Figure imgf000250_0001
wherein X is ΝR4, O or S;
Y is O or S;
Ai is substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, heteroarylarylalkyl;
Rl is O and R2 is NR5 Rβ, or Ri is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen or loweralkyl;
R5 and Rg are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and the pharmaceutically acceptable salts, esters and prodrugs thereof.
45. A compound of Claim 44 wherein X is NR4.
46. A compound of Claim 45 wherein R4 is hydrogen.
47. A compound of Claim 45 wherein R4 is methyl.
48. A compound of Claim 44 wherein Y is O.
49. A compound of Claim 44 wherein Ai is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclylcarbonylphenyl, heterocyclylphenyl, heterocyclylalkylphenyl, chlorophenyl, flourophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylamiήophenyl, alkylbromophenyl, alkylchlorophenyl, alkylflourophenyl, triflouromethylchlorophenyl, triflouromethylbromophenyl indenyl, 2,3-dihydroindenyl, tetralinyl, triflourophenyl, (triflouromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N- morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, 1- aceytl-2,3-dihydroindolyl, cycloheptyl, bicyclo[2.2.1]hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin- 1-yl, pyrrolidin- 1-ylalkyl, 4- amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-l-yl, piperidin- 1-yl, piperidin- 1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-l-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, l,4'-bipiperidin-l'-yl, and (1,4'- bipiperidin- 1 '-ylcarbonyl)phenyl.
50. A compound of Claim 44 wherein Ri is O and the dashed line represents a single or double bond.
51. A compound of Claim 44 wherein R2 is NR5R6, R5 is hydrogen and R6 is selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl.
52. A compound of Claim 44 wherein Ri is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group.
53. A compound of Claim 44 wherein R3 is loweralkoxy.
54. A compound of Claim 53 wherein R3 is methoxy.
55. A compound of Claim 44 wherein R4 is loweralkyl.
56. A compound of Claim 55 wherein R4 is methyl.
57. A compound of claim 44 wherein Ri is O, R2 is NR5R6, R5 is H, and R6 is methyl.
58. A compound of the formula (V) :
Figure imgf000252_0001
wherein X is i, O or S;
Ai is substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, heteroarylarylalkyl;
Rl is O and R2 is NR5 Rβ, or Ri is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen or loweralkyl;
R5 and Rg are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and the pharmaceutically acceptable salts, esters and prodrugs thereof.
59. A compound of Claim 58 wherein X is NR4.
60. A compound of Claim 59 wherein R4 is hydrogen.
61. A compound of Claim 59 wherein R is methyl.
62. A compound of Claim 58 wherein Ai is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclylcarbonylphenyl, heterocyclylphenyl, heterocyclylalkylphenyl, chlorophenyl, flourophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylflourophenyl, triflouromethylchlorophenyl, triflouromethylbromophenyl indenyl, 2,3-dihydroindenyl, tetralinyl, triflourophenyl, (triflouromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N- morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, 1- aceytl-2,3-dihydroindolyl, cycloheptyl, bicyclo[2.2.1]hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin- 1-yl, pyrrolidin- 1-ylalkyl, 4- amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-l-yl, piperidin- 1-yl, piperidin- 1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-l-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, l,4'-bipiperidin-l'-yl, and (1,4'- bipiperidin- 1 '-ylcarbonyl)phenyl.
63. A compound of Claim 58 wherein R is O and the dashed line represents a single or double bond.
64. A compound of Claim 58 wherein R2 is NR5R6, R5 is hydrogen and Rβ is selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl.
65. A compound of Claim 58 wherein Ri is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group.
66. A compound of Claim 58 wherein R3 is loweralkoxy.
67. A compound of Claim 66 wherein R3 is methoxy.
68. A compound of Claim 58 wherein R4 is loweralkyl.
69. A compound of Claim 68 wherein R4 is methyl.
70. A compound of claim 58 wherein Ri is O, R2 is NR5R6, R5 is H, and Rg is methyl.
71. A composition comprising an amount of a compound of claims 1, 16, 30, 44, or 58 effective to inhibit Raf activity in a human or animal subject when administered thereto, together with a pharmaceutically acceptable carrier.
72. A composition of Claim 71 which further comprises at least one additional agent for the treatment of cancer.
73. A composition of Claim 72 in which the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, 5- fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.
74. A method of inhibiting Raf kinase activity in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of claims 1, 16, 30, 44 or 58 effective to inhibit Raf kinase activity in the human or animal subject.
75. A method for treating a cancer disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of claims 1, 16, 30, 44 or 58 effective to inhibit Raf kinase activity in the human or animal subject.
76. A method of claim 75 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer.
77. A method of claim 76 in which the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.
78. A method for treating a hormone dependent cancer disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of claims 1, 16, 30, 44 or 58 effective to inhibit Raf kinase activity in the human or animal subject.
79. A method of claim 78 wherein the hormone dependent cancer is breast cancer or prostate cancer.
80. A method of claim 78 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer.
81. A method of claim 80 in which the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.
82. A method for treating a hematological cancer disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of claims 1, 16, 30, 44 or 58 effective to inhibit Raf kinase activity in the human or animal subject.
83. A method of claim 82 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer.
84. A method of claim 83 in which the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.
85. A compound of claims 1, 16, 30, 44 or 58 for use in the treatment of cancer.
86. Use of a compound of claims 1, 16, 30, 44 or 58 in the manufacture of a medicament for the treatment of cancer.
PCT/US2003/010117 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as raf kinase inhibitors WO2003082272A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CA2480638A CA2480638C (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as raf kinase inhibitors
DK03745683.7T DK1499311T3 (en) 2002-03-29 2003-03-31 Substituted benzols and their use as RAF kinase inhibitors
AU2003226211A AU2003226211B2 (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as RAF kinase inhibitors
SI200331745T SI1499311T1 (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as raf kinase inhibitors
EP03745683A EP1499311B1 (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as raf kinase inhibitors
BR0308854-5A BR0308854A (en) 2002-03-29 2003-03-31 Substituted benzazoles and their uses as raf kinase inhibitors
IL16430203A IL164302A0 (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as raf kinase inhibitors
EA200401284A EA007987B1 (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as raf kinase inhibitors
DE60329910T DE60329910D1 (en) 2002-03-29 2003-03-31 SUBSTITUTED BENZAZOLE AND THEIR USE AS RAF KINASE HEMMER
NZ535985A NZ535985A (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as RAF kinase inhibitors
KR1020047015523A KR101071123B1 (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as raf kinase inhibitors
APAP/P/2004/003161A AP1913A (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as raf kinase inhibitors
MXPA04009541A MXPA04009541A (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as raf kinase inhibitors.
AT03745683T ATE447404T1 (en) 2002-03-29 2003-03-31 SUBSTITUTED BENZAZOLES AND THEIR USE AS RAF-KINASE INHIBITORS
JP2003579810A JP4628678B2 (en) 2002-03-29 2003-03-31 Substituted benzazoles and their use as Raf kinase inhibitors
IL164302A IL164302A (en) 2002-03-29 2004-09-27 Substituted benzazoles, compositions and use thereof in the manufacture of a medicament for the inhibition of raf kinase activity
NO20044617A NO330563B1 (en) 2002-03-29 2004-10-26 Substituted benzazoles and their use as a drug as well as pharmaceutical compositions
HK05101491.7A HK1067945A1 (en) 2002-03-29 2005-02-22 Substituted benzazoles and use thereof as raf kinase inhibitors
HK05110735.4A HK1078779A1 (en) 2002-03-29 2005-11-25 Substituted benzazoles and use thereof as raf kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36906602P 2002-03-29 2002-03-29
US60/369,066 2002-03-29

Publications (1)

Publication Number Publication Date
WO2003082272A1 true WO2003082272A1 (en) 2003-10-09

Family

ID=28675563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010117 WO2003082272A1 (en) 2002-03-29 2003-03-31 Substituted benzazoles and use thereof as raf kinase inhibitors

Country Status (27)

Country Link
US (3) US7071216B2 (en)
EP (1) EP1499311B1 (en)
JP (3) JP4628678B2 (en)
KR (2) KR101071123B1 (en)
CN (1) CN100515419C (en)
AP (1) AP1913A (en)
AT (1) ATE447404T1 (en)
AU (1) AU2003226211B2 (en)
BR (1) BR0308854A (en)
CA (1) CA2480638C (en)
CO (1) CO5611108A2 (en)
CY (1) CY1109764T1 (en)
DE (1) DE60329910D1 (en)
DK (1) DK1499311T3 (en)
EA (1) EA007987B1 (en)
EC (1) ECSP045407A (en)
ES (1) ES2336094T3 (en)
HK (2) HK1067945A1 (en)
IL (2) IL164302A0 (en)
MX (1) MXPA04009541A (en)
NO (1) NO330563B1 (en)
NZ (1) NZ535985A (en)
PL (2) PL214800B1 (en)
PT (1) PT1499311E (en)
SI (1) SI1499311T1 (en)
WO (1) WO2003082272A1 (en)
ZA (1) ZA200408386B (en)

Cited By (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085425A1 (en) * 2003-03-21 2004-10-07 Amgen Inc Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors
WO2004087153A3 (en) * 2003-03-28 2005-03-17 Chiron Corp Use of organic compounds for immunopotentiation
WO2005032548A1 (en) * 2003-09-29 2005-04-14 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2005037273A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2005042520A1 (en) * 2003-10-24 2005-05-12 Merck Patent Gmbh Benzimidazolyl derivatives
WO2005070906A1 (en) * 2004-01-21 2005-08-04 Novartis Ag Organic compounds
WO2005070920A1 (en) 2004-01-21 2005-08-04 Bristol-Myers Squibb Company Amino-benzazoles as p2y1 receptor inhibitors
JP2005533038A (en) * 2002-06-04 2005-11-04 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Substituted thiophene, process for its production, its use as a pharmaceutical or diagnostic agent, and medicament containing it
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2007027950A1 (en) 2005-08-30 2007-03-08 Novartis Ag Substituted benzimidazoles and methods of preparation
JP2007511613A (en) * 2003-11-19 2007-05-10 アレイ バイオファーマ、インコーポレイテッド MEK bicyclic inhibitors and methods of use thereof
WO2007095124A3 (en) * 2006-02-10 2007-11-01 Transtech Pharma Inc Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2008000697A1 (en) * 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Novel 4-amino-3-(-azolyl-phenoxymethyl)-thieno[3,2]pyridine-7-carboxylic acid derivatives
WO2008011154A2 (en) * 2006-07-21 2008-01-24 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
WO2007136668A3 (en) * 2006-05-19 2008-01-24 Wyeth Corp N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008027523A2 (en) * 2006-08-30 2008-03-06 Novartis Ag Salts of benzimidazolyl pyridyl ethers and formulations thereof
WO2008030584A2 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase
JP2008525361A (en) * 2004-12-27 2008-07-17 ４エスツェー アクチェンゲゼルシャフト 2,5 and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
US7435823B2 (en) 2004-01-23 2008-10-14 Amgen Inc. Compounds and methods of use
WO2008144062A1 (en) * 2007-05-21 2008-11-27 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
WO2009025358A1 (en) 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009028655A1 (en) * 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009028629A1 (en) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009080694A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
US7576090B2 (en) * 2004-12-27 2009-08-18 4Sc Ag Benzazole analogues and uses thereof
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
US7678811B2 (en) 2002-02-11 2010-03-16 Bayer Healthcare Llc Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
WO2010064611A1 (en) 2008-12-01 2010-06-10 武田薬品工業株式会社 Heterocyclic compound and use thereof
WO2010064722A1 (en) 2008-12-02 2010-06-10 Takeda Pharmaceutical Company Limited Benzothiazole derivatives as anticancer agents
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
US7803825B2 (en) 2007-07-16 2010-09-28 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
US7820825B2 (en) 2006-03-15 2010-10-26 Wyeth Llc N-substituted-azacyclylamines as histamine-3 antagonists
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
EP2261223A1 (en) 2006-01-20 2010-12-15 Novartis AG Pyrimidine derivatives used as pi-3 kinase inhibitors
US7858623B2 (en) 2005-04-27 2010-12-28 Amgen Inc. Substituted amide derivatives and methods of use
WO2011000905A1 (en) 2009-07-02 2011-01-06 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
WO2011007257A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
US7932262B2 (en) 2006-04-06 2011-04-26 Novartis Ag Quinazolines for PDK1 inhibition
WO2011048561A1 (en) 2009-10-20 2011-04-28 Novartis Ag Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers
US7935719B2 (en) 2006-10-06 2011-05-03 Wyeth Llc N-substituted-azacyclylamines as histamine-3 antagonists
US7939528B2 (en) 2005-10-13 2011-05-10 Glaxosmithkline Llc Heterocycle compounds
WO2011058302A1 (en) 2009-11-10 2011-05-19 Guy's And St Thomas's Nhs Foundation Trust Bacteremia-associated antigen from staphylococcus aureus
US7968554B2 (en) 2007-08-14 2011-06-28 Hoffman-La Roche Inc. Pyrazolo[3,4-d]pyrimidine derivatives
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
EP2351772A1 (en) 2005-02-18 2011-08-03 Novartis Vaccines and Diagnostics, Inc. Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
EP2357184A1 (en) 2006-03-23 2011-08-17 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EP2368573A2 (en) 2005-11-04 2011-09-28 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP2368572A2 (en) 2005-11-04 2011-09-28 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2377551A2 (en) 2005-11-04 2011-10-19 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
EP2377552A2 (en) 2005-11-04 2011-10-19 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
CN101253169B (en) * 2005-08-30 2011-11-23 诺瓦提斯公司 Substituted benzimidazoles and methods of preparation
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
WO2011161551A2 (en) 2010-06-11 2011-12-29 Novartis Ag Omv vaccines
WO2012006359A1 (en) 2010-07-06 2012-01-12 Novartis Ag Delivery of self-replicating rna using biodegradable polymer particles
WO2012016970A1 (en) 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8163935B2 (en) 2005-04-27 2012-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN102432595A (en) * 2011-09-14 2012-05-02 湖南有色凯铂生物药业有限公司 N-indole-1-amides compounds and application of N-indole-1-amides compounds as anti-cancer drugs
US8173689B2 (en) 2006-04-19 2012-05-08 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
WO2012068546A1 (en) * 2010-11-19 2012-05-24 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
EP2478916A1 (en) 2006-01-27 2012-07-25 Novartis Vaccines and Diagnostics GmbH Influenza vaccines containing hemagglutinin and matrix proteins
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
EP2484377A1 (en) 2007-06-27 2012-08-08 Novartis AG Low-additive influenza vaccines
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
US8242128B2 (en) * 2003-09-24 2012-08-14 Merck Patent Gmbh 1,3-benzoxazolyl derivatives as kinase inhibitors
US8263631B2 (en) 2006-02-09 2012-09-11 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical compositions and methods for treating patients with cancer
EP2497495A2 (en) 2006-09-11 2012-09-12 Novartis AG Making influenza virus vaccines without using eggs
EP2510947A1 (en) 2009-04-14 2012-10-17 Novartis AG Compositions for immunising against Staphylococcus aureus
EP2514437A1 (en) 2006-07-20 2012-10-24 Novartis AG Frozen stockpiling of influenza vaccines
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
EP2532362A1 (en) 2006-12-06 2012-12-12 Novartis AG Vaccines including antigen from four strains of influenza virus
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
EP2548895A1 (en) 2007-01-11 2013-01-23 Novartis AG Modified saccharides
EP2572726A1 (en) 2007-08-01 2013-03-27 Novartis AG Compositions comprising pneumococcal antigens
EP2586790A2 (en) 2006-08-16 2013-05-01 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
EP2614709A1 (en) 2005-07-18 2013-07-17 Novartis AG Small animal model for HCV replication
EP2614835A1 (en) 2007-11-26 2013-07-17 Novartis AG Vaccination with multiple clades of H5 influenza A virus
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
USH2284H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
EP2659912A2 (en) 2007-07-17 2013-11-06 Novartis AG Conjugate purification
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
US8598190B2 (en) 2008-09-25 2013-12-03 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8609656B2 (en) 2004-02-23 2013-12-17 Chugai Seiyaku Kabushiki Kaisha Heteroarylphenylurea derivative
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
WO2014053521A2 (en) 2012-10-02 2014-04-10 Novartis Ag Nonlinear saccharide conjugates
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
US8853409B2 (en) 2007-09-21 2014-10-07 Array Biopharma Inc. Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
US8921405B2 (en) 2009-03-05 2014-12-30 Orexo Ab Compounds
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015068129A1 (en) 2013-11-08 2015-05-14 Novartis Ag Salmonella conjugate vaccines
US9056832B2 (en) 2010-09-17 2015-06-16 Purdue Pharma L.P. Pyridine compounds and the users thereof
EP2889042A2 (en) 2008-03-18 2015-07-01 Novartis AG Improvements in preparation of influenza virus vaccine antigens
EP2891498A1 (en) 2007-12-20 2015-07-08 Novartis AG Fermentation processes for cultivating streptococci and purification processes for obtaining CPS therefrom
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9573969B2 (en) 2014-09-12 2017-02-21 Novartis Ag Compounds and compositions as kinase inhibitors
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9718780B2 (en) 2012-03-16 2017-08-01 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
KR101770310B1 (en) 2015-08-24 2017-08-24 이화여자대학교 산학협력단 2-(phenylamino)benzo[d]oxazol-5-ol derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating inflammatory diseases containing the same as an active ingredient
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
EP3345617A1 (en) 2012-11-30 2018-07-11 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
EP4000619A1 (en) 2013-12-06 2022-05-25 Novartis AG Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
EP3876930A4 (en) * 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2022133098A3 (en) * 2020-12-16 2022-07-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12011449B2 (en) 2016-09-19 2024-06-18 Novartis Ag Therapeutic combinations comprising a c-RAF inhibitor

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902192B2 (en) 2003-05-15 2011-03-08 Arqule, Inc. Inhibitors of P38 and methods of using the same
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
MXPA06014696A (en) * 2004-06-15 2007-02-12 Astrazeneca Ab Substituted quinazolones as anti-cancer agents.
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
US7829560B2 (en) * 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
MX2007002208A (en) * 2004-08-25 2007-05-08 Targegen Inc Heterocyclic compounds and methods of use.
CA2577275A1 (en) * 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
MX2007002433A (en) * 2004-09-01 2007-05-04 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors.
AU2005293384A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as B Raf inhibitors
EP1809636A1 (en) * 2004-10-19 2007-07-25 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
JP2008518719A (en) * 2004-11-05 2008-06-05 アイシーユー メディカル インコーポレイテッド Medical soft grip connector
CA2589773A1 (en) * 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
US7429608B2 (en) * 2005-01-20 2008-09-30 Amgen Inc. Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments
AU2006208834A1 (en) * 2005-01-25 2006-08-03 Astrazeneca Ab Chemical compounds
WO2007071963A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
WO2007076474A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
BRPI0808526A2 (en) * 2007-03-02 2014-08-19 Novartis Ag Solid Forms of a RAF Kinase Inhibitor
KR20100072075A (en) * 2007-10-18 2010-06-29 노파르티스 아게 Csf-1r inhibitors for treatment of cancer and bone diseases
US7795254B2 (en) * 2007-10-29 2010-09-14 Amgen Inc. Benzomorpholine derivatives and methods of use
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
WO2009111280A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
AU2009222144A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine Raf inhibitors
CL2009000447A1 (en) * 2008-02-29 2010-01-04 Array Biopharma Inc Y Genentech Inc Compounds derived from (1h-pyrrolo {2,3-b} pyridin-5-yl) -sulfonamido-substituted benzamide; preparation procedure; pharmaceutical composition; and its use in the treatment of cancer, through the inhibition of raf.
CA2726376A1 (en) * 2008-06-13 2009-12-17 Novartis Ag Substituted benzimidazoles for neurofibromatosis
JP2012511021A (en) * 2008-12-05 2012-05-17 アークル インコーポレイテッド RAF inhibitors and uses thereof
US20110281917A1 (en) * 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
WO2010151441A1 (en) 2009-06-23 2010-12-29 Translational Genomics Research Institute Benzamide derivatives
WO2015031564A2 (en) * 2013-08-30 2015-03-05 University Of Utah Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
CN103450093A (en) * 2013-09-06 2013-12-18 中国药科大学 2-aminobenzimidazoles and applications thereof
MX2016008688A (en) * 2013-12-30 2017-01-12 Lifesci Pharmaceuticals Inc Therapeutic inhibitory compounds.
JP6612874B2 (en) 2014-12-16 2019-11-27 アクソファント サイエンシーズ ゲーエムベーハー Geminal-substituted quinuclidineamide compounds as agonists of α7-nicotinic acetylcholine receptors
CN105949178B (en) * 2015-03-09 2020-05-26 西格莱(苏州)生物医药有限公司 Benzimidazole compound, preparation method, intermediate and application thereof
CA2988968A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH Geminal substituted aminobenzisoxazole compounds as agonists of 7-nicotinic acetylcholine receptors
WO2018168899A1 (en) * 2017-03-15 2018-09-20 大日本住友製薬株式会社 Method for producing benzimidazole derivative
WO2020055760A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN111848505A (en) * 2019-04-26 2020-10-30 广东东阳光药业有限公司 Preparation method of vatacostat intermediate
EP4039676A4 (en) * 2019-10-02 2024-04-03 Klotho Sciences Compound for inducing expression of anti-aging gene klotho and use thereof
CN111138428B (en) * 2019-12-26 2021-02-19 深圳市老年医学研究所 Preparation method of African tetrandrine and African tetrandrine
EP4269394A1 (en) * 2021-01-29 2023-11-01 Korea Research Institute of Chemical Technology Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as active ingredient
CN114276266A (en) * 2021-12-30 2022-04-05 兰州康鹏威耳化工有限公司 Preparation method of 4-amino-2-fluorobenzamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062778A1 (en) * 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
WO2001066539A1 (en) * 2000-03-06 2001-09-13 Smithkline Beecham P.L.C. Imidazol derivatives as raf kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63190880A (en) * 1986-09-09 1988-08-08 Nippon Tokushu Noyaku Seizo Kk Novel n-benzothiazolyl-amides and insecticide
US6248771B1 (en) * 1997-03-05 2001-06-19 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
EP1060166A1 (en) * 1998-02-03 2000-12-20 Boehringer Ingelheim Pharma KG Five-membered, benzo-condensed heterocycles used as antithrombotic agents
ES2234300T3 (en) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3- (3-CHLORO-4-HYDROXYPHENYLAMINE) -4- (2-NITROPHENYL) -1H-PIRROL-2,5-DIONA AS A GLUCOGEN INHIBITOR CINASA-3 (GSK-3) SYNTHEASE.
US6211177B1 (en) * 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
SK14372001A3 (en) * 1999-04-12 2002-06-04 Aventis Pharma Limited Substituted bicyclic heteroaryl compounds as integrin antagonists, and pharmaceutical composition comprising same
ATE339406T1 (en) * 1999-09-23 2006-10-15 Astrazeneca Ab CHINAZOLINE COMPOUNDS AS REMEDIES
DE60120881T2 (en) * 2000-04-07 2007-01-18 Samsung Electronics Co., Ltd., Suwon SULPHONAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS
HUP0400651A2 (en) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors and pharmaceutical compositions containing them
EP1341771A2 (en) 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
CA2430978C (en) * 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
FR2833948B1 (en) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic NOVEL BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS
CA2477505A1 (en) * 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
US7071216B2 (en) * 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
CA2520124A1 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
MX2008013427A (en) * 2006-04-19 2008-11-04 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062778A1 (en) * 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
WO2001066539A1 (en) * 2000-03-06 2001-09-13 Smithkline Beecham P.L.C. Imidazol derivatives as raf kinase inhibitors

Cited By (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US8841330B2 (en) 1999-01-13 2014-09-23 Bayer Healthcare Llc Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US8242147B2 (en) 2002-02-11 2012-08-14 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
US8618141B2 (en) 2002-02-11 2013-12-31 Bayer Healthcare Llc Aryl ureas with angiogenesis inhibiting activity
US7678811B2 (en) 2002-02-11 2010-03-16 Bayer Healthcare Llc Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US8071616B2 (en) 2002-02-11 2011-12-06 Bayer Healthcare Llc Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US7728010B2 (en) 2002-03-29 2010-06-01 Novartis Vaccines And Diagnostics, Inc. Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
US8614330B2 (en) 2002-03-29 2013-12-24 Novartis Vaccines And Diagnostics, Inc. Substituted benz-azoles and methods of their use as inhibitors of RAF kinase
JP2005533038A (en) * 2002-06-04 2005-11-04 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Substituted thiophene, process for its production, its use as a pharmaceutical or diagnostic agent, and medicament containing it
WO2004085425A1 (en) * 2003-03-21 2004-10-07 Amgen Inc Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
EP2258365A1 (en) * 2003-03-28 2010-12-08 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
WO2004087153A3 (en) * 2003-03-28 2005-03-17 Chiron Corp Use of organic compounds for immunopotentiation
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
US8242128B2 (en) * 2003-09-24 2012-08-14 Merck Patent Gmbh 1,3-benzoxazolyl derivatives as kinase inhibitors
EA011890B1 (en) * 2003-09-29 2009-06-30 Новартис Вэксинес Энд Дайэгностикс, Инк. Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2005032548A1 (en) * 2003-09-29 2005-04-14 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2005037273A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
US8415382B2 (en) 2003-10-16 2013-04-09 Novartis Vaccines And Diagnostics, Inc. Substituted benzazoles and methods of their use as inhibitors of RAF Kinase
US7423150B2 (en) 2003-10-16 2008-09-09 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of Raf kinase
WO2005042520A1 (en) * 2003-10-24 2005-05-12 Merck Patent Gmbh Benzimidazolyl derivatives
AU2004285643B2 (en) * 2003-10-24 2011-06-02 Merck Patent Gmbh Benzimidazolyl derivatives
US7470702B2 (en) 2003-10-24 2008-12-30 Merck Patent Gmbh Benzimidazoles
JP4856546B2 (en) * 2003-10-24 2012-01-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazolyl derivatives
JP2007511613A (en) * 2003-11-19 2007-05-10 アレイ バイオファーマ、インコーポレイテッド MEK bicyclic inhibitors and methods of use thereof
JP2007518809A (en) * 2004-01-21 2007-07-12 ブリストル−マイヤーズ　スクイブ　カンパニー Aminobenzazole compounds as P2Y1 receptor inhibitors
US8053450B2 (en) 2004-01-21 2011-11-08 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors with pyridine ring and heterocyclic components
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005070906A1 (en) * 2004-01-21 2005-08-04 Novartis Ag Organic compounds
CN100567273C (en) * 2004-01-21 2009-12-09 诺瓦提斯公司 Organic compound
WO2005070920A1 (en) 2004-01-21 2005-08-04 Bristol-Myers Squibb Company Amino-benzazoles as p2y1 receptor inhibitors
EP2281819A1 (en) * 2004-01-21 2011-02-09 Novartis AG Benzimidazolyl or benzoxazolyl derivatives
US7435823B2 (en) 2004-01-23 2008-10-14 Amgen Inc. Compounds and methods of use
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
US8178557B2 (en) 2004-01-23 2012-05-15 Amgen Inc. Compounds and methods of use
US8609656B2 (en) 2004-02-23 2013-12-17 Chugai Seiyaku Kabushiki Kaisha Heteroarylphenylurea derivative
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
US7576090B2 (en) * 2004-12-27 2009-08-18 4Sc Ag Benzazole analogues and uses thereof
JP2008525361A (en) * 2004-12-27 2008-07-17 ４エスツェー アクチェンゲゼルシャフト 2,5 and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
EP2351772A1 (en) 2005-02-18 2011-08-03 Novartis Vaccines and Diagnostics, Inc. Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
US8088794B2 (en) 2005-04-27 2012-01-03 Amgen Inc. Substituted amide derivatives and methods of use
US8163935B2 (en) 2005-04-27 2012-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8685983B2 (en) 2005-04-27 2014-04-01 Amgen Inc. Method of treating cancer with substituted amide derivatives
US7858623B2 (en) 2005-04-27 2010-12-28 Amgen Inc. Substituted amide derivatives and methods of use
WO2006124780A3 (en) * 2005-05-12 2007-01-11 Kalypsys Inc Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
EP2614709A1 (en) 2005-07-18 2013-07-17 Novartis AG Small animal model for HCV replication
EA014230B1 (en) * 2005-08-30 2010-10-29 Новартис Аг Substituted benzimidazoles as kinase inhibitors
JP2009507794A (en) * 2005-08-30 2009-02-26 ノバルティス アクチエンゲゼルシャフト Substituted benzimidazole and method for producing the same
AU2006284666B2 (en) * 2005-08-30 2011-04-28 Novartis Ag Substituted benzimidazoles and methods of preparation
US7732465B2 (en) 2005-08-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Substituted benzimidazoles and methods of their use
WO2007030377A1 (en) * 2005-08-30 2007-03-15 Novartis Ag Substituted benzimidazoles as kinase inhibitors
WO2007027950A1 (en) 2005-08-30 2007-03-08 Novartis Ag Substituted benzimidazoles and methods of preparation
CN101253169B (en) * 2005-08-30 2011-11-23 诺瓦提斯公司 Substituted benzimidazoles and methods of preparation
AU2006287688B2 (en) * 2005-08-30 2010-08-19 Elanco Tiergesundheit Ag Substituted benzimidazoles as kinase inhibitors
US8592459B2 (en) 2005-08-30 2013-11-26 Novartis Ag Substituted benzimidazoles and methods of their use
US7939528B2 (en) 2005-10-13 2011-05-10 Glaxosmithkline Llc Heterocycle compounds
EP3714900A1 (en) 2005-11-04 2020-09-30 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2377552A2 (en) 2005-11-04 2011-10-19 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
EP2377551A2 (en) 2005-11-04 2011-10-19 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
EP2368572A2 (en) 2005-11-04 2011-09-28 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2368573A2 (en) 2005-11-04 2011-09-28 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP2261223A1 (en) 2006-01-20 2010-12-15 Novartis AG Pyrimidine derivatives used as pi-3 kinase inhibitors
EP3753574A1 (en) 2006-01-27 2020-12-23 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
EP2478916A1 (en) 2006-01-27 2012-07-25 Novartis Vaccines and Diagnostics GmbH Influenza vaccines containing hemagglutinin and matrix proteins
US8263631B2 (en) 2006-02-09 2012-09-11 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical compositions and methods for treating patients with cancer
EP2295432A1 (en) * 2006-02-10 2011-03-16 TransTech Pharma Inc. Process for the preparation of aminobenzimidazole derivatives
US7820821B2 (en) 2006-02-10 2010-10-26 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2007095124A3 (en) * 2006-02-10 2007-11-01 Transtech Pharma Inc Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
US8377983B2 (en) 2006-02-10 2013-02-19 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
US7820825B2 (en) 2006-03-15 2010-10-26 Wyeth Llc N-substituted-azacyclylamines as histamine-3 antagonists
EP2357184A1 (en) 2006-03-23 2011-08-17 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
US7932262B2 (en) 2006-04-06 2011-04-26 Novartis Ag Quinazolines for PDK1 inhibition
US8173689B2 (en) 2006-04-19 2012-05-08 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US8710048B2 (en) 2006-04-19 2014-04-29 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
WO2007136668A3 (en) * 2006-05-19 2008-01-24 Wyeth Corp N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
US7842715B2 (en) 2006-05-19 2010-11-30 Wyeth Llc N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
WO2008000697A1 (en) * 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Novel 4-amino-3-(-azolyl-phenoxymethyl)-thieno[3,2]pyridine-7-carboxylic acid derivatives
JP2009541424A (en) * 2006-06-29 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー Novel 4-amino-3- (3-azolyl-phenoxymethyl) -thieno [3,2-C] pyridine-7-carboxylic acid derivative
KR101143286B1 (en) 2006-06-29 2012-05-24 에프. 호프만-라 로슈 아게 Novel 4-amino-3-3-azolyl-phenoxymethyl-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
EP2514437A1 (en) 2006-07-20 2012-10-24 Novartis AG Frozen stockpiling of influenza vaccines
US8455662B2 (en) 2006-07-21 2013-06-04 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
AU2007275634B2 (en) * 2006-07-21 2011-01-20 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
WO2008011154A3 (en) * 2006-07-21 2008-06-26 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
WO2008011154A2 (en) * 2006-07-21 2008-01-24 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
EP2586790A2 (en) 2006-08-16 2013-05-01 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2008027523A2 (en) * 2006-08-30 2008-03-06 Novartis Ag Salts of benzimidazolyl pyridyl ethers and formulations thereof
US8501785B2 (en) 2006-08-30 2013-08-06 Novartis Ag Salts of benzimidazolyl pyridyl ethers and formulations thereof
WO2008027523A3 (en) * 2006-08-30 2008-04-10 Novartis Ag Salts of benzimidazolyl pyridyl ethers and formulations thereof
US8202998B2 (en) 2006-08-30 2012-06-19 Novartis Ag Salts of benzimidazolyl pyridyl ethers and formulations thereof
JP2010502717A (en) * 2006-09-07 2010-01-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド Modulator of interleukin 1 receptor related kinase
WO2008030584A2 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase
US8293923B2 (en) 2006-09-07 2012-10-23 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
WO2008030584A3 (en) * 2006-09-07 2008-07-17 Biogen Idec Inc Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase
EP3456348A1 (en) 2006-09-11 2019-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2497495A2 (en) 2006-09-11 2012-09-12 Novartis AG Making influenza virus vaccines without using eggs
US7935719B2 (en) 2006-10-06 2011-05-03 Wyeth Llc N-substituted-azacyclylamines as histamine-3 antagonists
EP2679240A1 (en) 2006-12-06 2014-01-01 Novartis AG Vaccines including antigen from four strains of influenza virus
EP2532362A1 (en) 2006-12-06 2012-12-12 Novartis AG Vaccines including antigen from four strains of influenza virus
EP2548895A1 (en) 2007-01-11 2013-01-23 Novartis AG Modified saccharides
WO2008144062A1 (en) * 2007-05-21 2008-11-27 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
JP2010528009A (en) * 2007-05-21 2010-08-19 ノバルティス アーゲー CSF-1R inhibitors, compositions and methods of use
US8293769B2 (en) 2007-05-21 2012-10-23 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
EP2484377A1 (en) 2007-06-27 2012-08-08 Novartis AG Low-additive influenza vaccines
US7803825B2 (en) 2007-07-16 2010-09-28 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
US9463250B2 (en) 2007-07-17 2016-10-11 Glaxosmithkline Biologicals Sa Conjugate purification
EP2659912A2 (en) 2007-07-17 2013-11-06 Novartis AG Conjugate purification
EP2572726A1 (en) 2007-08-01 2013-03-27 Novartis AG Compositions comprising pneumococcal antigens
US7968554B2 (en) 2007-08-14 2011-06-28 Hoffman-La Roche Inc. Pyrazolo[3,4-d]pyrimidine derivatives
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009025358A1 (en) 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP5350247B2 (en) * 2007-08-29 2013-11-27 武田薬品工業株式会社 Heterocyclic compounds and uses thereof
WO2009028629A1 (en) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8344135B2 (en) 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009028655A1 (en) * 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8853409B2 (en) 2007-09-21 2014-10-07 Array Biopharma Inc. Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
US9079890B2 (en) 2007-09-21 2015-07-14 Array Biopharma Inc. Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives
EP2614835A1 (en) 2007-11-26 2013-07-17 Novartis AG Vaccination with multiple clades of H5 influenza A virus
WO2009080694A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
EP2891498A1 (en) 2007-12-20 2015-07-08 Novartis AG Fermentation processes for cultivating streptococci and purification processes for obtaining CPS therefrom
EP2889042A2 (en) 2008-03-18 2015-07-01 Novartis AG Improvements in preparation of influenza virus vaccine antigens
EP3459563A1 (en) 2008-03-18 2019-03-27 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
US8916599B2 (en) 2008-09-25 2014-12-23 Orexo Ab 1H-benz imidazole-5-carboxamides as anti-inflammatory agents
US8598190B2 (en) 2008-09-25 2013-12-03 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8703796B2 (en) 2008-09-25 2014-04-22 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents
US9040565B2 (en) 2008-09-25 2015-05-26 Orexo Ab 1H-benzimidazole-5-carboxamides as anti-inflammatory agents
WO2010064611A1 (en) 2008-12-01 2010-06-10 武田薬品工業株式会社 Heterocyclic compound and use thereof
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8497274B2 (en) 2008-12-02 2013-07-30 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2010064722A1 (en) 2008-12-02 2010-06-10 Takeda Pharmaceutical Company Limited Benzothiazole derivatives as anticancer agents
US8143258B2 (en) 2008-12-02 2012-03-27 Takeda Pharmaceutical Company Limited Benzothiazole compounds useful for Raf inhibition
US8921405B2 (en) 2009-03-05 2014-12-30 Orexo Ab Compounds
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
EP3549602A1 (en) 2009-03-06 2019-10-09 GlaxoSmithKline Biologicals S.A. Chlamydia antigens
EP2510947A1 (en) 2009-04-14 2012-10-17 Novartis AG Compositions for immunising against Staphylococcus aureus
EP3263128A2 (en) 2009-04-14 2018-01-03 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
USH2284H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
WO2011000905A1 (en) 2009-07-02 2011-01-06 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
EP3178490A2 (en) 2009-07-15 2017-06-14 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
WO2011007257A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
EP2837386A1 (en) 2009-07-16 2015-02-18 Novartis AG Detoxified Escherichia coli immunogens
WO2011048561A1 (en) 2009-10-20 2011-04-28 Novartis Ag Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers
WO2011058302A1 (en) 2009-11-10 2011-05-19 Guy's And St Thomas's Nhs Foundation Trust Bacteremia-associated antigen from staphylococcus aureus
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
EP3399021A1 (en) 2010-06-11 2018-11-07 GlaxoSmithKline Biologicals S.A. Omv vaccines
WO2011161551A2 (en) 2010-06-11 2011-12-29 Novartis Ag Omv vaccines
WO2012006359A1 (en) 2010-07-06 2012-01-12 Novartis Ag Delivery of self-replicating rna using biodegradable polymer particles
EP3611269A1 (en) 2010-07-06 2020-02-19 GlaxoSmithKline Biologicals SA Delivery of self-replicating rna using biodegradable polymer particles
US9765029B2 (en) 2010-07-16 2017-09-19 Purdue Pharma L.P. Pyridine compounds as sodium channel blockers
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
WO2012016970A1 (en) 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US9056832B2 (en) 2010-09-17 2015-06-16 Purdue Pharma L.P. Pyridine compounds and the users thereof
US9611222B2 (en) 2010-09-17 2017-04-04 Purdue Pharma L.P. Pyridine compounds and the uses thereof
US9266874B2 (en) 2010-11-19 2016-02-23 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
US10030034B2 (en) 2010-11-19 2018-07-24 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
CN103298792A (en) * 2010-11-19 2013-09-11 利亘制药公司 Heterocycle amines and uses thereof
RU2632900C2 (en) * 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Heterocyclic amines and their application
US11186593B2 (en) 2010-11-19 2021-11-30 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
US11773110B2 (en) 2010-11-19 2023-10-03 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
EP2730564A1 (en) * 2010-11-19 2014-05-14 Ligand Pharmaceuticals Inc. Heterocycle amines and uses thereof
WO2012068546A1 (en) * 2010-11-19 2012-05-24 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
US10604533B2 (en) 2010-11-19 2020-03-31 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
EP3527224A1 (en) 2011-01-26 2019-08-21 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
EP4144368A1 (en) 2011-01-26 2023-03-08 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
EP4159232A1 (en) 2011-01-26 2023-04-05 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
EP3275892A2 (en) 2011-05-13 2018-01-31 GlaxoSmithKline Biologicals S.A. Pre-fusion rsv f antigens
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
CN102432595A (en) * 2011-09-14 2012-05-02 湖南有色凯铂生物药业有限公司 N-indole-1-amides compounds and application of N-indole-1-amides compounds as anti-cancer drugs
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
US9718780B2 (en) 2012-03-16 2017-08-01 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
WO2014053521A2 (en) 2012-10-02 2014-04-10 Novartis Ag Nonlinear saccharide conjugates
EP3345617A1 (en) 2012-11-30 2018-07-11 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US10709712B2 (en) 2013-03-14 2020-07-14 Novartis Ag Biaryl amide compounds as kinase inhibitors
US10245267B2 (en) 2013-03-14 2019-04-02 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9694016B2 (en) 2013-03-14 2017-07-04 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015068129A1 (en) 2013-11-08 2015-05-14 Novartis Ag Salmonella conjugate vaccines
EP4000619A1 (en) 2013-12-06 2022-05-25 Novartis AG Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
US11834447B2 (en) 2014-04-07 2023-12-05 Purdue Pharma L.P. Indole derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US9573969B2 (en) 2014-09-12 2017-02-21 Novartis Ag Compounds and compositions as kinase inhibitors
US9809610B2 (en) 2014-09-12 2017-11-07 Novartis Ag Compounds and compositions as kinase inhibitors
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
US11858938B2 (en) 2015-03-16 2024-01-02 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
KR101770310B1 (en) 2015-08-24 2017-08-24 이화여자대학교 산학협력단 2-(phenylamino)benzo[d]oxazol-5-ol derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating inflammatory diseases containing the same as an active ingredient
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
US12011449B2 (en) 2016-09-19 2024-06-18 Novartis Ag Therapeutic combinations comprising a c-RAF inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
EP3876930A4 (en) * 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
US20230183204A9 (en) * 2018-11-07 2023-06-15 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2022133098A3 (en) * 2020-12-16 2022-07-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors

Also Published As

Publication number Publication date
PL214800B1 (en) 2013-09-30
US7728010B2 (en) 2010-06-01
US20100196368A1 (en) 2010-08-05
US20070299039A1 (en) 2007-12-27
EP1499311B1 (en) 2009-11-04
PL402389A1 (en) 2013-04-02
JP5265629B2 (en) 2013-08-14
NZ535985A (en) 2007-04-27
PT1499311E (en) 2010-03-10
EA007987B1 (en) 2007-02-27
ES2336094T3 (en) 2010-04-08
CA2480638C (en) 2013-02-12
IL164302A (en) 2010-12-30
DK1499311T3 (en) 2010-03-08
NO330563B1 (en) 2011-05-16
AU2003226211B2 (en) 2008-05-29
CO5611108A2 (en) 2006-02-28
CN100515419C (en) 2009-07-22
US7071216B2 (en) 2006-07-04
EA200401284A1 (en) 2005-04-28
HK1078779A1 (en) 2006-03-24
JP2010275317A (en) 2010-12-09
AP2004003161A0 (en) 2004-12-31
ZA200408386B (en) 2006-05-31
KR101071123B1 (en) 2011-10-07
HK1067945A1 (en) 2005-04-22
CN1655779A (en) 2005-08-17
JP4628678B2 (en) 2011-02-09
EP1499311A1 (en) 2005-01-26
JP2006193533A (en) 2006-07-27
AU2003226211A1 (en) 2003-10-13
DE60329910D1 (en) 2009-12-17
IL164302A0 (en) 2005-12-18
US8614330B2 (en) 2013-12-24
CY1109764T1 (en) 2014-09-10
PL372852A1 (en) 2005-08-08
SI1499311T1 (en) 2010-03-31
JP2005529089A (en) 2005-09-29
ECSP045407A (en) 2005-01-03
KR20040095355A (en) 2004-11-12
KR20110015702A (en) 2011-02-16
BR0308854A (en) 2005-02-22
US20040087626A1 (en) 2004-05-06
AP1913A (en) 2008-10-31
ATE447404T1 (en) 2009-11-15
CA2480638A1 (en) 2003-10-09
MXPA04009541A (en) 2005-01-25
NO20044617L (en) 2004-12-28

Similar Documents

Publication Publication Date Title
EP1499311B1 (en) Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) Substituted benzazoles and methods of their use as inhibitors of raf kinase
ES2327418T3 (en) BENZAZOLES REPLACED AND USE OF THE SAME AS INHIBITORS OF THE QUINASA RAF.
WO2005037285A1 (en) 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1433/KOLNP/2004

Country of ref document: IN

Ref document number: 01433/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2480638

Country of ref document: CA

Ref document number: 1-2004-501541

Country of ref document: PH

Ref document number: 2003579810

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 372852

Country of ref document: PL

Ref document number: PA/a/2004/009541

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047015523

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200408386

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 535985

Country of ref document: NZ

Ref document number: 2003226211

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: AP/P/2004/003161

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: DZP2004000298

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200401284

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2003745683

Country of ref document: EP

Ref document number: 1200401136

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020047015523

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003812193X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003745683

Country of ref document: EP